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The continuous development and refinement of techniques is a key attribute of the discipline 
of surgery. Robust evidence derived from randomised clinical trials and subsequent synthesis 
using meta-analysis methods is therefore an indispensable tool in modern evidence-based 
surgical practice. This thesis aimed to address two challenges to the development of this 
evidence, namely the synthesis of trial data where multiple treatment comparisons exist, and 
the influence of sources of bias on the results of surgical randomised trials. 
 
Research synthesis typically employs pairwise meta-analysis methods to summarise trial data. 
However, there are more than two treatment options available for most conditions, meaning 
that data pertaining to all treatments cannot be incorporated using pairwise methodology. 
Network meta-analysis allows for the simultaneous comparison of multiple treatments and 
enables their ranking in terms of benefit and harm. This thesis used two different examples to 
explore this method’s utility in surgical research synthesis.  
 
Firstly, network meta-analysis methodology was used to investigate the efficacy of 
preoperative carbohydrate loading for patients undergoing elective surgery. None of the 
previously published pairwise meta-analyses had been able to account for the different doses 
and control treatments used in trials. This network meta-analysis represents the most 
comprehensive synthesis of the available evidence, and showed that carbohydrate loading 
confers a small reduction in length of stay when compared to fasting, but no significant 
difference when compared to water or placebo, and no other clinically important effect on 
postoperative outcomes. 
 
Secondly, all described anti-reflux operations were assessed and ranked using network meta-
analysis methods to summarise the entirety of available randomised trial data, to determine the 
optimal procedure for the treatment of gastro-oesophageal reflux disease. This had remained 
an unresolved question despite numerous pairwise meta-analyses. The results showed that a 
posterior partial fundoplication provides the best balance of long-term, durable reflux control 
with less dysphagia, compared to other treatments. 
 
The second half of this thesis explored the effect of non-blinding and other methodological 
deficiencies on surgical trials. Recent pooled studies have provided empirical evidence that 
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these potential sources of bias significantly influence reported trial results by exaggerating the 
effect estimate of the studied treatment. Surgical randomised trials have important differences 
to drug trials, and it is important to determine whether this effect also applies to them. A study 
using meta-epidemiological methods at an individual trial level was conducted to determine 
how lack of bias-minimisation measures including blinding affects the reported outcomes of 
surgical randomised trials, using data from over 300 trials. The results showed that trials that 
did not use blinding or adequate random sequence generation reported a significantly greater 
difference between treatment groups compared to trials that used such measures. 
 
This thesis has demonstrated the utility of network meta-analysis in surgical research synthesis, 
and produced definitive evidence-based answers to two questions. Many more clinically 
relevant questions can be answered in future using the same methods. This thesis has also 
empirically proven the importance of implementing blinding in surgical trials, which is relevant 
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Introduction – Evidence-based practice, research synthesis and 
trial design 
 
1.1 Evidence-based practice  
The development of surgical practice and expansion of its boundaries over the past 50 years has 
been extraordinary (Barkun et al., 2009; Meakins, 2009). Today, there are more major surgical 
operations performed than childbirths worldwide (Ashrafian et al., 2009), and surgery is a 
substantial contributor to improved health and wellbeing. Doing so efficiently and reliably requires 
practice that is informed by robust scientific evidence (Meakins, 2006; Rothenberger, 2004). 
 
Evidence-based practice aims to provide patients with the best treatment, based on scientific data 
derived from clinical trials. The randomised clinical trial (RCT) is the gold standard method of 
assessing the benefits and harms of healthcare interventions (Gattellari et al., 2001; Hrobjartsson 
et al., 2012), as it is the only trial design that accounts for unknown confounders (Lombardi, 2014). 
High quality evidence derived from these trials can guide health policy and clinical decision-
making, and provide a high standard of care for patients (Potter et al., 2014), by recommending 
the best available interventions and treatments (Vecht et al., 2009).  
 
The evaluation of a new procedure or treatment however may not be complete after just one or 
two RCTs. Different patient populations, healthcare environments and standard (control) therapies 
need to be accounted for by conducting multiple RCTs assessing the same treatments in different 
settings. The results of these trials are often variable due to factors including the setting, patient 
numbers, the control treatment, the outcomes of interest and the follow-up period. This leads to 
the publication of many papers addressing the same or a similar question with the same trial design 
(RCT), but with different results and conclusions. It can therefore become difficult, if not 
impossible, to assimilate these findings to derive an objective, evidence-based summary and 
recommendation without further statistical synthesis (Mant, 1999). This problem is compounded 
by the contemporary ‘epidemic of evidence’ (Jackson, 2018), the number of novel interventions 




1.1.1 A brief history 
The need for an objective, structured approach to synthesis of trial results to guide evidence-based 
practice and enable prompt introduction of proven treatments was recognised decades ago, as 
individual clinicians do not have the time or resources required to do this themselves 
(Rothenberger, 2004; Sackett et al., 1996; Sauerland et al., 1999). Archibald Cochrane (1909 – 
1988), a Scottish epidemiologist, penned this need in the form of a challenge facing the medical 
profession in his seminal work Effectiveness and Efficiency, Random reflections on health services 
(Cochrane, 1972). He and others argued that this need was urgent because of the difficulties 
clinicians faced in remaining up-to-date with a burgeoning number of clinical trials, which meant 
that proven effective treatments were not being adopted quickly enough while less effective or less 
safe treatments continued to be used (Abraham, 2006). There were also increasing calls for the 
need to honour the very reasonable expectation of clinical trial participants, that their contribution 
to medical knowledge is not wasted (Chalmers et al., 2013; Naylor, 1997).  
 
Prenatal steroid administration to premature infants to accelerate foetal lung maturation is perhaps 
one of the best examples of the need for prompt synthesis of accumulating RCT data, in order to 
achieve timely dissemination and implementation of evidence into clinical practice. An Auckland 
Professor of Obstetrics, Graham Liggins, began investigating preterm labour in sheep in 1959. He 
co-incidentally found that in-utero corticosteroid administration accelerated lung maturation 
(Reynolds and Tansey, 2005) and subsequently conducted an RCT on human babies in 
collaboration with a Paediatrician, Ross Howie, which showed a significant reduction in 
respiratory distress syndrome in preterm infants who received prenatal steroids (Liggins and 
Howie, 1972). Despite this, uptake of this simple and effective treatment was virtually non-
existent, as most research at the time was focussed on preventing preterm labour, rather than 
managing it (Reynolds and Tansey, 2005). Subsequent RCTs published by other groups showed 
similar results, and these were included in reviews as early as 1981 (Crowley, 1981). However, 
even by 1990 less than 20% of preterm infants outside Australia and New Zealand were receiving 
prenatal steroids. Routine administration in the UK only became a reality in the late 1990s 
(Reynolds and Tansey, 2005), almost three decades after the first RCT and more than fifteen years 
after the first narrative review promoting its use. A cumulative meta-analysis (Sinclair, 1995) 
around this time demonstrated that the RCTs published after the initial studies had not changed 
the overall effect estimate or the confidence intervals to any major extent. Thus, these additional 
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trials were unnecessary, and thousands of infants were needlessly randomised to placebo instead 
of receiving a proven treatment. Timely synthesis and dissemination of the accumulating RCT 
evidence would have profoundly decreased premature infant mortality rates worldwide. 
 
1.1.2 The Cochrane Collaboration 
These calls and examples led to the founding of an international body to champion healthcare 
research synthesis, standardise the methodology, and promote the timely dissemination and 
implementation of high quality evidence into clinical practice.  
 
In 1992, a group of Oxford clinicians and epidemiologists led by Sir Iain Chalmers established the 
Cochrane Centre to prepare and promote systematic reviews on obstetric healthcare, and named 
in honour of Archibald Cochrane who had died four years earlier. A year later, the Cochrane 
Collaboration was launched, and it is now the largest international organisation of its kind (Green 
and McDonald, 2005). Its logo incorporates a meta-analysis of the first seven RCTs investigating 
steroid administration to premature babies (Reynolds and Tansey, 2005), as a poignant reminder 
of the importance of research synthesis and evidence-based practice. The Collaboration now has 
over 38,000 contributors from more than 130 countries (Cochrane.org, 2018a), working in 50 
review groups responsible for preparing and maintaining systematic reviews within specific 
healthcare areas, and supported by Methods groups, Cochrane Centres and Fields (Higgins and 
Green, 2011). The Collaboration maintains the Cochrane Library including the Cochrane Database 
of Systematic Reviews, which is one of the most widely used evidence-based practice resources 
worldwide. The freely available Cochrane Handbook (Higgins and Green, 2011), and RevMan 
(Nordic Cochrane Centre, Copenhagen), a review management and meta-analysis software 
package, are also produced by the Collaboration. 
 
1.1.3 Systematic reviews and meta-analysis 
A systematic review collates all empirical evidence in order to answer a specific research question. 
It uses explicit systematic methods designed to incorporate all relevant data and minimise bias, 
thus providing findings from which conclusions can be drawn, and evidence-based 
recommendations and decisions made (Oxman and Guyatt, 1993). The key characteristics of a 
well-designed systematic review include predefined eligibility criteria for studies, a systematic 
search of databases and trial repositories for all potentially relevant studies, explicit and 
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reproducible methods, an assessment of the quality of available evidence, and finally a systematic 
presentation and synthesis of the findings of the included studies, usually using meta-analysis 
(MA) methodology if appropriate (Higgins and Green, 2011).  
 
Pairwise MA is the statistical combination of results from two or more separate studies (Glass, 
1976) comparing an experimental intervention with a control, or comparing two experimental 
interventions (Higgins and Green, 2011). This provides a more precise estimate of the effects of a 
healthcare intervention by pooling the study population and therefore increasing power. MA also 
allows the consistency of effects across studies to be investigated, as well as the heterogeneity or 
differences between them, thereby helping settle controversies arising from apparently conflicting 
studies (Higgins and Green, 2011; Lau et al., 2006). MA is therefore a powerful tool that can help 
answer the research question posed in a systematic review (Salanti et al., 2008a). International 
guidelines groups have produced consensus statements detailing the appropriate conduct and 
reporting of systematic reviews and meta-analyses of healthcare interventions (Moher et al., 2009; 
Shamseer et al., 2015). 
 
It is important to note that pairwise MA, like any statistical method, can be misused, leading to 
invalid or clinically meaningless results. Statistically combining the results of primary studies may 
not always be possible or appropriate, such as in the presence of considerable population, 
methodological or statistical heterogeneity, or when there is evidence of significant publication or 
reporting bias in the primary studies (Higgins and Green, 2011). This highlights the importance of 
combining specific subject and methodological expertise for the conduct of MA. 
 
1.1.4 Limitations of pairwise meta-analysis 
Pairwise MA is used to combine studies comparing two interventions, but for many healthcare 
interventions there may be more than two treatment options; each with a unique profile of risks 
and benefits. Research synthesis should ideally incorporate all available data pertaining to all 
available treatments (Song et al., 2009), but this cannot be achieved with pairwise MA where only 





Systematic reviewers have traditionally tried to circumvent this problem by employing one of two 
strategies (Salanti et al., 2008a). The first is to select two interventions for a given condition, 
subject the relevant RCTs to MA, then compare the findings with other MAs that have investigated 
the other available interventions. This frequently produces confusing conclusions as each MA uses 
different study selection criteria, outcome measures and follow-up time points. One such example 
is encapsulated in the title of an overview of antipsychotic drugs: “Why olanzapine beats 
risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine” (Heres et al., 2006). 
Another example is a review of different methods of earwax removal, which reported that 
“…cerumol, sodium bicarbonate, olive oil and water are all more effective than no treatment, 
triethanolamine polypeptide is better than olive oil, wet irrigation is better than dry irrigation, 
sodium bicarbonate drops followed by irrigation by nurse is more effective than sodium 
bicarbonate drops followed by self-irrigation, softening with triethanolamine polypeptide and self-
irrigation is more effective than self-irrigation only, and endoscopic de-waxing is better than 
microscopic de-waxing” (Clegg et al., 2010). The aim of research synthesis is to produce succinct, 
clinically applicable conclusions based on available data; which cannot be easily achieved by 
examining multiple pairwise MAs. Another strategy is to pool the multiple interventions into two 
groups and perform a pairwise MA comparing them. Examples include grouping surgical or 
medical interventions together (Ma et al., 2012; Peters et al., 2009), or combining placebo with no 
intervention (Awad et al., 2013). Although the conclusions of such reviews appear more succinct 
than those produced by the alternate strategy discussed earlier, this approach risks “combining 
apples with oranges” (Higgins and Green, 2011) as there is an assumption that different 
interventions can be regarded as identical. The results are therefore clinically less meaningful, and 
important differences in effect within each group are obscured. 
 
An alternate statistical method that simultaneously compares multiple interventions is therefore 
needed, in order for research synthesis to remain clinically relevant, and evidence-based practice 
to remain a realistic goal (Caldwell et al., 2005). 
 
1.1.5 Network meta-analysis 
Network meta-analysis (NMA) (Lumley, 2002), also called mixed treatment comparison meta-
analysis or multiple treatments meta-analysis (Salanti, 2012), is an extension of the standard 
pairwise (A vs. B) meta-analysis to a structure that includes multiple treatments (A vs. B vs. C) 
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and all the possible direct and indirect comparisons within (Figure 1.1), while fully respecting 
randomisation (Caldwell et al., 2005; Lu and Ades, 2004). A major advantage of NMA over 
pairwise MA is the ability to simultaneously compare multiple treatments for a given condition, 
and rank those treatments in terms of their benefit and harm (Caldwell et al., 2012; Lu and Ades, 
2004; Riley et al., 2017). This is particularly useful in situations where there is not enough direct 
evidence available (Song et al., 2009), where all possible comparisons have not been made in 
RCTs (Mills et al., 2013) or where RCTs have used different control treatments (Higgins and 
Welton, 2015). NMA also increases the precision of the effect estimate of each comparison within 
the network by incorporating indirect evidence, and therefore more data (Caldwell et al., 2005).  
 
Formulae for NMA have been developed and validated using both Bayesian and frequentist 
statistical approaches (Caldwell et al., 2005; Franchini et al., 2012; Hutton et al., 2014; Lu and 
Ades, 2004). The resulting routines have become available across multiple software platforms 
(Bafeta et al., 2014; Brown et al., 2014; Efthimiou et al., 2016; Viechtbauer, 2010). The routine 
package developed by Georgia Salanti and co-workers (Chaimani et al., 2013; Chaimani and 
Salanti, 2015) based on Stata (StataCorp LP., College Station, Texas) utility commands (Harris et 
al., 2008; White, 2009, 2011) is widely used. It is also one of the packages recommended for use 
by the Cochrane Methods Group (Cochrane.org, 2018b). As with pairwise MA, there are 
international consensus guidelines on the conduct and reporting of systematic reviews which 
include NMA (Hutton et al., 2015). 
 
1.1.6 Important considerations in NMA 
As NMA can be considered an extension of pairwise MA (Jansen et al., 2008), the underlying 
principles of MA apply, but to a greater extent (Song et al., 2009). There is an assumption that 
RCTs of different treatment comparisons are essentially similar in all ways other than the 
interventions being compared (Higgins and Green, 2011). All included RCTs should therefore 
have sufficient methodological, population and statistical similarity to allow for a valid synthesis 
(Mills et al., 2013). The influence of any potentially significant differences should be checked and 




Figure 1.1 Schematic representation of network meta-analysis 
In Box 1, two treatments for a given condition (A and B) have been compared in RCTs (A v B 
trials). The solid arrow between them represents a standard head-to-head, or pairwise MA, which 
summarises the effect estimate of treatment A compared to treatment B, as reported in those RCTs. 
Such methodology would be unable to simultaneously include a third available treatment C, (Box 
2), which has been compared to treatment A in other RCTs (A v C trials), but would summarise 
this comparison separately (solid arrow). NMA on the other hand, allows inferences about the 
relationship between treatments B and C to be drawn (vertical dashed arrow), using the common 
comparator treatment A, even if there have been no B v C trials. This can also be expressed as: 
 
C – B = (C – A) – (B – A) 
 
NMA also uses the indirect evidence available in the network (diagonal dashed arrows) to increase 
the precision of the effect estimate for each of the included treatments, and to incorporate the 




The degree of connectedness of the various treatments through RCT head-to-head comparisons, 
or the ‘geometry’ of the network is a key consideration (Bafeta et al., 2014; Salanti et al., 2008a). 
For example, a ‘star-shaped’ network where all treatments have been compared to placebo only 
but not one another is too heavily reliant on indirect evidence which may introduce excess 
heterogeneity (Salanti et al., 2008b). The results of such NMAs should be interpreted with caution 
and should guide future trials by identifying missing evidence (Mills et al., 2013). 
 
Another important principle in NMAs is the transitivity assumption (Efthimiou et al., 2016; 
Salanti, 2012). This is the premise that patients who were randomised to the different treatments 
in the included RCTs are similar, and that any patient can potentially receive any of the treatments 
compared in the network (Salanti et al., 2008a). Another way to consider this is whether each of 
the included network treatments could hypothetically make up one arm of a multi-group RCT 
(Salanti, 2012). Furthermore, each treatment within the network must be similar across all the 
studies that included it as a comparison (Chaimani et al., 2017). The network therefore becomes 
invalid if some of the included treatments are not clinically possible to administer to a subgroup 
of patients in the network, or if the administration of an included treatment was considerably 
different (Chaimani and Salanti, 2012; Donegan et al., 2010). This is an extension of the same 
principle in pairwise MA where the included RCTs compare identical treatment groups to which 
a sample patient population with the same clinical condition were randomised (Baker and Kramer, 
2002). 
 
As mentioned earlier, one of the strengths of NMA is the ability to draw on indirect evidence to 
increase the precision of the effect estimate and provide a comparison, even when no direct 
evidence is available. However, such indirect comparisons are not randomised and may suffer the 
biases of observational studies such as confounding (Jansen et al., 2008). They should therefore 
be used to supplement rather than supersede or replace direct evidence, although they can be more 
reliable in cases where direct evidence is only available from low quality RCTs (Donegan et al., 
2010; Salanti et al., 2008a; Song et al., 2009). Testing for significant differences between the direct 
and indirect evidence for a given comparison within the network, termed inconsistency or 
incoherence, is an important step (Lumley, 2002; Riley et al., 2017; White et al., 2012). A 
statistical test for this is available within most packages (Chaimani et al., 2013), usually through 
the calculation of an inconsistency factor (Dias et al., 2010) or the difference between the direct 
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and indirect evidence within a ‘closed’ loop, or a loop formed by three (or four) treatments with 
direct and indirect comparisons between all of them (Efthimiou et al., 2016; Higgins et al., 2012). 
In addition, a manual comparison of the direct and indirect results should be performed (Chaimani 
et al., 2017) as lack of statistical evidence of inconsistency does not necessarily imply consistency 
(Bafeta et al., 2014). Statistical inconsistency should be investigated both qualitatively, by 
examining the contributing RCTs for heterogeneity, and quantitatively, using sensitivity analysis, 
before deciding on whether to include the indirect (and combined) evidence (Jansen et al., 2008; 
Salanti, 2012).  
 
The included RCTs in any MA are not identical and clinical and methodological diversity 
inevitably leads to heterogeneity (Naylor, 1997). Testing for the degree of between-study 
statistical heterogeneity, or the differences between studies in terms of their treatment effect 
estimates is an integral component of pairwise MA through the calculation of the I2 statistic 
(Higgins and Green, 2011). This describes the percentage of the between-study variability in effect 
estimates that is attributable to heterogeneity as opposed to chance or a sampling error. This is 
used along with a qualitative assessment to assess whether the heterogeneity in the included RCTs 
is significant or not (Mills et al., 2013). There is no direct equivalent to the I2 statistic in NMA as 
there are multiple sources (direct and indirect) for each effect estimate (Caldwell et al., 2012), but 
calculation of predictive intervals (Bafeta et al., 2014) or the range within which any future RCT’s 
effect estimate is likely to lie for that comparison (Chaimani et al., 2013) is a useful proxy (Salanti 
et al., 2014). Wide predictive intervals indicate that the contributing RCTs’ results are 
heterogeneous, meaning that the NMA effect estimate for that comparison should be interpreted 
with caution (Chaudhry et al., 2015). 
 
As discussed earlier, any statistical methodology is prone to misuse if not applied correctly and 
NMA is no exception (Salanti, 2012; Song et al., 2009). Guidelines groups recommend both expert 
statistical support and subject expertise to facilitate the preparation, conduct and reporting of NMA 
(Higgins and Green, 2011; Hutton et al., 2015; Salanti et al., 2014). 
 
1.1.7 Applying NMA to surgical questions 
Surgical practice, like all medical practice, is constantly changing. As new treatments, techniques 
and procedures become available, their potential benefits and harms need to be compared to 
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existing interventions (Potter et al., 2014). As discussed earlier, NMA synthesis has clear 
advantages over standard MA when more than two treatment options are being compared 
(Chaudhry et al., 2015). However, comparing drug treatments using NMA is more straightforward 
than comparing procedural interventions. This may explain why the uptake of NMA methodology 
has been quickest in medical disciplines where drug therapy is the mainstay, such as psychiatry 
(Cipriani et al., 2011; Cipriani et al., 2018a; Cipriani et al., 2018b; Cipriani et al., 2016; Davies et 
al., 2018; Miura et al., 2014) and cardiology (Palmer et al., 2015; Siontis et al., 2015; Wu et al., 
2018). A recent review of all published NMAs found that 83% assessed pharmacological 
interventions (Bafeta et al., 2014). 
 
A small number of NMAs addressing surgical interventions have been published, using relatively 
simple network constructs and variable statistical rigour (Bracale et al., 2012; Mazaki et al., 2015; 
Padwal et al., 2011; Simillis et al., 2015). Advanced NMA methods are well suited to answering 
many surgical questions where multiple options are available and have been compared in RCTs. 
Surgical RCTs are more methodologically heterogeneous than drug trials, so it is possible that this 
would lead to wide confidence intervals in a complex surgical NMA, and therefore uncertain effect 
estimates and rankings and clinically less meaningful conclusions.  
 
The first part of this thesis utilises advanced NMA to address two practical surgical questions; 
carbohydrate loading prior to elective surgery, and anti-reflux surgery. These examples 
demonstrate different applications of NMA methodology, and in both examples the results provide 
new information and conclusions that were not evident from existing published MAs. 
 
 
1.2 Bias in clinical trials 
Although RCTs are the gold standard method for assessing the benefits and harms of healthcare 
interventions, their results are only valid if they are well designed and conducted (Sinha et al., 
2009). RCT validity has two main components, referred to as external validity (whether the RCT 
question is appropriate and clinically meaningful) and internal validity (whether the RCT answers 
the question in a manner that is free from bias) (Juni et al., 2001). Factors that affect external 




Bias is defined as systematic distortion of a statistical result (Fowler and Fowler, 2011). This can 
lead to either an under- or over-estimation of the true treatment effect in an RCT (Wood et al., 
2008), leading to false positive or false negative results, particularly with respect to subjective 
outcomes (Hrobjartsson et al., 2014). Such bias often arises unintentionally from subconscious 
tendencies (Day and Altman, 2000) including the so-called placebo effect. 
 
1.2.1 The placebo effect 
The word placebo is defined as a medicine or procedure prescribed for psychological, rather than 
physiological effect (Fowler and Fowler, 2011). Meaning “I shall please” in Latin, the term was 
introduced into medicine in the late 18th century to mean a treatment that is given to please, placate 
or console rather than benefit the patient (Bernstein and Brown, 2017; de Craen et al., 1999; 
Sonawalla and Rosenbaum, 2002). The placebo effect relates to our psychological predisposition 
to hope and positive expectation, and is well known to influence our judgement of the efficacy of 
a treatment (Beecher, 1955; Feys et al., 2014). Optimism bias, a term borrowed by Sir Iain 
Chalmers from the psychology literature, refers to the tendency for patients to assume that novel 
treatments are an advance on currently available ones (Chalmers, 1997; Chalmers and Matthews, 
2006).  
 
Observer bias, also known as ascertainment or detection bias (Hrobjartsson et al., 2012), can be 
thought of as the equivalent phenomenon affecting the treatment administrator (or assessor), 
resulting from the interaction between the observer’s predispositions and the subjectivity of the 
outcome being assessed (Hrobjartsson et al., 2014). This is particularly influential when 
investigators have strong convictions regarding the evaluated treatment, leading to intervention 
preoccupation (overrating the intervention group) (Hrobjartsson et al., 2012) or compliant 
responses from patients (Beecher, 1955; Spanos et al., 1992). 
 
The ‘bias blind spot’ is a term coined by Emily Pronin, a social psychologist at Princeton 
University, to describe the natural tendency of recognising the impact of biases on the judgement 
of others while failing to see the impact of biases on one’s own judgement (Pronin et al., 2002). 
One of her group’s findings in a study of 600 US residents was that more than 85% believed they 
were less biased than the average American, and only one participant thought they were more 




The placebo effect and bias blind spot are just two examples of a range of factors that can introduce 
bias in an RCT, significantly altering the results. This in turn can affect the conclusions of 
subsequent synthesis (Goodman and Dickersin, 2011; Moher et al., 1998) and lead to erroneous 
recommendations for clinical practice (Detsky et al., 1992). Classifying and controlling for 
potential sources of bias is therefore critical to the validity of healthcare intervention RCTs. 
 
1.2.2 Common sources of bias 
The Cochrane Collaboration’s tool for assessing the risk of bias in RCTs (Higgins et al., 2011) 
employs a useful classification into selection, performance, detection, attrition and reporting bias, 
with definitions for each (Higgins and Green, 2011). A brief outline of this follows, along with 
strategies to effectively minimise the influence of these biases as recommended by the Cochrane 
Collaboration and guidelines groups (Higgins and Green, 2011; Schulz et al., 2010). 
 
Selection bias is used to describe systematic differences between the baseline characteristics of 
study groups. It is avoided by effective randomisation, which has two essential components, 
namely the generation of an allocation (or randomisation) sequence that is based on chance and 
strict implementation of that random sequence by concealment, meaning that it is impossible to 
know which group the next trial participant will be allocated to (Odgaard-Jensen et al., 2011). 
 
Systematic differences between the groups in the provided care or in exposure to factors other than 
the intervention of interest is referred to as performance bias. The risk of such bias is minimised 
by blinding (Savovic et al., 2012), or ensuring that study participants do not know which group 
they were allocated to. Blinding of study investigators additionally ensures that all participants, 
regardless of the group they were allocated to, receive identical treatment apart from the trial 
interventions. Outcome differences between the groups are therefore more likely to reflect 
differences in intervention effect (Hall, 2010). This is particularly important in instances where 
there are prevalent preconceptions about a particular therapy. 
 
Detection bias refers to systematic variation between the groups in the way outcomes are assessed 
and recorded, and is particularly problematic when evaluating subjective outcomes. Paradoxically, 
some conscientious assessors may overcompensate for an expected subconscious bias in favour of 
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the intervention by consciously favouring the control (Hrobjartsson et al., 2013). Detection bias is 
countered by blinding the outcome assessors (Wood et al., 2008). Other strategies such as the use 
of correlation coefficients to assess inter-observer agreement are not effective (Hrobjartsson et al., 
2013). 
 
Systematic disparity between the groups in study withdrawals and exclusions is referred to as 
attrition bias, and leads to non-random missing outcome data. This can be because data of some 
trial participants have been intentionally excluded from the analyses or are not available to the 
investigators (Wood et al., 2008). Performing an intention-to-treat (or as per randomisation) 
instead of an as-treated (or per protocol) analysis can minimise this risk of bias (Juni et al., 2001). 
 
Finally, reporting bias (or selective reporting bias) refers to systematic differences between the 
reported and unreported findings of a study (Chalmers, 1990; Higgins and Green, 2011; McGauran 
et al., 2010). This usually manifests as preferential reporting of results with statistically significant 
differences. There are other potential sources of reporting bias such as the use of different time-
points, outcome assessment instruments or analyses to show a statistically significant difference 
(Chalmers et al., 2013). The risk of reporting bias is minimised by determining a priori how the 
data will be analysed and reported, publishing a trial protocol including a detailed statistical 
analysis plan and publishing all the results (Schulz et al., 2010). 
 
Other biases and factors may affect the results of RCTs. These include contamination (where 
participants of a drug versus placebo trial decide to mix and evenly distribute the trial drugs so 
each participant has an equal chance of receiving the active treatment) and co-intervention (where 
study controls are provided non-study interventions by well-meaning carers) (Dechartres et al., 
2013; Sackett, 2007; Shun-Shin and Francis, 2013). However, the classification described above 
covers the common sources of bias. The effect of these biases on the results of RCTs can be 
examined in methodological studies using meta-epidemiology techniques. 
 
1.2.3 Meta-epidemiology 
A meta-epidemiological study analyses MAs with respect to a particular methodological or other 
study-level characteristic in the included RCTs (Sterne et al., 2002). In brief, the difference in the 
pooled effect estimate (such as the odds ratio or mean difference) between studies that contain that 
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characteristic (such as blinding) and those that do not is calculated within each meta-analysis. 
These differences (or ratios) are then combined across the meta-analyses into what is also called a 
meta-meta-analysis (Higgins and Green, 2011). The result is a quantitative estimate of the effect 
of that study-level characteristic on the RCTs’ results.  
 
Recent meta-epidemiological studies have provided empiric evidence that the potential sources of 
bias discussed earlier significantly influence the results of RCTs by exaggerating the effect 
estimate of the studied treatment (Savovic et al., 2012; Schulz et al., 1995; Wood et al., 2008). 
Selection, performance and detection bias have been found to be particularly influential, with a 
combined exaggerated treatment effect of up to 37% (Moher et al., 1998; Wood et al., 2008). A 
recent editorial clearly demonstrated this cumulative bias effect using trials assessing renal artery 
denervation for the treatment of hypertension as an example (Shun-Shin et al., 2014).  
 
The methodological studies performed to date have pooled data from trials across several medical 
disciplines with RCTs of pharmacological interventions constituting the vast majority. Surgical 
RCTs have important differences to drug trials (Barkun et al., 2009; Love, 1975; Solomon and 
McLeod, 1995) and these differences influence susceptibility to various forms of bias (Stirrat et 
al., 1992). 
 
1.2.4 Considerations in surgical trials 
The impossibility of blinding the operating surgeon, and the difficulties in blinding patients and 
carers to surgical procedures, are well recognised (Boutron et al., 2004; Hill et al., 2002; Schulz 
and Grimes, 2002). There is ample evidence that the placebo effect of procedures is even greater 
than for drugs (Kaptchuk et al., 2000; McRae et al., 2004). Some authors have argued that blinding 
in surgical trials is not possible, and should not be considered (Patel et al., 2013; Pham et al., 2009; 
Vinuela et al., 2012). A review of orthopaedic trauma trials reported that outcome assessment had 
not been blinded in 90% of trials (Karanicolas et al., 2008), even though that was possible 
(Bingener et al., 2015; McCulloch et al., 2002). Such widespread non-blinding is likely to 
influence the results and interpretation of many surgical RCTs (Penninga et al., 2014).  
 
Surgical RCTs are affected by surgeon and patient preference in procedure selection and patient 
eligibility (Jack et al., 1990; Lassen et al., 2005), with greater optimism bias. This may persist 
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even after blinded evaluation shows no benefit in the novel procedure (Freed et al., 2001; 
Wartolowska et al., 2014). Procedures such as laparoscopic cholecystectomy spread rapidly due 
to surgeon and patient enthusiasm before RCT evaluation (Cuschieri, 1989; Cuschieri et al., 1990; 
Russell, 1995). Optimism bias can also lead to cross-over of enrolled patients between treatment 
groups, which may significantly influence the results in an intention-to-treat (or as randomised) 
analysis (Cunningham, 2011).  
 
Expert opinion can sometimes suggest that surgical RCTs are impractical or inappropriate (Kenny 
et al., 1997), which may or may not be justified (Gattellari et al., 2001; McCulloch et al., 2002; 
Meakins, 2006). The influence of selection bias may therefore increase in surgical trials if 
appropriate generation of the randomisation sequence and allocation concealment is not employed.  
 
Multiple other factors contribute to the added complexity of surgical RCTs compared to drug trials, 
such as the difficulty of standardising interventions and procedures (Neugebauer et al., 1991; Sinha 
et al., 2009; Solomon and McLeod, 1995) and the timing of an RCT for a novel intervention with 
respect to the learning curve (Ergina et al., 2009; McCulloch et al., 2002).  
 
One of the conclusions of the Balliol Colloquia, a series of meetings between 2007 and 2009 at 
the eponymous College in Oxford, held to discuss the advancement of surgical research (Waxman, 
2016), was that none of these challenges were beyond the design of a clinical trial (Lancet, 2009). 
Indeed, some of the earliest high quality RCTs were designed and conducted by surgeons (Cobb 
et al., 1959; Dimond et al., 1960; Livingston, 1953), with John Goligher’s RCT on duodenal ulcer 
surgery being an excellent early example that included random sequence generation, allocation 
concealment, blinded outcome assessment and >99% follow-up (Goligher et al., 1964). Surgical 
RCTs can therefore be held to the same high standards as other trials (Horton, 1996; Stirrat et al., 
1992). 
 
The question of whether blinding and other sources of bias significantly influence the results of 
surgical RCTs is important for two reasons.  Firstly, there are implications for the interpretation 
of published surgical RCTs that form the basis of current evidence-based surgical practice. 
Secondly, this information will help guide future surgical RCT design. Although difficult to 
incorporate and therefore seldom attempted, blinding should be considered in the design of future 
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surgical trials if shown to have a significant impact on outcome measures. The second part of this 
thesis reports on a meta-epidemiological study that specifically examined this question. 
 
 
1.3 Aims  
The aims of this thesis are: 
1. To apply network meta-analysis techniques to specific surgical questions. 
2. To determine the effect of blinding, and other bias-minimisation strategies, on the results 
of surgical randomised clinical trials 
 
Chapter Two uses NMA methods to investigate the efficacy of preoperative carbohydrate loading 
for patients undergoing elective surgery. A number of published pairwise meta-analyses reported 
conflicting conclusions, as they were unable to account for the different doses, and control 
treatments, used in the RCTs. 
 
NMA methodology is used in Chapter Three to determine which anti-reflux operation provides 
the best balance of benefit and risk for the treatment of gastro-oesophageal reflux disease (GORD). 
This has remained an unresolved question despite dozens of RCTs and numerous pairwise MAs. 
 
Chapter Four uses meta-epidemiological methods to quantify the effect of lack of blinding and 
other methodological deficiencies that pose a risk of bias, on surgical RCT results. It draws on 
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My contribution to this chapter 
This project was conceived jointly by myself and my supervisors (JLM, GPH and MDS). It builds 
on earlier work published by them and other co-authors (Smith et al., 2014). I updated the 
systematic search, selected and extracted data from additional eligible trials (with co-author 
duplication) and performed all of the analysis with guidance from GPH and MDS. All drafts and 
the final manuscript of the resulting publication were written by myself, with revisions in 
conjunction with my supervisors and journal reviewers. This chapter is adapted from the published 
paper (Amer et al., 2017). 
 
 
2.1 Chapter summary 
Recent MAs have summarised the results of RCTs investigating the effects of preoperative 
carbohydrate (CHO) administration on clinically relevant postoperative outcomes in adult patients 
undergoing elective surgery. However, these MAs could not account for the different doses of 
CHO administered and the different controls used. NMA allows for robust synthesis of all 
available evidence in these situations. Article databases were systematically searched for RCTs 
comparing preoperative carbohydrate administration with water, a placebo drink or fasting. A four 
18 
 
treatment NMA was performed comparing two CHO dose groups (low: 10–44g; high: >45g) with 
two control groups (fasting; water or placebo). Primary outcomes were length of hospital stay and 
the postoperative complication rate. Secondary outcomes included postoperative insulin 
resistance, vomiting and fatigue. Forty three trials involving 3110 participants were included. 
Compared to fasting, preoperative low dose and high dose CHO administration decreased 
postoperative length of stay by 0.4 days (95% confidence interval (CI) 0.03 – 0.7) and 0.2 days 
(95% CI 0.04 – 0.4) respectively. There was no significant decrease in length of stay compared to 
water or placebo. There was no significant difference in the postoperative complication rate or in 
most of the secondary outcomes between the CHO and control groups. These results show that 
preoperative CHO administration is safe, but does not provide a clinically relevant benefit over 




Enhanced recovery after surgery (ERAS), or fast-track recovery, is a set of perioperative principles 
and strategies brought together in an integrated pathway to optimise patients’ operative journeys 
and minimise morbidity. ERAS is now in widespread use across many surgical disciplines 
internationally, as it has been shown to reduce complications, facilitate recovery and hasten 
discharge (Gouvas et al., 2009).  
 
However, the evidence supporting the use of some individual components of ERAS is variable, 
meaning their routine inclusion in ERAS remains debatable (Lubowski, 2014). An example of this 
is the preoperative administration of a CHO load, usually as an oral solution, promoted as a counter 
to postoperative hyperglycaemia (Ljungqvist et al., 2002). 
 
Surgery, as a form of stress, is known to induce peripheral insulin resistance which can lead to 
hyperglycaemia, which in turn may lead to postoperative complications and prolonged recovery 
(Nygren, 2006). Studies have shown that a preoperative CHO load large enough to stimulate a 
prompt insulin response decreases postoperative insulin resistance by around 50% (Ljungqvist et 
al., 2002). Over 30 RCTs have investigated whether this effect results in improved postoperative 
outcomes. These have been summarised in several recent MAs (Awad et al., 2013; Li et al., 2012; 




However, these MAs arrived at variable conclusions. This variability is partly due to different 
inclusion and exclusion criteria, meaning different RCTs were included in each MA. More 
importantly however, a standard pairwise MA cannot account for the different CHO doses and 
different controls used in the included RCTs. As a result, these MAs either combined different 
control groups (such as fasting, water and placebo) into one treatment arm (Awad et al., 2013; 
Smith et al., 2014) or performed several different head-to-head MAs (Li et al., 2012; Smith et al., 
2014), thereby limiting their interpretability. Thus, there remains a need for an inclusive, 
methodologically sound analysis of all the available evidence to resolve ongoing uncertainty 
around the true clinical benefits of CHO loading (Zargar-Shoshtari and Hill, 2008). 
 
NMA offers a validated method of synthesis in instances such as this, as detailed in Chapter 1. 
This chapter reports the results of a systematic review and NMA to determine the effects of 
preoperative CHO administration on clinically relevant postoperative outcomes in adult patients 




2.3.1 Search strategy and selection criteria 
A systematic review of RCTs of preoperative CHO administration for elective surgical patients 
was performed using the same process and outcomes described in the Cochrane review on the 
same topic (Smith et al., 2014). In brief, article databases and trial registries were searched to June 
2016 using a structured sensitivity maximising search strategy (Appendix B1) and no language 
restrictions. All citations were in English, as translated by the databases. Abstracts and full texts 
in French, German and Japanese were able to be translated by the data extractors. Studies in other 
languages were translated using Google translate (Jackson et al., 2019). Two authors 
independently screened all titles and abstracts for eligibility, and trial authors were contacted when 
further information was required to decide on eligibility.  
 
All randomised and quasi-randomised trials comparing the preoperative administration of at least 
10g CHO (either orally or intravenously) within 4 hours of surgery start time with fasting, water 
or placebo, to adults undergoing any type of elective surgical procedure were included.  Studies 
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that co-administered other substances (such as glutamine) were included as long as the dose of 
CHO was greater than 10g. Studies that did not administer CHO within four hours prior to surgery 
and studies that included patients undergoing emergency surgery (defined as within 24 hours of 
first physician contact) were excluded. 
 
2.3.2 Outcome measures 
All trials that reported any of the following outcomes were included. 
 
Primary outcomes: 
1. Length of postoperative stay (in days). 
2. Postoperative complication rate (as defined by trial authors). 
 
Secondary outcomes: 
1. Aspiration pneumonitis rate (defined as observed regurgitation or vomiting in association with 
abnormal chest imaging). 
2. Vomiting within the first 24 hours postoperatively (measured as an incidence count). 
3. Insulin resistance (measured by the Homeostatic model assessment of insulin resistance 
(HOMA-IR) method). 
4. Insulin sensitivity (measured by the hyperinsulinaemic-euglycaemic clamp method). 
5. Nausea at 24 hours postoperatively (measured on ordinal, visual analogue or composite scales). 
6. Postoperative general well-being (measured on ordinal, visual analogue or composite scales). 
7. Postoperative fatigue (measured on ordinal, visual analogue or composite scales). 
8. Return of intestinal function (number of postoperative days to first passage of flatus, and first 
passage of bowel motion). 
 
2.3.3 Data extraction and quality assessment 
For studies that were also included in the Cochrane review (Smith et al., 2014), data already 
extracted were used. For the additional studies included in this review, the same structured paper 
form used in the Cochrane review was employed to collect extracted data (Appendix B2). 
Extracted data included study characteristics, patient characteristics, intervention details and 




Missing standard deviations were calculated from standard errors or confidence intervals (Higgins 
and Green, 2011), or from ranges or interquartile ranges (Hozo et al., 2005). When standard 
deviations could not be calculated, and attempts to contact the study authors were exhausted, they 
were imputed using the median of reported standard deviations from other similar trials. 
 
The methodological quality of all included trials was assessed using the Cochrane Risk of Bias 
tool (Higgins et al., 2011) across the following domains: random sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete 
outcome data, selective reporting and other potential sources of bias (such as baseline imbalances 
or differential diagnostic activity). Each domain was assessed as high risk, low risk or unclear risk. 
 
2.3.4 Statistical analysis 
A random-effects NMA was performed using the suite of Stata (StataIC 13, StataCorp LP., College 
Station, Texas) routines developed specifically for this purpose (Chaimani et al., 2013; Chaimani 
and Salanti, 2015; White, 2015). The main analysis comprised four treatment groups (nodes): low 
dose CHO (10g – 44g), high dose CHO (≥45g), water/placebo and fasting. Fasting was allocated 
as the reference treatment in the network. Comparisons between the water/placebo group and the 
fasting group are not reported as this review does not include all RCTs that compared preoperative 
fasting with water only. CHO arms of multiple-group RCTs where those arms received the same 
amount of carbohydrate (with or without additives such as glutamine) were combined. A network 
map was produced to provide a visual summary of the network of evidence available. 
 
The results for continuous data were summarised as a mean difference (MD) or standardised mean 
difference (SMD) as appropriate, with 95% confidence intervals (CI). An SMD was used if studies 
assessing the same outcome used different measures or the results for that outcome were 
substantially different due to study population differences. Categorical data were summarised as 
an odds ratio with 95% CI. Where an SMD was appropriate, the original result in standard 
deviations (SD) is reported as well as the back-transformed approximations to the initial unit 
(Higgins and Green, 2011). 
 
For primary outcomes with statistically significant differences between the groups, the probability 
of each treatment group ranking as the best, second, third or worst treatment in the network was 
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calculated and presented as a rankogram if one treatment was clearly superior (>90% probability 
of ranking best) (Dias et al., 2012).  
 
A meta-regression analysis for outcomes with statistically significant differences between the 
groups was also performed to further evaluate any relationship with CHO dose. The network meta 
command (Chaimani et al., 2013) was run, and the resulting effect estimate and standard error for 
each study were used to run metareg (Harbord and Higgins, 2008). Both the R2 value and ‘bubble 
plot’ (regression line of best fit) were inspected to determine whether a dose–response relationship 
existed. Three-arm trials (where two different carbohydrate doses were used) were dealt with by 
using the two effect estimates derived from them as two separate entries into metareg. A sensitivity 
analysis was performed for this by assuming they were two different studies then serially excluding 
each entry. 
 
Cumulative pairwise MA for the outcome of length of postoperative stay was also performed. This 
was undertaken with R (Version 3.3.1, R Foundation for Statistical Computing, Vienna) using the 
meta package (Schwarzer, 2016). High-dose carbohydrate was compared with placebo, water or 
fasting, with studies being sequentially added by date of publication. 
 
Subgroup analyses by type of surgery for outcomes where there were sufficient data to allow for 
this were performed. Major surgery was defined as all procedures with a reported mean length of 
postoperative stay of two or more days, and minor surgery as all procedures with a reported mean 
length of postoperative stay of less than two days.  
 
Several sensitivity analyses were performed. First, the influence of imputed versus reported data 
was assessed by excluding studies where data were imputed. Second, the transitivity assumption 
was tested by splitting the ‘water or placebo’ node within the network. Third, blinded trials were 
analysed as a separate node within the network to assess the influence of un-blinded studies.  
 
Between-study heterogeneity was assessed by calculating predictive intervals, or the interval 
within which the treatment effect estimate of a future study is expected to lie (Chaimani et al., 
2013). Inconsistencies between direct and indirect evidence in the network (loop-specific 
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heterogeneity) were also tested for by calculating the difference between the two (the 
inconsistency factor) in each closed loop (Dias et al., 2010).  
 
To investigate publication bias a comparison-adjusted funnel plot was visually inspected, which 
accounted for the fact that the included studies estimated treatment effects for different 




2.4.1 Search results and study characteristics 
The database search and study selection process is summarised in Figure 2.1. Forty-three RCTs 
fulfilled the inclusion criteria, involving 3110 patients (Table 2.1).  
 
 
Figure 2.1 Systematic search and study selection flowchart 
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Table 2.1 Details of included studies 
Reference Country Type of elective surgery 
CHO dose 





(An et al., 2008) China Colonic cancer resection 50g, oral Fasting 51 NR 
(Aronsson et al., 2009) Sweden Hip replacement 25g, oral Flavoured water 28 NR 
(Asakura et al., 2015) Japan Body surface surgery‡ 45g, oral§ Fasting 91 I–II 
(Bisgaard et al., 2004) Denmark Laparoscopic cholecystectomy 50g, oral Placebo¶ 86 I–II 
(Braga et al., 2012) Italy Pancreaticoduodenectomy 50g, oral Low energy 
drink# 
36 NR 
(Breuer et al., 2006) Germany CABG or valve replacement 50g, oral Placebo¶; fasting 160 III–IV 
(Canbay et al., 2014) Turkey Open radical prostatectomy 50g, oral Fasting 50 I–II 
(Chen et al., 2014) China Open gastrectomy for cancer 50g, oral Water; fasting 36 NR 
(Chen et al., 2015) China Open gastrectomy for cancer 50g, oral Fasting 35 NR 
(Dock-Nascimento et al., 
2012) 
Brazil Laparoscopic cholecystectomy 25g, oral Water; fasting 48 I–II 
(Faria et al., 2009) Brazil Laparoscopic cholecystectomy 25g, oral Fasting 21 I–II 
(Feguri et al., 2012) Brazil CABG 25g, oral Water 40 NR 
(Harsten et al., 2012) Sweden Hip replacement 50g, oral Placebo¶ 60 I–III 
(Hausel et al., 2005) Sweden Laparoscopic cholecystectomy 50g, oral Placebo¶; fasting 172 I–II 
(Henriksen et al., 2003) Denmark Bowel resection 50g, oral Fasting 48 NR 
(Itou et al., 2012) Japan Mixed** 12.5g, oral Fasting 274 I–II 
(Jarvela et al., 2008) Finland CABG 50g, oral Fasting 101 NR 
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Table 2.1 continued       
Reference Country Type of elective surgery 
CHO dose 





(Karlsson et al., 2016) Sweden Laparoscopic Roux-en-Y gastric 
bypass 
50g, oral†† Water 51 NR 
(Kaska et al., 2010) Czechia Colorectal surgery 50g, oral; 
25g, IV 
Fasting 221 I–II 
(Lauwick et al., 2009) Belgium Thyroidectomy 50g, oral Water 200 I–II 
(Lidder et al., 2013) UK Colorectal surgery 50g, oral Placebo‡ 120 NR 
(Ljunggren and Hahn, 
2012) 
Sweden Hip replacement 50g, oral Water; fasting 57 I–III 
(Ljunggren et al., 2014) Sweden Hip replacement 50g, oral Flavoured water 22 I–III 
(Ljungqvist et al., 1994) Sweden Open cholecystectomy 250g, IV‡‡ Fasting 12 NR 
(Mathur et al., 2010) New Zealand Colorectal or liver resection 50g, oral Placebo¶ 142 I–III 
(Meisner et al., 2008) Germany Laparoscopic gynaecological 
surgery 
30g, oral§§ Fasting 42 I–II 
(Noblett et al., 2006) UK Colorectal surgery 47.5g, oral Water; fasting 35 Median 
II 
(Ozdemir et al., 2011) Turkey Hysterectomy¶¶ or inguinal 
hernia repair## 
50g, oral Water; fasting 90 I–II 
(Perrone et al., 2011) Brazil Cholecystectomy*** or inguinal 
hernia repair 
54g, oral Water 17 I–II 
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Table 2.1 continued       
Reference Country Type of elective surgery 
CHO dose 





(Pexe-Machado et al., 
2013) 
Brazil Laparotomy for gastrointestinal 
malignancy††† 
67g, oral Fasting 22 I–III 
(Raksakietisak et al., 
2014) 
Thailand Unilateral total knee joint 
replacement 
40g, oral Fasting 98 I–III 
(Rapp-Kesek et al., 2007) Sweden CABG 50g, oral Fasting 18 NR 
(Sada et al., 2014) Kosovo Colorectal resection or open 
cholecystectomy‡‡‡ 
50g, oral Placebo¶; fasting 138 I–II 
(Singh et al., 2015) India Laparoscopic cholecystectomy 25g, oral Flavoured water; 
fasting 
120 NR 
(Soop et al., 2001) Sweden Hip replacement 50g, oral Placebo¶ 15 NR 
(Soop et al., 2004) Sweden Hip replacement 50g, oral Placebo¶ 14 I–II 
(Tran et al., 2013) Canada CABG or spinal surgery with 
fusion 
50g, oral Fasting 38 NR 
(Wang et al., 2010) China Open colorectal cancer surgery 50g, oral Placebo¶; fasting 48 NR 
(Yang et al., 2012) China Open radical distal gastrectomy 50g, oral Sweetened 
water§§§ 
48 NR 
(Yildiz et al., 2013) Turkey Laparoscopic cholecystectomy 50g, oral Fasting 60 I–II 
(Yilmaz et al., 2013) Turkey Laparoscopic cholecystectomy 50g, oral Fasting 40 I–II 
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Table 2.1 continued       
Reference Country Type of elective surgery 
CHO dose 





(Yuill et al., 2005) UK Open major abdominal surgery¶¶¶ 50.4g, oral Placebo¶ 65 NR 
(Zelic et al., 2012) Croatia Colorectal cancer surgery 50g, oral Fasting 40 I–II 
*CHO dose administered within 4h of surgery start time, calculated using reported volumes and concentrations. †Multiple groups separated 
by semicolon. ‡Across multiple disciplines, as reported by the study authors; most patients underwent transperineal prostate brachytherapy. 
§The study included a treatment group of patients who were given a 2.5% oral CHO solution, to be consumed from the night before to 2h 
before surgery; this group was excluded as the amount of CHO received within 4h of surgery start time was less than 10g. ¶A specially 
formulated oral solution, reported to be indistinguishable from the CHO solution. #Oral drink containing orange juice, starch, sodium, 
saccharine and colours. **Patients underwent otorhinolaryngeal, orthopaedic, plastic, gynaecological, breast, thyroid or thoracic surgery. 
††The study included a treatment group of patients who were given a protein-rich solution containing 2.8g CHO, 2h before surgery; this 
group was excluded as the amount of CHO was less than 10g. ‡‡Calculated approximation; patients received an IV glucose infusion at 
5mg/kg/min from within 1h after the last meal on the night before surgery (approximately 06.00 hours), to within 30–60 min before induction 
of anaesthesia the following morning (between 08.30 and 12.30 hours). §§Patients were allowed an unlimited intake of an oral CHO drink; 
the reported average intake was 250 ml (30 g). ¶¶Abdominal approach. ##Patients were randomly allocated to a treatment arm within each 
of the two operative categories (major, hysterectomy; minor, inguinal hernia), and the authors reported the results for each category separately. 
***Open or laparoscopic. †††Procedures included subtotal gastrectomy, hemicolectomy and anterior resection. ‡‡‡Patients were randomly 
allocated to a treatment arm within each of the two operative categories (colorectal resection and open cholecystectomy), and the authors 
reported the results for each category separately. §§§CHO-free. ¶¶¶Procedures included liver resection, pancreatic resection and gastrectomy. 
ASA, American Society of Anesthesiologists; CHO, carbohydrate; IV, intravenous; NR, not reported; CABG, coronary artery bypass grafting.  
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One trial (Aronsson et al., 2009) could not be included in the NMA as the only relevant reported 
outcome was the aspiration pneumonitis rate, which was zero across all groups in all RCTs. 
Another trial (Singh et al., 2015) reported nausea as a mean incidence rate which could not be 
included in the NMA but is included in the qualitative synthesis. 
 
Patients in the included RCTs underwent a wide variety of open and laparoscopic surgical 
procedures for benign and malignant pathology including colorectal and upper gastrointestinal 
surgery, endocrine surgery, orthopaedic surgery, cardiothoracic surgery and gynaecological 
surgery. The majority of RCTs were conducted in Europe and involved the administration of high 
dose CHO preoperatively (mostly 45 – 55g). Two studies administered CHO intravenously (Kaska 
et al., 2010; Ljungqvist et al., 1994) and only one study directly compared low and high dose CHO 
(Kaska et al., 2010).  
 
The risk of bias assessment of the included trials is presented in Figures 2.2 and 2.3. Of the 43 
included trials, only six were judged as adequately blinded with low risk of performance or 
detection bias (Bisgaard et al., 2004; Lidder et al., 2013; Mathur et al., 2010; Soop et al., 2001; 
Soop et al., 2004; Yuill et al., 2005). There was evidence of selection bias in the majority of the 
included studies. Only two trials (Lidder et al., 2013; Mathur et al., 2010) were judged as low risk 
of bias across all domains. 
 
 


























































Figure 2.3 Risk of bias assessment by individual study 
           denotes low risk;             denotes unclear risk;        denotes high risk of bias, for each given domain, as judged by the authors. 
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2.4.2 Length of postoperative stay 
Length of postoperative stay was the most commonly reported outcome and was therefore used 
for the sensitivity analyses and funnel plot. Figure 2.4 summarises the network of direct evidence 
available for this outcome. This was reported by twenty five studies involving 1890 participants 
(An et al., 2008; Asakura et al., 2015; Braga et al., 2012; Breuer et al., 2006; Canbay et al., 2014; 
Dock-Nascimento et al., 2012; Feguri et al., 2012; Harsten et al., 2012; Hausel et al., 2005; Kaska 
et al., 2010; Lidder et al., 2013; Ljunggren and Hahn, 2012; Mathur et al., 2010; Noblett et al., 
2006; Ozdemir et al., 2011; Perrone et al., 2011; Pexe-Machado et al., 2013; Raksakietisak et al., 
2014; Sada et al., 2014; Soop et al., 2001; Soop et al., 2004; Tran et al., 2013; Yang et al., 2012; 
Yildiz et al., 2013; Yuill et al., 2005). 
 
 
Figure 2.4 Network map for evidence for length of postoperative stay 
The size of each circle (node) is proportional to the number of patients who received the treatment. 
The width of the lines represents the number of RCTs that directly compared the connected pair 
of treatments. The values in parentheses denote the number of RCTs that investigated the 
associated comparison, followed by the combined number of patients in those RCTs. 
CHO = Carbohydrate. 
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Mean length of postoperative stay in the included studies ranged from one day to seventeen. NMA 
results are presented in Figure 2.5 and Table 2.2. Compared to fasting, patients administered CHO 
preoperatively were discharged earlier (high dose CHO 0.2 SD earlier [SMD, 95% CI 0.04 – 0.4], 
low dose CHO 0.4 SD earlier [SMD, 95% CI 0.03 – 0.7]). On back-transformation into days, high 
dose CHO administration decreased length of stay for patients undergoing major surgery (mean 
length of stay >2 days) by 0.7 days (95% CI 0.1 – 1.4), and for patients undergoing minor surgery 
(mean length of stay <2 days) by 0.07 days (95% CI 0.01 – 0.1). When compared to water or 
placebo, no significant benefit was shown for either low or high dose CHO with respect to time to 
hospital discharge. No statistically significant difference was found between the two CHO groups 
in the network. None of the treatments was clearly superior on calculation of ranking probabilities 
for this outcome.  
 
 
Figure 2.5 Composite forest plot of comparisons for length of postoperative stay 
Boxes and horizontal lines represent the standardised mean difference and 95% confidence 
intervals for each comparison, respectively. 




Table 2.2 Network meta-analysis results 
 vs Fasting vs Water/Placebo vs Low dose CHO 
Length of postoperative stay 
High dose CHO* 
Low dose CHO* 
-0.2 SD (-0.4, -0.04) † 
-0.4 SD (-0.7, -0.03) † 
-0.2 SD (-0.4, 0.02) 
-0.3 SD (-0.7, 0.05) 




High dose CHO 
Low dose CHO 
Minor Surgery¶ 
High dose CHO 
Low dose CHO 
 
 
-0.7 days (-1.4, -0.1) † 
-1.4 days (-2.4, -0.1) † 
 
-0.07 days (-0.1, -0.01) † 
-0.1 days (-0.2, -0.01) † 
 
 
-0.7 days (-1.4, 0.07) 
-1.0 days (-2.4, 0.2) 
 
-0.07 days (-0.1, 0.01) 
-0.1 days (-0.2, 0.02) 
 
 
0.3 days (-0.7, 1.7) 
 
 
0.04 days (-0.07, 0.2) 
Subgroup Analysis# 
Major Abdominal Surgery 
High dose CHO 
Low dose CHO 
Minor Abdominal Surgery 
High dose CHO 
Low dose CHO 
Orthopaedic Surgery 
High dose CHO 
Low dose CHO 
 
 
-1.7 days (-3.2, -0.1) † 
-1.9 days (-5.2, 1.5) 
 
-0.09 days (-0.4, 0.2) 
-0.07 days (-0.5, 0.4) 
 
-0.7 days (-2.3, 1.0) 
0.0 days (-2.0, 2.0) 
 
 
-1.4 days (-2.7, -0.1) † 
-1.6 days (-5.1, 1.9) 
 
0.0 days (-0.05, 0.05) 
0.02 days (-0.4, 0.4) 
 
-0.3 days (-1.0, 0.4) 
-0.3 days (-2.2, 2.9) 
 
 
0.2 days (-3.1, 3.6) 
 
 
-0.02 days (-0.4, 0.4) 
 
 




Table 2.2 continued    
 vs Fasting vs Water/Placebo vs Low dose CHO 
Length of postoperative stay (continued) 
Subgroup analysis (continued)# 
Cardiac Surgery 
High dose CHO 
Low dose CHO 
 
 
-0.5 days (-3.4, 2.3) 
-2.9 days (-7.8, 2.0) 
 
 
0.4 days (-3.1, 3.9) 
-2.0 days (-5.4, 1.5) 
 
 
2.4 days (-2.5, 7.2) 
Postoperative complication rate** 
High dose CHO 
Low dose CHO 
1.0 (0.6, 2.0) 
1.0 (0.4, 2.5) 
0.8 (0.6, 1.2) 
0.8 (0.3, 2.0) 
1.0 (0.4, 2.5) 
Vomiting** 
High dose CHO 
Low dose CHO 
1.4 (0.7, 3.2) 
1.0 (0.6, 1.7) 
1.2 (0.6, 2.4) 
0.9 (0.3, 2.1) 
1.4 (0.6, 3.4) 
Insulin resistance# 
High dose CHO 
Low dose CHO 
-2.2 (-4.3, -0.09) † 
-1.4 (-4.9, 2.1) 
-2.5 (-4.9, -0.2) † 
-1.8 (-5.2, 1.7) 
-0.8 (-4.5, 2.9) 
Insulin sensitivity#†† 
High dose CHO 1.2 ml/kg/min (-1.0, 3.4) 0.2 ml/kg/min (-0.7, 1.0)  
Nausea*†† 
High dose CHO 
 
 
-0.6 (-1.4, 0.07) -0.7 (-1.1, -0.2) †  
34 
 
Table 2.2 continued    
 vs Fasting vs Water/Placebo vs Low dose CHO 
Postoperative well-being* 
High dose CHO 
Low dose CHO 
0.1 (-0.2, 0.4) 
0.06 (-0.6, 0.7) 
-0.01 (-0.3, 0.2) 
-0.01 (-0.8, 0.6) 
0.06 (-0.6, 0.7) 
Postoperative fatigue*†† 
High dose CHO -0.08 (-0.7, 0.5) 0.1 (-0.3, 0.5)  
Return of intestinal function (time to first bowel motion#††) 
High dose CHO -0.5 days (-1.6, 0.6) -0.8 days (-2.0, 0.3)  
*Standardised mean difference (unit is standard deviations). †P < 0.05. ‡The standardised mean difference was converted back to a mean 
difference in days, using the standard deviations reported in the included trials. §The mean standard deviation (3.4 days) of all trials reporting 
major surgery (mean length of stay greater than 2 days) was used in this calculation, the mean length of stay in this group was 8.1 days. ¶The 
mean standard deviation (0.4 days) of all trials reporting minor surgery (mean length of stay less than 2 days) was used in this calculation, 
the mean length of stay in this group was 1.1 days. #Mean difference. **Odds ratio. ††No low dose CHO data available for this outcome. 
CHO = Carbohydrate. SD = Standard deviation.
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Meta-regression also demonstrated no relationship between CHO dose and length of postoperative 
stay (Figure 2.6), with none of the heterogeneity in the model explained by the dose of 
carbohydrate administered (R2 = 0) (Harbord and Higgins, 2008). Cumulative meta-analysis of 
high dose CHO versus control showed that further studies are unlikely to significantly change this 
effect estimate (Figure 2.7). 
 
 
Figure 2.6 Meta-regression (Bubble Plot) for length of postoperative stay 
The circles represent the effect estimate from each study, sized according to the precision of each 
estimate. The line of best fit (regression line) is almost horizontal, suggesting no relationship 
between CHO dose and length of postoperative stay.  







Figure 2.7 Cumulative meta-analysis (length of postoperative stay)  
Trials comparing high dose carbohydrate loading with fasting, water or placebo. 
CI = Confidence interval. (chole) = Cholecystectomy. (colon) = Colonic resection. (mj) = Major 
surgery. (mn) = Minor surgery. SMD = Standardised mean difference. 
 
Testing for inconsistency between the direct and indirect evidence for this analysis yielded low 
inconsistency factors for all evidence loops, ranging from 0.06 to 0.4. There were also no 
significant differences between the results obtained using the direct evidence alone, the indirect 
evidence alone, and the combined network. All predictive intervals for the comparisons in this 
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analysis included zero, indicating moderate between-study heterogeneity. All sensitivity analyses 
showed similar results to the main analysis.  
 
Subgroup analysis results are presented in Table 2.2. Except for two comparisons within the major 
abdominal surgery subgroup (defined as a mean length of postoperative stay of more than two 
days), none of the other subgroup comparisons showed a statistically significant difference. 
Inconsistency between the direct and indirect evidence for the major abdominal surgery subgroup 
was high (inconsistency factor of 2.4, with 95% CI up to 11.0), and all the predictive intervals in 
this subgroup included zero.  
 
Visual inspection of a comparison-adjusted funnel plot for this outcome (Figure 2.8) suggests the 
presence of publication bias towards studies reporting a significant difference between the CHO 
groups and the controls. 
 
2.4.3 Postoperative complications 
This outcome was reported by seventeen studies, involving 1094 participants (Braga et al., 2012; 
Dock-Nascimento et al., 2012; Faria et al., 2009; Hausel et al., 2005; Kaska et al., 2010; Lidder et 
al., 2013; Mathur et al., 2010; Noblett et al., 2006; Perrone et al., 2011; Pexe-Machado et al., 2013; 
Soop et al., 2001; Soop et al., 2004; Tran et al., 2013; Yang et al., 2012; Yilmaz et al., 2013; Yuill 
et al., 2005; Zelic et al., 2012). All NMA comparisons for this outcome showed no statistically 
significant difference (Table 2.2).  
 
Sensitivity analysis showed that exclusion of one trial with a much higher complication event rate 
than the other studies (Tran et al., 2013) did not significantly alter the results. Inconsistency 
analysis showed no evidence of a significant difference between the direct and indirect evidence 






Figure 2.8 Comparison-adjusted funnel plot (length of postoperative stay) 
The zero central line represents the null hypothesis that the study-specific effect sizes do not differ 
from the comparison-specific pooled estimates. Different coloured points on the plot represent the 
different comparisons, as in the key. 
CHO = Carbohydrate. 
 
2.4.4 Secondary outcomes 
Aspiration pneumonitis 
There were no aspiration pneumonitis events reported in any of the nineteen studies that reported 
this outcome (Aronsson et al., 2009; Bisgaard et al., 2004; Canbay et al., 2014; Dock-Nascimento 
et al., 2012; Itou et al., 2012; Jarvela et al., 2008; Lidder et al., 2013; Mathur et al., 2010; Meisner 
et al., 2008; Noblett et al., 2006; Perrone et al., 2011; Raksakietisak et al., 2014; Soop et al., 2001; 
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Soop et al., 2004; Tran et al., 2013; Wang et al., 2010; Yang et al., 2012; Yildiz et al., 2013; Yuill 
et al., 2005) therefore NMA was not performed. 
 
Vomiting 
Eight studies (Bisgaard et al., 2004; Faria et al., 2009; Feguri et al., 2012; Hausel et al., 2005; Itou 
et al., 2012; Jarvela et al., 2008; Raksakietisak et al., 2014; Yang et al., 2012) reported the rate of 
postoperative vomiting, involving 820 participants. NMA results are summarised in Table 2.2. 
There were no statistically significant differences between the groups in the network. 
Inconsistency for this analysis was low (inconsistency factor of up to 0.4). 
 
Insulin resistance 
Thirteen studies (Canbay et al., 2014; Chen et al., 2014, 2015; Dock-Nascimento et al., 2012; Faria 
et al., 2009; Feguri et al., 2012; Mathur et al., 2010; Perrone et al., 2011; Pexe-Machado et al., 
2013; Rapp-Kesek et al., 2007; Tran et al., 2013; Wang et al., 2010; Yang et al., 2012) measured 
insulin resistance using the HOMA-IR method, involving 503 participants. Table 2.2 shows the 
NMA results for all the comparisons in this network. High dose CHO administration resulted in a 
statistically significant decrease in insulin resistance compared to fasting, and water or placebo, 
but with wide confidence intervals approaching non-significance. One study (Wang et al., 2010) 
reported very different numerical results compared to all other trials, despite reporting the same 
methodology and formulae. Sensitivity analysis excluding this study showed no statistically 
significant differences between any of the groups. Inconsistency in this network was high 
(inconsistency factors of 2.4 and 4.8).  
 
Insulin sensitivity 
Four studies (Ljunggren et al., 2014; Ljungqvist et al., 1994; Soop et al., 2001; Soop et al., 2004) 
involving 62 participants measured insulin sensitivity using the hyperinsulinaemic-euglycaemic 
clamp method. No low dose CHO studies were available for this outcome. NMA showed no 
significant difference in any of the comparisons (Table 2.2).  
 
Nausea 
This was reported by four studies (Hausel et al., 2005; Karlsson et al., 2016; Mathur et al., 2010; 
Sada et al., 2014) with data available on 423 participants. All used a visual analogue scale. NMA 
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showed that administration of high dose CHO resulted in a moderate reduction in nausea (0.7 SD 
[SMD, 95% CI 0.2 – 1.1]) compared with water or placebo, but no statistically significant 
difference when compared with fasting (Table 2.2). All predictive intervals for this analysis 
included zero (no significant difference). Sensitivity analysis (reported vs imputed data) showed 
that exclusion of one study (Sada et al., 2014) resulted in no statistically significant findings 
between high dose CHO and either control treatment node.  
 
A further study (Singh et al., 2015) reported this outcome at various postoperative time points in 
a three-arm RCT comparing preoperative fasting, oral placebo and oral low dose CHO. This could 
not be incorporated in the NMA as the authors reported only a mean incidence count at each time 
point. They found no statistically significant difference at time points beyond 12h after surgery. 
 
Postoperative well-being 
This was reported by six studies (Asakura et al., 2015; Bisgaard et al., 2004; Henriksen et al., 
2003; Ljunggren and Hahn, 2012; Mathur et al., 2010; Meisner et al., 2008), most using a visual 
analogue scale, with data available on 443 participants. NMA found no significant difference 
between the groups in any of the comparisons (Table 2.2). The inconsistency factor for this 
analysis was low (0.2). 
 
Postoperative fatigue 
Six studies (Bisgaard et al., 2004; Harsten et al., 2012; Henriksen et al., 2003; Lauwick et al., 
2009; Mathur et al., 2010; Yildiz et al., 2013) reported postoperative fatigue scores using a visual 
analogue or ten-point ordinal scale, with data available on 576 patients. None of the studies 
investigating low dose CHO reported this outcome. There were no significant differences in any 
of the comparisons within the network (Table 2.2). 
 
Return of intestinal function 
Two studies (An et al., 2008; Noblett et al., 2006) reported time to passage of flatus, so there were 
insufficient data to perform NMA. One (An et al., 2008), involving 51 patients, reported a 
reduction of 0.4 days in the time to postoperative passage of flatus in patients given high dose 
CHO compared to patients who were fasted before surgery. The other study (Noblett et al., 2006) 
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was a three-arm trial (high dose CHO, water and fasting) that found no significant difference 
between the groups. 
 
Two studies (Noblett et al., 2006; Ozdemir et al., 2011) reported time to passage of first bowel 
motion, with one (Ozdemir et al., 2011) reporting the outcome for patients undergoing major and 
minor abdominal surgery separately. Both studies investigated high dose CHO administration 
compared with fasting and water in a three-arm design. NMA showed no significant differences 




This NMA shows that administration of a preoperative CHO load within four hours of surgery 
start time led to a small reduction in length of postoperative stay when compared to fasting, but no 
significant effect compared to allowing patients water or a placebo drink before surgery.  
Heterogeneity analysis for this outcome using predictive interval calculations showed moderate 
between study heterogeneity, and evidence of publication bias was suggested on examination of 
the comparison-adjusted funnel plot.  Further, sensitivity analysis splitting the water/placebo node, 
then the placebo subgroup into blinded and un-blinded studies showed no significant difference 
between any of the placebo groups and the CHO groups. In addition, cumulative MA of this 
outcome also suggests that future studies are unlikely to show a larger effect than in this review. 
 
SMD was used for length of postoperative stay to account for the wide variety in expected length 
of stay between the different procedures. Procedures with differing expected lengths of stay cannot 
be directly compared using MD as any effect of CHO administration could be expected to be 
proportional to the actual length of stay. SMD can be interpreted using rules of thumb (Higgins 
and Green, 2011) where an SMD of 0.4 SD or less is considered to indicate a small effect, 
suggesting that the difference found between the CHO and fasting groups was small. The back-
transformation results support this conclusion, showing a reduction in length of stay of 
approximately 10% in both CHO groups compared to fasting.  It is important not to conclude from 
the subgroup analysis that the effect of preoperative CHO loading on major abdominal surgery is 
larger than on other procedures as the relative reduction in length of stay was similar between 




This review found no evidence that high dose CHO was more or less effective in reducing length 
of stay compared to low dose CHO. Available data for low dose CHO in the network were much 
fewer, highlighted by wider confidence intervals than the high dose CHO comparisons. Sensitivity 
analysis using meta-regression supported this finding, showing no evidence of a CHO dose-
response relationship.  
 
There was no significant difference in the postoperative complication rate for patients given a 
CHO load compared to patients who remained fasted or those who were given water or a placebo 
drink. Although high dose CHO conferred a reduction in nausea scores at 24 hours compared to 
water or placebo, this was based on a small number of studies and there was no statistically 
significant difference in the incidence of vomiting between the groups. No other significant 
differences were found between the CHO and control groups in any of the other clinical secondary 
outcomes investigated. The confidence intervals for some of these outcomes were wide however, 
reflecting a relative paucity of available data and heterogeneity. No instances of aspiration 
pneumonitis were reported in any of the trials. 
 
The effect of CHO loading on postoperative insulin resistance was investigated as it is this effect 
in particular that provided the rationale for introducing preoperative CHO loading (Ljungqvist et 
al., 2002; Nygren et al., 1998). There was no statistically significant difference in insulin 
sensitivity (measured by the gold standard hyperinsulinaemic-euglycaemic clamp method) in this 
NMA. This may however be a type II error (false negative finding) as only four studies were 
available to assess insulin sensitivity. Further, a statistically significant difference in insulin 
resistance (measured by homeostatic modelling) between high dose CHO and both control 
treatment groups was found, though with high inconsistency, and sensitivity analysis suggesting 
this finding was influenced by the reported results of a single study (Wang et al., 2010). A 
reduction in postoperative insulin resistance per se may not be clinically important unless it in turn 
leads to improved postoperative outcomes. 
 
Three previous MAs have investigated the effect of preoperative CHO loading (Awad et al., 2013; 
Li et al., 2012; Smith et al., 2014). The findings of this present review are broadly consistent with 
the largest and most recent of these (Smith et al., 2014), which included 27 trials and found a small 
43 
 
decrease (0.4 days) in length of postoperative stay for patients given a CHO load (high dose) only 
when compared to fasting, an increase in insulin sensitivity compared to the control treatments 
and a shorter time to passage of flatus by less than half a day. No other significant differences were 
found for an identical set of outcomes as this review. 
 
This is the first review on this subject to use NMA methodology. This has allowed the 
incorporation of more data than all previous reviews and the use of all the direct and indirect 
evidence available, thereby increasing the precision of the effect estimates. The fasting, 
water/placebo and CHO dosing regimens were also analysed simultaneously as separate groups in 
a manner that fully respects randomisation (Caldwell et al., 2005), unlike subgroup analysis  (Sun 
et al., 2014), thus eliminating an important source of clinical heterogeneity and bias in previous 
MAs. This increases the external validity and applicability of these results. The review process 
and quality assessment were conducted in accordance with the Cochrane Collaboration’s 
recommended standard methodology (Higgins and Green, 2011) and the PRISMA guidelines for 
NMA (Hutton et al., 2015).  
 
There are some potential limitations to this study. Firstly, the validity of the results of any MA is 
dependent to a large degree on the quality of included trials, and most trials were of low to 
moderate quality with the risk of performance and selection bias being of particular concern. A 
lack of well-designed, placebo controlled trials in particular led to the combination of placebo and 
water into one group for the main analysis. This issue was addressed through sensitivity analysis 
by splitting the groups, which did not show significantly different results. Secondly, there was 
evidence of moderate statistical heterogeneity and inconsistency between the direct and indirect 
evidence for some outcomes. This is to be expected given the heterogeneity in trial design, 
endpoints measured and clinical settings. Nevertheless, subgroup and sensitivity analyses to 
explore this heterogeneity did not reveal significantly different results. Thirdly, comparisons 
involving low dose CHO administration for some outcomes were informed by only one or two 
head-to-head RCTs, with the majority of data derived from indirect evidence. Although this may 
affect the power and reliability of those effect estimates (Mills et al., 2013), all the results for high 
dose CHO administration were comparable, suggesting that the true effect of low dose CHO 




Current anaesthetic guidelines recommend allowing patients clear fluids up to two hours before 
surgery (American Society of Anesthesiologists, 2011; Smith et al., 2011),  based on the 
established safety of this practice in patients who are not at high risk of aspiration (Brady et al., 
2003). Recently published ERAS guidelines strongly recommend the routine use of oral 
carbohydrate loading before a variety of elective procedures including colonic resection 
(Gustafsson et al., 2013), rectal/pelvic surgery (Nygren et al., 2013), gastrectomy (Mortensen et 
al., 2014), pancreaticoduodenectomy (Lassen et al., 2012) and radical cystectomy (Cerantola et 
al., 2013). This is despite an acknowledgement that the evidence supporting this recommendation 
is of low to moderate quality, and for some procedures only by extrapolation (Cerantola et al., 
2013; Lassen et al., 2012; Mortensen et al., 2014). This review, incorporating the results of over 
40 RCTs and involving over 3000 patients, shows that the administration of preoperative CHO 
within four hours of surgery start time is safe but may not provide a clinically relevant benefit over 
water or a flavoured drink with no calories. This needs to be considered when developing elective 
ERAS protocols, particularly given the costs involved in routine CHO loading. Future trials 





This review represents the most comprehensive synthesis of the available evidence to date, and 
demonstrates the utility of NMA in synthesising surgical RCT data when different control 
treatments have been used. It shows that CHO loading before elective surgery confers a small 
reduction in length of stay when compared to fasting, but no significant difference when compared 
to water or placebo. No other clinically relevant effect on post-operative outcomes was found.  
 
Therefore, current RCT evidence does not support routine preoperative CHO loading for adults 
undergoing elective surgery. This is acknowledged in the latest ERAS guidelines by the Society 
of American Gastrointestinal and Endoscopic Surgeons, and the American Society of Colon and 
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3.1 Chapter summary 
Proton pump inhibitors (PPI) are the mainstay of treatment for GORD, but are associated with 
ongoing cost and side effects. Anti-reflux surgery is cost-effective, and is preferred by many 
patients. A total (360o or Nissen) fundoplication is the traditional procedure, but other variations 
including partial fundoplications are also commonly performed, with the aim of achieving durable 
reflux control with minimal dysphagia. Many RCTs and some pairwise MAs have compared some 
of these procedures but there is ongoing uncertainty about which, if any, is superior. NMA allows 
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for multiple simultaneous comparisons and robust synthesis of the available evidence in these 
situations. An NMA comparing all anti-reflux procedures was performed, to identify which has 
the most favourable outcomes at short (3 – 12 months), medium (1 – 5 years) and long-term (6 – 
10 years, and > 10 year) follow-up. Article databases were systematically searched for all eligible 
RCTs. Primary outcomes were quality of life measures and dysphagia. Secondary outcomes 
included reflux symptoms, pH studies and complications. NMA was performed using Stata 13.1 
routines. Fifty one RCTs were included, involving 5357 patients, and fourteen different treatments. 
Posterior partial fundoplication (PPF) ranked best in terms of control of reflux symptoms, and 
caused less dysphagia compared to most other interventions including Nissen fundoplication. This 
was consistent across all time-points and outcome measures. This study shows that PPF provides 
the best balance of long-term, durable reflux control with less dysphagia, compared to other 
treatments. PPF should be considered the standard intervention for the surgical management of 




GORD affects up to 20% of the population in the Western world (Dent et al., 2005). PPI therapy 
has been the mainstay of treatment for GORD for the last twenty years, with surgery reserved 
mainly for patients with refractory GORD (Wileman et al., 2010). However the cost, 
inconvenience and potential side effects of long-term acid suppression mean many patients prefer 
surgery (Broeders et al., 2010; Grant et al., 2013), and several recent RCTs have confirmed the 
long-term cost-effectiveness of surgical intervention compared with continued medical therapy 
(Anvari et al., 2011; Faria et al., 2013; Goeree et al., 2011; Grant et al., 2013). Surgical procedures 
for GORD largely involve a fundoplication, or the creation of a flap valve and higher pressure 
zone, by wrapping the gastric fundus around the gastro-oesophageal junction (Mackay et al., 
2010). Several variations of this are commonly performed including a total (360o or Nissen) 
fundoplication (NF) (Nissen, 1956), and partial fundoplications positioned either posterior or 
anterior to the oesophagus as it enters the abdomen via the oesophageal hiatus of the diaphragm. 
The aim of partial wraps is to reduce the incidence of dysphagia and other obstructive side effects 





More than fifty RCTs have compared various fundoplication procedures, involving thousands of 
patients and years of follow-up data. Although many have been pooled in pairwise MAs, all these 
MAs have inherent limitations as they have either combined different fundoplication techniques 
together to allow a head-to-head analysis (Broeders et al., 2011; Ma et al., 2012; Memon et al., 
2015; Varin et al., 2009), or compared only two techniques in isolation (Broeders et al., 2010; 
Broeders et al., 2013; Shan et al., 2010; Tan et al., 2011). It therefore remains difficult more than 
40 years after the first RCT was published (Demeester et al., 1974), to determine which 
fundoplication technique is superior both in terms of reflux control and potential harms (Fuchs et 
al., 2014). Some calls have been made for even more RCTs (Thompson and Watson, 2015), while 
others have suggested that the choice of procedure should be left to the surgeon as it is not possible 
to determine which technique is best (Daud et al., 2015; Stefanidis et al., 2010).  
 
NMA allows for simultaneous comparison and ranking of multiple different treatments for a given 
condition, as explained in Chapter 1. This chapter details the results of a systematic review and 
NMA comparing all anti-reflux procedures subjected to RCT evaluation in adults with GORD, to 
identify which technique has the most favourable outcome profile in terms of reflux control and 
side effects such as dysphagia. As the degree of reflux control and prevalence of dysphagia can 
change considerably over time following surgery, data from four different follow-up time points 




This study was conducted in accordance with the Cochrane Collaboration’s recommended 
methodology (Higgins and Green, 2011) and PRISMA guidelines (Moher et al., 2009), including 
those specifically concerning NMA (Hutton et al., 2015). The study protocol was prepared and 
published a priori (Amer et al., 2014). 
 
3.3.1 Search strategy and selection criteria 
All randomised and quasi-randomised clinical trials that compared surgical procedures 
(laparoscopic or open) for the treatment of GORD or a surgical procedure with best medical 




Studies that enrolled adult participants with an established diagnosis of GORD based on symptoms 
and an objective measure such as endoscopy or pH manometry, and who were deemed appropriate 
for surgical management, were included. Studies that included patients with established Barrett's 
or extra-oesophageal symptoms only were excluded.  
 
Trials assessing endoscopic treatment of GORD were excluded. Non-fundoplication procedures, 
including those discontinued because of safety concerns (Kmiot et al., 1991) were included, but 
subjected to sensitivity analysis. Interventions with other variations such as different wrap lengths, 
omission of a hiatoplasty or fixation to the right hiatal pillar as part of the procedure, were 
permitted, but such variations were noted. Interventions involving fundoplication in combination 
with another procedure (such as Heller's myotomy for achalasia) were excluded. Authors of 
published trials were contacted for clarification when randomisation status was not clear. 
 
The following article databases and grey literature sources were searched, using a structured search 
strategy (Appendix C1), to identify eligible trials: 
1. The Cochrane Central Register of Controlled Trials (CENTRAL), to March 2017 
2. MEDLINE (1966 to March 2017). 
3. EMBASE (1980 to March 2017). 
4. Web of Science (1945 to March 2017). 
 
No language, publication status or year of publication restrictions were applied. All citations were 
in English, as translated by the databases. Abstracts and full texts in French, German and Japanese 
were able to be translated by the data extractors. Studies in other languages were translated using 
Google translate (Jackson et al., 2019). The search strategy was developed in consultation with an 
expert health librarian using a combination of subject headings and free text terms relating to the 
surgical treatment of GORD. The Cochrane sensitivity maximising search strategy was used to 
search for RCTs in MEDLINE (Higgins and Green, 2011). The British Medical Journal's 





The reference lists of all eligible studies and of reviews of the topic were also hand-searched to 
identify any additional studies. Experts in the field were contacted to identify any unpublished 
research or ongoing trials. 
 
In addition, the World Health Organisation's International Clinical Trials Registry Platform and 
clinicaltrials.gov were searched to identify ongoing trials. Contact authors were then approached 
by letter or email requesting any available information to date. 
 
The results of searches from both the electronic databases and other resources were combined in 
a spreadsheet. Duplicate citation records and publications were excluded. Multiple publications of 
the same trial were retained in case different outcome data were reported in each. Two authors 
independently screened all titles and abstracts for eligibility. The full text of potentially eligible 
trials were subsequently obtained and reviewed against the pre-defined inclusion criteria. Any 
exclusions at this point were independently recorded (together with the reason for exclusion) 
before a final list of included trials was drawn up. Disagreements were resolved by discussion and 
consensus, and arbitration by a third author when required.  
 
3.3.2 Outcome measures 
Trials that reported any of the following outcomes were included. 
 
Primary outcomes: 
1. General/health-related quality of life scores, measured on an appropriate validated tool. A higher 
value indicated better quality of life. 
2. GORD/gastrointestinal-specific quality of life scores, measured on an appropriate validated 
tool. A higher value indicated better quality of life. 
3. Dysphagia, measured either as a dichotomous variable or on a validated scale (such as Dakkak). 
A higher scale value indicated less dysphagia (as per Dakkak’s original description (Dakkak and 
Bennett, 1992)). 
 
Secondary outcomes:   
1. Reflux symptoms, measured as a dichotomous variable or on a patient-reported scale. A higher 
scale value indicated more reflux. 
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2. Oesophageal acid exposure, measured as a DeMeester score or similar. A higher value indicated 
more acid exposure. 
3. Total oesophageal acid exposure time (as a percentage) on pH monitoring. A higher value 
indicated a longer acid exposure time. 
4. Dilatation for dysphagia rate, defined as the need for oesophageal dilatation for symptomatic 
dysphagia postoperatively. 
5. Reoperation rate, defined as the number of patients who required revision surgery for ongoing 
symptoms, severe dysphagia and/or objective findings of persistent GORD during follow-up. 
6. Postoperative complications as defined by the trial authors. 
7. Gas bloat syndrome (Walker et al., 1992), measured as a dichotomous variable or on a patient-
reported scale. A higher value indicated more gas bloat. Data on hyper-flatulence, epigastric pain 
or abdominal bloating in isolation were not considered indicative of gas bloat syndrome and were 
not included. 
 
For each of these outcomes, different scales with an opposite direction of severity were inverted 
by subtracting the mean from the maximum possible value for the scale, to ensure all scales point 
in the same direction (Higgins and Green, 2011).  
 
Composite patient satisfaction scores (such as Visick) were not used as these do not specify which 
symptom patients are suffering from, and so cannot be used to assess reflux or dysphagia, and are 
not validated quality of life assessment tools. Similarly, gastrointestinal symptom rating scale 
scores were only used when subscores for reflux were reported separately. 
 
3.3.3 Data extraction and quality assessment 
A structured, pre-piloted data extraction form based on the Cochrane Collaboration's Data 
Collection Form Template (Cochrane, 2013) was used by two authors to independently extract and 
record data, including study design, patient and intervention characteristics and outcome data 
(Appendix C2). Continuous (score) and dichotomous (rate) data for each outcome were both 
included and recorded separately. For all primary outcomes and all secondary outcomes except 
postoperative complications data were collected and analysed separately in four groups according 
to follow-up time, where enough data were available to make this meaningful:  
1. From 3 months, up to and including 1 year. 
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2. From over 1 year, up to and including 5 years. 
3. From over 5 years, up to and including 10 years. 
4. Over 10 years. 
 
Where one trial reported the same outcome for different follow-up time points, data were included 
in the appropriate groups ensuring that duplication was avoided. Where trials reported two sets of 
data for the same outcome within the same time point (such as three years and four years), the 
most recent data (four years in this example) were included.  
 
Discrepancies were resolved by discussion with arbitration by a third author when required. 
Requests for further data were made when required by emailing the contact author of the relevant 
trial, where an email address was available. 
 
Where data were missing or not available, study authors were contacted to request this, where an 
email address was available. Missing statistics such as standard deviations were calculated from 
reported data where possible (Higgins and Green, 2011; Hozo et al., 2005). When standard 
deviations could not be calculated and attempts to contact study authors were exhausted, these 
were imputed using the reported standard deviations from other trials that used the same 
measure/scale where possible. Sensitivity analysis was performed to explore the effect of imputed 
versus reported data. 
 
Where trials used a combination of different surgical techniques (i.e. more than one type of 
fundoplication) in one arm, individual patient data were sought where this was not reported. If this 
was not available, the trial was excluded. The review protocol had stated that such trials would be 
included in the analysis if more than 80% of patients in the affected arm of the study underwent 
the same single procedure, but no such instances were encountered. 
 
The methodological quality of each included study was independently assessed by two authors as 
part of the data extraction process. This was based on the Cochrane Collaboration's Risk of Bias 
tool (Higgins et al., 2011), using the following domains: random sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete 
outcome data, selective outcome reporting, and any other potential sources of bias (such as 
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baseline imbalances or differential diagnostic activity). Each domain was assessed as low risk, 
high risk, or unclear. Disagreements were resolved by discussion and arbitration by a third author 
where consensus could not be reached. 
 
3.3.4 Statistical analysis 
A random-effects NMA was performed using the suite of specific Stata (StataIC 13, StataCorp 
LP., College Station, Texas) routines available for this (Chaimani et al., 2013; Chaimani and 
Salanti, 2015; White, 2015). The main analysis comprised up to 14 treatment groups representing 
the treatments for which data were available for that outcome and follow-up time point, with PPI 
allocated as the reference treatment. Fundoplications were divided into groups as follows: 
1. Total (360o) or Nissen fundoplication (with or without the division of the short gastric arteries, 
and with or without the use of a bougie). 
2. 90o fundoplication. 
3. Anterior partial fundoplication (APF, 120o or more). 
4. Posterior partial fundoplication (PPF, 180o or more). 
 
Where no data for PPI were available, a fundoplication technique (90o, APF, PPF) was instead 
allocated as the reference, in that order. Network maps for each outcome were produced to provide 
a visual summary of the network of evidence available. 
 
For outcome time points with data available from five RCTs or more, and statistically significant 
differences between the treatments, the probability of each fundoplication technique (and PPI, as 
the reference) ranking as the best, second, third, fourth or worst treatment in the network was 
calculated, and presented as a rankogram. Rankings were otherwise not calculated to avoid over-
interpretation (Dias et al., 2012). Where enough data were available, the ranking  scores (surface 
under the cumulative ranking curve (SUCRA)) for the most commonly reported effectiveness 
(reflux) and adverse (dysphagia) outcomes were then combined by time point into clustered 
ranking plots, to enable a simultaneous comparison of benefit and harm between the treatments. 
 
For each comparison between different techniques, continuous data were summarised as an MD 
(with units) or SMD (expressed as SD), as appropriate, with 95% CI. An SMD was used when 
studies assessing the same outcome used different measures or scales which were not possible to 
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compare directly. Categorical data were summarised as odds ratios with 95% CI. An intention-to-
treat analysis was used. 
 
The following sensitivity analyses were performed for all individual outcome time point analyses 
where possible. Firstly, the analysis was rerun excluding all non-fundoplication procedures (but 
including PPI as the reference treatment where possible). Secondly, the Nissen node in the 
fundoplication/PPI analysis (above) was split into up to four nodes according to whether a bougie 
was used or not and whether the short gastric vessels were preserved or divided, to address the 
heterogeneity of that node. Studies that used Nissen fundoplication but did not specify these 
variables were excluded from this analysis, whereas studies that compared two such Nissen 
variations (and were therefore excluded from the main analysis) were included. Thirdly, the 
influence of imputed versus reported data was assessed by excluding studies where data were 
imputed and comparing the results with the main analysis. Post-hoc sensitivity analysis was also 
performed for the dysphagia and reflux networks by serially excluding trials that included a PPF 
arm, to assess whether one trial significantly influenced the results, and by moving 120 degree 
fundoplication from the APF node to the 90o fundoplication node. Sensitivity analysis results were 
reported if they were significantly different from the main analysis results. 
 
Statistical heterogeneity was assessed by calculating predictive intervals (Chaimani et al., 2013). 
Inconsistency in the evidence structure was also assessed (Dias et al., 2010) by calculating the 
difference between the direct and indirect estimates (the inconsistency factor) in each closed loop 
formed by the network of trials. Any significant inconsistencies were investigated further to 
determine possible causes, where enough data were available. Publication bias was assessed by 
visual inspection of comparison-adjusted funnel plots (Chaimani et al., 2013) for primary 




3.4.1 Search results and study characteristics 
The database search and study selection process is summarised in Figure 3.1. Fifty one RCTs 
(reported in 77 papers with eligible data) were included, involving 5357 patients, and 13 different 
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surgical procedures in addition to PPIs (Table 3.1). The most common comparison was NF versus 
PPF, and NF was compared to every other fundoplication in at least three RCTs.  
 
Table 3.2 details the characteristics and relevant outcomes of each included RCT, and Table 3.3 
summarises the number of trials and patients for which data were available for each outcome and 
follow-up time point. 
 
 
Figure 3.1 Systematic search and study selection flowchart 
* Includes duplicate publications, and papers reporting results for an included trial with no 
additional relevant data 




Table 3.1 Summary of included trials 
 Trials* Patients† Publication year‡ Trial Location 
Europe Americas Oceania Asia/Africa 
Nissen vs. PPF 19 2153 1989 – 2015  14 2  3 
Nissen vs. APF 6 530 2004 – 2016  3  1 2 
Nissen vs. 90o fundoplication 3 225 1989 – 2012  1  2  
Nissen vs. PPI 3 803 2008 – 2011  2 1   
PPF vs. APF 4 339 2007 – 2017 3  1  
PPF vs. 90o fundoplication 1 32 1989 1    
        
Nissen vs. Angelchik 3 163 1984 - 1994 3    
Nissen vs. Hill 2 132 1974 - 2012  2   
Nissen vs. Other§ 7 706 1974 - 2015 4 3   
PPF vs. FND 360o 1 252 2012  1   
        
NSGVD vs. NSGVP 6 438 1999 – 2009 4 1 1  
Bougie vs. no bougie¶ 1 171 2000  1   
        
BM IV vs. Hill repair 1 30 1974  1   
*The number of trials reporting this comparison. Three arm trials are therefore included three times in this table, to account for all three direct 
pairwise comparisons in them. †The total number of patients randomised to each comparison. The number for whom data were reported for 
different outcomes at different time-points varies. Patients recruited in three-arm trials are counted twice to account for the two direct 
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comparisons each patient was involved in. ‡Year each trial’s index paper was published. Subsequent follow-up papers were included in this 
review, but are not included in this column. §Single trial comparisons. ‘Other’ included the following procedures: Belsey Mark IV; Roux-
en-Y duodenal diversion; cardia calibration with posterior gastropexy; Nissen with mesh hiatoplasty; Nissen with fascial graft; fixed ‘non-
deformable’ 360 degree fundoplication; mesh hiatoplasty and cardiophrenicopexy. ¶Nissen with, and without a bougie for calibration. 
APF = Anterior partial fundoplication. BM IV = Belsey Mark IV. FND 360o = Fixed ‘non-deformable’ 360o fundoplication. NSGVD = Nissen 
with short gastric vessel division. NSGVP = Nissen with short gastric vessel preservation. PPF = Posterior partial fundoplication. PPI = 
Proton pump inhibitor.  
57 
 
Table 3.2 Characteristics of included trials 
Trial references Country Interventions Reported outcomes* - and time points† Patients‡ 
(Anvari et al., 
2006, 2011) 
Canada Nissen (SGVD, NB) vs. 
PPI 
QOL; pH<4; Complications - 1 and 3 years 104 
 Dysphagia (cont); Reflux (cont) - 1 year  
     
(Aye et al., 2012) USA Nissen (SGVD, B) vs. 
Hill repair 
GQOL; Dysphagia (cont); DMS; pH<4; Dilatations; 
Reoperations; Complications - 1 year 
111 
     
(Baigrie et al., 
2005; Broeders et 




Nissen (SGVP, B) vs. 
APF 
Dysphagia (cont and dich); Reflux (cont) - 1, 5 and 12 years 163 
 Dilatations; Reoperations - 5 and 12 years  
 GBS (dich) - 12 years  
     
(Blomqvist et al., 
2000; Mardani et 
al., 2009) 
Sweden Nissen (SGVP, B) vs. 
Nissen (SGVD, B) 
QOL; Dysphagia (dich); Reflux (cont and dich); GBS (dich); 
Complications - 1 and 10 years 
99 
  Dysphagia (cont) - 10 years  
  GQOL; pH<4; Reoperations - 1 year  
     
(Booth et al., 
2008) 
UK Nissen (SGVD, D) vs. 
PPF 
Dysphagia (dich); Reflux (dich); Dilatations; Complications 
- 1 year 
127 
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Table 3.2 continued 
Trial references Country Interventions Reported outcomes* - and time points† Patients‡ 
(Bouillot et al., 
1999) 
France Nissen (SGVD, NS) vs. 
PPF 
Dysphagia (dich); Reflux (dich); Complications - 1 year 45 
     
(Cao et al., 2012) China Nissen (SGVP, NB) vs. 
APF 
Dysphagia (cont); Reflux (cont); DMS - 1, 2 and >5 years 100 
  Reflux (dich); Reoperations - >5 years  
     
(Chrysos et al., 
2001) 
Greece Nissen (SGVD, B) vs. 
Nissen (SGVP, B) 
Dysphagia (dich); Reflux (dich); DMS; GBS (dich); 
Complications - 1 year 
56 
     
(Chrysos et al., 
2003) 
Greece Nissen (SGVP, NB) vs. 
PPF 
Dysphagia (dich); Reflux (dich); DMS; Dilatations; GBS 
(dich); Complications - 1 year 
33 
     
(Chrysos et al., 
2004) 
Greece Nissen (SGVP, NB) vs. 
APF 
Reflux (dich) - 5 months 24 
     
(Csendes et al., 
2000) 
Chile Nissen (SGVD, NS) vs. 
Cardia calibration with 
posterior gastropexy 
pH<4; Reoperations - >1 year 164 
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Table 3.2 continued 
Trial references Country Interventions Reported outcomes* - and time points† Patients‡ 
(Demeester et al., 
1974) 
USA Nissen (NS, B) vs. 
Belsey Mark IV vs. Hill 
Dysphagia (dich); Dilatations; Complications - 5 months 45 
     
(Djerf et al., 
2016) 
Sweden Nissen (NS) vs. APF QOL; Dysphagia (cont); Reflux (cont); pH<4; Reoperations 
- 1 and 10 years 
72 
     
(Farah et al., 
2007) 
Brazil Nissen (SGVP, NB) vs. 
Nissen (SGVD, NB) 
Dysphagia (dich); Reflux (dich); Dilatations; Complications 
- 1 year 
90 
     
(Ferulano et al., 
2000) 
Italy Nissen (SGVP, NS) vs. 
PPF 
Dysphagia (dich); Reflux (dich); DMS; pH<4; 
Complications - 6 months 
25 
     
Fibbe (Strate et 
al., 2008; Zornig 
et al., 2002) 
Germany Nissen (SGVD, B) vs. 
PPF 
Dysphagia (dich); Reflux (dich); Reoperations - 4 months 
and 2 years 
200 
  DMS; Dilatations - 4 months  
     
Gear (Eyre-Brook 
et al., 1993; Gear 
et al., 1984) 
UK Nissen (SGVD, B) vs. 
Angelchik 
Reoperations; GBS (dich); Complications - 1 and 3 years 52 
 Dysphagia (dich); Reflux (dich) - 1 year  
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Table 3.2 continued 
Trial references Country Interventions Reported outcomes* - and time points† Patients‡ 
(Granderath et al., 
2005) 
Austria Nissen (SGVD, NS) vs. 
Nissen with mesh 
hiatoplasty 
Dysphagia (dich); Reflux (dich); DMS - 1 year 100 
     
(Granderath et al., 
2007) 
Austria Nissen (SGVD, NS) vs. 
PPF 
Dysphagia (dich); Reflux (dich); DMS; GBS (cont and 
dich); Complications - 3 months 
56 
     
(Guerin et al., 
2007) 
Belgium Nissen (SGVP, B) vs. 
PPF 
Dysphagia (dich); Reflux (dich); Complications - 1 and 3 
years 
140 
     
(Engstrom et al., 
2007; Hagedorn 
et al., 2003) 
Sweden PPF vs. APF Dysphagia (dich); Reflux (dich); Reoperations - 1 and >5 
years 
95 
  pH<4 - 1 year  
     
(Khan et al., 
2009) 
UK Nissen (SGVP, B) vs. 
PPF 
Dysphagia (cont and dich); Reflux (dich); pH<4; 
Reoperations; Complications - 1 year 
121 
     
(Khan et al., 
2010) 
UK PPF vs. APF Dysphagia (cont and dich); Reflux (dich); pH<4; 
Reoperations; Complications - 1 year 
103 
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Table 3.2 continued 
Trial references Country Interventions Reported outcomes* - and time points† Patients‡ 
(Kmiot et al., 
1991) 
UK Nissen (SGVD, B) vs. 
Angelchik 
Dysphagia (dich); Reflux (dich); GBS (dich); Complications 
- 2 years 
50 
 pH<4; Reoperations - 1 year  
     
(Koch et al., 
2013) 
Austria Nissen (NS) vs. PPF GQOL; Dysphagia (cont); Reflux (cont); DMS; GBS (cont); 
Reoperations - 1 year 
125 
     
(Kosek et al., 
2009) 
Austria Nissen (SGVP, B) vs. 
Nissen (SGVD, B) 
Dysphagia (dich); Reflux (dich); Dilatations - 6 months and 
5 years 
41 
   GQOL; DMS - 5 years  
     
(Laws et al., 
1997) 
USA Nissen (SGVD, B) vs. 
PPF 
Dysphagia (dich); Dilatations; Complications - 2 years 39 
     
LOTUS 
(Galmiche et al., 
2011; Hatlebakk 
et al., 2016) 
Sweden Nissen (SGVD, B) vs. 
PPI 
pH<4 - 6 months and >5 years 554 
 GQOL; Dysphagia (dich); Reflux (cont and dich) - 6 months 
and 3 years 
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Table 3.2 continued 
Trial references Country Interventions Reported outcomes* - and time points† Patients‡ 
Lundell 
(Hagedorn et al., 
2002; Lundell et 
al., 1996; Lundell 
et al., 1991; 
Rydberg et al., 
1999) 
Sweden Nissen (SGVD, NB) vs. 
PPF 
Dysphagia (dich); Reflux (dich); Complications - 1, 3 and 12 
years 
137 
 pH<4 - 1 and 3 years  
  Reoperations - 3 and 12 years  





Luostarinen et al., 
1996) 
Finland Nissen (SGVP, B) vs. 
Nissen (SGVD, B) 
Dysphagia (dich); Reflux (dich); Dilatations - 6 months and 
3 years 
50 
     
(Mahon et al., 
2005; Mehta et 
al., 2006) 
UK Nissen (SGVP, NS) vs. 
PPI 
DMS; pH<4; Dilatations; Reoperations; Complications - 1 
year 
217 
     
     
63 
 
Table 3.2 continued 





Lithuania Nissen (SGVD, B) vs. 
PPF 
Dysphagia (dich); Reflux (dich); Dilatations; GBS (dich); 
Complications - 1 and 5 years 
153 
  DMS - 1 year  
     
(Mucio et al., 
2012) 
Mexico Nissen (SGVD, B) vs. 
PPF vs. FND 360o§ 
Reoperations; Complications - 15 years 385 
 QOL - 10 years  
 Dysphagia (dich) - 1 year  





Nissen (SGVD, B) vs. 
Mesh hiatoplasty with 
cardiophrenicopexy 
GQOL; Dysphagia (cont); Reflux (cont); GBS (cont); 
Complications - 1 and 3 years 
90 
Dilatations; Reoperations - 3 years  
DMS - 1 year  
     
(Patterson et al., 
2000) 
USA Nissen (SGVD, B) vs. 
Nissen (SGVD, NB) 
Dysphagia (cont and dich); Dilatations - 6 months 171 
     
(Qin et al., 2013) China Nissen (NS) vs. PPF Reflux (dich) - 5 years 383 
  Dysphagia (dich); DMS - 3 months  
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Table 3.2 continued 
Trial references Country Interventions Reported outcomes* - and time points† Patients‡ 
(Raue et al., 
2011) 
Germany Nissen (SGVD, B) vs. 
APF 
GQOL; DMS; Dilatations; Reoperations; Complications - 18 
months 
64 
     
(Roks et al., 
2017b) 
Netherlands PPF vs. APF Dysphagia (cont and dich); Reflux (cont and dich); pH<4; 
Reoperations; GBS (dich); Complications - 1 year 
94 
     
(Segol et al., 
1989) 
France Nissen (SGVP, B) vs. 
PPF vs. 90o¶ 
Dysphagia (dich); Reflux (dich); DMS; Reoperations; 
Complications - 2 years 
47 
     




Nissen (SGVD, B) vs. 
PPF 
Dysphagia (cont); Reflux (cont); GBS (cont) - 3 months and 
5 years 
100 
Reoperations - 5 years  
DMS; pH<4 - 3 months  
     
Stuart (Hill et al., 
1994; Stuart et al., 
1989) 
Ireland Nissen (SGVP, NS) vs. 
Angelchik 
Dysphagia (dich); Complications - 3 and 7 years 61 
 pH<4 - 1 and 7 years  
 Dilatations - 7 years  
 GBS (dich) - 3 years  
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Table 3.2 continued 
Trial references Country Interventions Reported outcomes* - and time points† Patients‡ 
(Thor and 
Silander, 1989) 
Sweden Nissen (SGVD, B) vs. 
PPF 
Dysphagia (dich); Complications - 5 years 31 
     
Walker (Baxter et 
al., 1996; Walker 
et al., 1992) 
UK Nissen (NS, B) vs. PPF pH<4; Complications - 13 months and 10 years 52 
 Dysphagia (dich); Reflux (dich); Dilatations; GBS (dich) - 
13 months 
 
     
(Wang et al., 
2015) 
China Nissen (SGVD, NB) vs. 
PPF 
Dysphagia (dich); Reflux (dich); DMS; Complications - 4 
years 
84 
     
(Washer et al., 
1984) 
UK Nissen (NS) vs. REY 
duodenal diversion 
Dilatations; Reoperations; Complications - 5 years 44 
     
Watson 1997 
(O'Boyle et al., 
2002; Watson et 
al., 1997; Yang et 
al., 2008) 
Australia Nissen (SGVD, B) vs. 
Nissen (SGVP, B) 
Dysphagia (cont and dich); Reflux (cont and dich); 
Reoperations; Complications - 6 months, 5 and 10 years 
102 
 Dilatations - 5 years  
 pH<4 - 3 months  
     
     
66 
 
Table 3.2 continued 
Trial references Country Interventions Reported outcomes* - and time points† Patients‡ 
Watson 1999 (Cai 
et al., 2008; 
Ludemann et al., 
2005; Watson et 
al., 1999) 
Australia Nissen (SGVP, B) vs. 
APF 
Dysphagia (cont and dich); Reflux (cont and dich); 
Reoperations; Complications - 6 months, 5 and 10 years 
107 
 Dilatations - 6 months  
     
Watson 2004 
(Nijjar et al., 
2010; Watson et 
al., 2004; 




Nissen (SGVD, B) vs. 
90o 
QOL; Dysphagia (cont and dich); Reflux (cont and dich); 
Reoperations; Complications - 1 and 5 years 
112 
pH<4 - 3 months  
     
Watson 2012 
(Spence et al., 
2006; Watson et 
al., 2012) 
Australia Nissen (SGVP, B) vs. 
90o 
Dysphagia (cont and dich); Reflux (cont and dich); 
Reoperations; Complications - 1 and 5 years 
79 
 pH<4 - 6 months  
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Table 3.2 continued 
Trial references Country Interventions Reported outcomes* - and time points† Patients‡ 
Watson 2013 
(Daud et al., 
2015) 
Australia PPF vs. APF Dysphagia (cont and dich); Reflux (cont and dich); 
Complications - 1 year 
47 
  pH<4 - 6 months  
     
(Yigit et al., 
2012) 
Turkey Nissen (NS) vs. Nissen 
with fascial graft 
Dysphagia (dich) - 7 months 24 
*Outcomes relevant to this review. †Follow-up time points at which trial data for eligible outcomes were reported and used in this review 
(except for postoperative complications, which were not split in this review by follow-up time point). Some trials reported data for more than 
one time point within this review’s pre-specified follow-up periods, in such instances the latter time point was used. Where a specific figure 
was not reported by the trial investigators, the mean follow-up time was used. ‡Total number of patients randomised in the trial, or number 
analysed if total number randomised not reported. The number of patients for whom data were reported for different outcomes at different 
time points varied. §Trial report also included a fourth observational PPI arm, which was excluded as not randomised. ¶This arm in the trial 
underwent a Lortat-Jacob procedure, which is the same in principle and technique as a 90 degree fundoplication. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. B = Bougie. Cont = Continuous data (scores). Dich = Dichotomous 
data (rates). DMS = DeMeester score (oesophageal acid exposure). FND 360o = Fixed ‘non-deformable’ 360 degree fundoplication. GBS = 
Gas bloat syndrome. GQOL = Gastrointestinal, or reflux disease specific quality of life score. NB = No bougie. NS = Short gastric vessel 
division and/or use of bougie use (in Nissen) not specified in methods, or left up to the individual surgeon with no further information 
available. pH<4 = Total oesophageal acid exposure time (percentage time pH < 4). PPI = Proton pump inhibitor therapy. PPF = Posterior 




Table 3.3 Data available for each outcome follow-up time point 
Outcome 3-12 months >1-5 years >5-10 years >10 years 
Trials Patients Trials Patients Trials Patients Trials Patients 
Health-related QOL 3 259 2 205 2 284 0 0 
Gastrointestinal/reflux specific QOL 4 706 3 478 0 0 0 0 
Dysphagia rate 22 2708 16 1717 2 136 2 200 
Dysphagia scores 16 1436 7 686 4 327 1 85 
Reflux rate 20 1961 13 1806 3 273 1 110 
Reflux scores 13 1565 8 1045 3 246 1 90 
Oesophageal acid exposure scores 11 1283 4 280 1 96 0 0 
Total oesophageal acid exposure time 17 1430 4 280 4 336 0 0 
Dilatation for dysphagia rate 8 940 7 688 1 47 0 0 
Reoperation rate 14 1513 13 1309 3 273 3 432 
Gas bloat rate 5 360 5 333 0 0 1 90 
Gas bloat scores 4 349 2 155 0 0 0 0 
Postoperative complications are not included in this table as this outcome was not split by follow-up time point. Postoperative complications 
were reported by 31 trials, with data available for 2688 patients. 




Figure 3.2 summarises the risk of bias assessment of the included trials, and Figure 3.3 shows the 
domain assessment for individual trials, categorised by comparison. Only seven trials were judged 
at low risk of bias across all domains. Many trials did not provide details on blinding and allocation 
concealment, although over a quarter were judged as well-blinded.  
 
 















































Figure 3.3 Risk of bias assessment by individual study 
           denotes low risk;          denotes unclear risk;        denotes high risk of bias, for each given 
domain, as judged by the authors. Sorted by comparison.  
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPI = Proton pump 
inhibitor therapy. PPF = Posterior partial fundoplication. SGVD = Short gastric vessel division.  
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3.4.2 Quality of life scores 
Both general (health-related) and gastrointestinal/reflux specific QOL scores were reported by a 
small number of trials, with all time point analyses for these two outcomes containing data from 
just four trials or fewer (Table 3.3). This paucity of data led to a decision, prior to analysis, to add 
reflux as a primary outcome, to facilitate its use as the main measure of efficacy in this review.  
 
Figures 3.4 and 3.5 summarise the direct evidence available for these outcomes at 3-12 months, 
and Tables 3.4 and 3.5 report the NMA results. In general, patients who underwent surgery had 
significantly better QOL scores than those on PPI therapy, and those who underwent an APF or 
PPF had better general QOL scores than those who underwent a Nissen fundoplication, though 
this was not always statistically significant across all time points. Pairwise meta-analysis and all 
sensitivity analyses showed similar findings to the main analysis. There were not enough data to 
statistically test for heterogeneity or inconsistency. 
 
 
Figure 3.4 Network map of direct evidence for health-related quality of life scores 
3-12 month data. The size of each circle (node) is proportional to the number of patients who 
received the treatment. The width of the lines represents the number of RCTs that directly 
compared the connected pairs of treatments. The values in parentheses denote the number of RCTs 
that investigated the associated comparison, followed by the combined number of patients in those 
RCTs. 





Figure 3.5 Network map of direct evidence for gastrointestinal/reflux specific quality 
of life scores 
3-12 month data. The size of each circle (node) is proportional to the number of patients who 
received the treatment. The width of the lines represents the number of RCTs that directly 
compared the connected pairs of treatments. The values in parentheses denote the number of RCTs 
that investigated the associated comparison, followed by the combined number of patients in those 
RCTs. 





Table 3.4 Network meta-analysis results – Health-related quality of life scores 
3-12 months 
 90o APF Nissen   
PPI 1.71 (1.11, 2.31)* 0.79 (0.13, 1.46)* 0.38 (-0.05, 0.82)   
90o  -0.92 (-1.56,- 0.27)* -1.33 (-1.74, -0.92)*   
APF   -0.41 (-0.91, 0.08)   
1-5 years 
 90o Nissen    
PPI 0.28 (-0.28, 0.83) 0.34 (-0.07, 0.75)    
90o  0.06 (-0.31, 0.43)    
5-10 years 
 PPF Nissen   
APF -0.32 (-0.90, 0.25) 0.15 (-0.35, 0.66)   
PPF  0.47 (0.21, 0.74)*   
*P < 0.05. Values in parentheses are 95% confidence intervals. Standardised mean difference, 
expressed as standard deviations. A positive value indicates that patients who underwent the 
treatment in the corresponding cell in the top row had better quality of life scores than patients 
who underwent the treatment in the corresponding cell in the left hand column, and a negative 
value indicates the opposite. Missing treatments/time points mean no data available at this follow-
up time point.  





Table 3.5 Network meta-analysis results – Gastrointestinal/reflux specific quality of 
life scores 
3-12 months 
 PPF Nissen Hill MHWC  
PPI 0.84 (0.41, 1.27)* 0.56 (0.35, 0.76)* 0.56 (0.07, 1.04)* 0.50 (0.03, 0.97)*  
PPF  -0.29 (-0.67, 0.09) -0.29 (-0.87, 0.29) -0.34 (-0.92, 0.23)  
Nissen   0.00 (-0.44, 0.44) -0.06 (-0.48, 0.37)  
Hill    -0.06 (-0.67, 0.55)  
1-5 years 
 APF Nissen MHWC   
PPI 0.39 (-0.18, 0.96) 0.47 (0.25, 0.70)* 0.52 (0.03, 1.01)*   
APF  0.08 (-0.44, 0.61) 0.13 (-0.56, 0.81)   
Nissen   0.04 (-0.39, 0.48)   
*P < 0.05. Values in parentheses are 95% confidence intervals. Standardised mean difference, 
expressed as standard deviations. A positive value indicates that patients who underwent the 
treatment in the corresponding cell in the top row had better quality of life scores than patients 
who underwent the treatment in the corresponding cell in the left hand column, and a negative 
value indicates the opposite. Missing treatments/time points mean no data available at this follow-
up time point. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. MHWC = Mesh hiatoplasty 







Reflux was the most commonly reported efficacy outcome (Table 3.3). Figures 3.6 and 3.7 
summarise the direct evidence available at 3-12 months, for rates and scores respectively.  
 
 
Figure 3.6 Network map of direct evidence for reflux rate 
3-12 month data. The size of each circle (node) is proportional to the number of patients who 
received the treatment. The width of the lines represents the number of RCTs that directly 
compared the connected pairs of treatments. The values in parentheses denote the number of RCTs 
that investigated the associated comparison, followed by the combined number of patients in those 
RCTs. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial 








Figure 3.7 Network map of direct evidence for reflux scores 
3-12 month data. The size of each circle (node) is proportional to the number of patients who 
received the treatment. The width of the lines represents the number of RCTs that directly 
compared the connected pairs of treatments. The values in parentheses denote the number of RCTs 
that investigated the associated comparison, followed by the combined number of patients in those 
RCTs. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial 
fundoplication. PPI = Proton pump inhibitor.  
 
Tables 3.6 (rate data) and 3.7 (score data) report reflux NMA results. Across all time points, rate 
and score data showed similar overall results and rankings, despite minor variations in the 
treatment effect point estimates and confidence intervals.
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Table 3.6 Network meta-analysis results – Reflux rate 
3-12 months 
 90o APF PPF Nissen Angelchik 
PPI 0.69 (0.17, 2.85) 0.79 (0.22, 2.81) 0.47 (0.15, 1.45) 0.34 (0.13, 0.92)* 0.02 (0.00, 0.50)* 
90o  1.14 (0.31, 4.20) 0.68 (0.21, 2.18) 0.50 (0.18, 1.38) 0.03 (0.00, 0.74)* 
APF   0.59 (0.30, 1.19) 0.43 (0.19, 0.97)* 0.03 (0.00, 0.60)* 
PPF    0.73 (0.42, 1.27) 0.04 (0.00, 0.96)* 
Nissen     0.06 (0.00, 1.26) 
1-5 years 
 90o APF PPF Nissen Angelchik 
PPI 0.72 (0.12, 4.46) 1.08 (0.11, 10.75) 0.47 (0.09, 2.49) 0.47 (0.11, 2.07) 0.98 (0.04, 23.32) 
90o  1.50 (0.19, 11.63) 0.66 (0.20, 2.14) 0.65 (0.23, 1.88) 1.36 (0.07, 27.13) 
APF   0.44 (0.07, 2.94) 0.43 (0.08, 2.51) 0.91 (0.03, 24.65) 
PPF    0.99 (0.47, 2.10) 2.08 (0.11, 37.58) 
Nissen     2.09 (0.13, 34.26) 
5-10 years 
 PPF Nissen    
APF 0.21 (0.08, 0.53)* 0.87 (0.40, 1.88)    
PPF  4.10 (1.24, 13.56)*    
*P < 0.05. Values in parentheses are 95% confidence intervals. Unit is odds ratio. A value >1 indicates that patients who underwent the treatment 
in the corresponding cell in the top row had a higher reflux rate than patients who underwent the treatment in the corresponding cell in the left hand 
column, and a value <1 indicates the opposite. Missing treatments/time points mean no data available at this follow-up time point.  
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial fundoplication. PPI = Proton pump inhibitor.  
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Table 3.7 Network meta-analysis results – Reflux scores 
3-12 months 
 90o APF PPF Nissen MHWC  
PPI -0.51 (-0.93, -0.10)* -0.59 (-0.91, -0.26)* -0.72 (-1.09, -0.36)* -0.74 (-0.99, -0.48)* -0.17 (-0.71, 0.37)  
90o  -0.07 (-0.46, 0.31) -0.21 (-0.62, 0.20) -0.22 (-0.55, 0.10) 0.35 (-0.23, 0.92)  
APF   0.35 (-0.23, 0.92) -0.13 (-0.40, 0.13) -0.15 (-0.35, 0.05)  
PPF    -0.01 (-0.27, 0.24) 0.55 (0.01, 1.09)*  
Nissen     0.57 (0.09, 1.04)*  
1-5 years 
 90o APF PPF Nissen MHWC  
PPI -0.30 (-0.87, 0.27) -0.51 (-1.01, -0.01)* -0.95 (-1.67, -0.24)* -0.57 (-0.98, -0.16)* 0.09 (-0.61, 0.79)  
90o  -0.21 (-0.70, 0.28) -0.66 (-1.36, 0.05) -0.28 (-0.67, 0.12) 0.39 (-0.30, 1.08)  
APF   -0.45 (-1.10, 0.20) -0.06 (-0.36, 0.23) 0.60 (-0.04, 1.24)  
PPF    0.38 (-0.20, 0.96) 1.05 (0.23, 1.86)*  
Nissen     0.67 (0.10, 1.23)  
5-10 years 
 Nissen      
APF -0.41 (-0.82, 0.01)      
*P < 0.05. Values in parentheses are 95% confidence intervals. Standardised mean difference, expressed as standard deviations. A positive value indicates 
that patients who underwent the treatment in the corresponding cell in the top row had a higher reflux score (more reflux) than patients who underwent 
the treatment in the corresponding cell in the left hand column, and a negative value indicates the opposite. Missing treatments/time points mean no data 
available at this follow-up time point. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. MHWC = Mesh hiatoplasty with cardiophrenicopexy. PPF = Posterior partial 
fundoplication. PPI = Proton pump inhibitor. 
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At 3-12 month follow-up, NF showed a significantly lower rate of reflux symptoms than PPI 
therapy or APF, and was the only fundoplication with similarly low reflux rates as Angelchik. 
Fundoplication rankings for reflux rate are shown in Figure 3.8, with NF and PPF ranking as the 
best treatments, followed by the other fundoplications and PPI respectively. Sensitivity analysis 
splitting the Nissen node into four groups (according to bougie use and short gastric 
division/preservation) showed no significant difference between Nissen fundoplication and APF. 
Sensitivity analysis reallocating 120o anterior partial fundoplications to 90o resulted in a 
statistically significant decrease in the rate of reflux with PPF in comparison with PPI or 90o, as 
well as the difference between Nissen and 90o becoming statistically significant. The difference 




Figure 3.8 Rankogram of fundoplications according to reflux rate 
The probability of each included fundoplication ranking as the best, second best, third, fourth or 
worst treatment in the network is represented by the coloured bars. There were no significant 
differences at 1-5 years, and insufficient data for ranking at 5-10 years, so rankograms for those 
time points are not shown. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial 




Analysis of score data at 3-12 months showed that all fundoplications had significantly lower 
reflux scores compared to PPI therapy, but there were no significant differences between the 
fundoplications. Sensitivity analysis splitting the Nissen node into four groups resulted in the 
difference between PPI and all partial fundoplications except PPF to become no longer statistically 
significant. Both NF and PPF had significantly lower reflux scores than mesh hiatoplasty with 
cardiophrenicopexy (MHWC). Figure 3.9 shows the fundoplication rankogram for reflux scores, 
with similar rankings to reflux rate. 
 
At 1-5 year follow-up, there were no significant differences between the groups in the main 
analysis of rate data. Sensitivity analysis splitting the Nissen node into four groups (according to 
bougie use and short gastric division/preservation) revealed a significant reduction in the rate of 
reflux with PPF in comparison with PPI and APF, with no other significant differences between 
the treatments. Score data analysis showed a significant reduction in reflux scores with any 
fundoplication in comparison with PPI, except 90o. PPF alone showed significantly lower reflux 
scores compared to MHWC. Sensitivity analysis splitting the Nissen node into four groups resulted 
in the difference between APF and PPI to become no longer statistically significant. The 
fundoplication rankogram for score data is shown in Figure 3.9, with PPF ranking as the best 
treatment. 
 
At long-term follow-up, PPF patients were significantly less likely to report reflux symptoms than 
APF or NF patients, though this was based on rate data from only three studies. Score data were 
only available for APF and NF, with no significant difference found. One study reported data at 
>10 years follow-up, with no significant difference in reflux rates shown between NF and PPF. 
 
Apart from the 5-10 year comparisons where predictive intervals were wide (suggesting significant 
between-study heterogeneity), there was no evidence of significant inconsistency or heterogeneity 




Figure 3.9 Rankogram of fundoplications according to reflux scores 
The probability of each included fundoplication ranking as the best, second best, third, fourth or 
worst treatment in the network is represented by the coloured bars, at each time point. Missing 
time points mean insufficient data available at that time point for ranking.  
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial 




A large number of trials reported this outcome (Table 3.3). Figures 3.10 and 3.11 summarise the 
direct evidence available at 3-12 months, for rates and scores respectively.  
 
 
Figure 3.10 Network map of direct evidence for dysphagia rate 
3-12 month data. The size of each circle (node) is proportional to the number of patients who 
received the treatment. The width of the lines represents the number of RCTs that directly 
compared the connected pairs of treatments. The values in parentheses denote the number of RCTs 
that investigated the associated comparison, followed by the combined number of patients in those 
RCTs. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial 





Figure 3.11 Network map of direct evidence for dysphagia scores 
3-12 month data. The size of each circle (node) is proportional to the number of patients who 
received the treatment. The width of the lines represents the number of RCTs that directly 
compared the connected pairs of treatments. The values in parentheses denote the number of RCTs 
that investigated the associated comparison, followed by the combined number of patients in those 
RCTs. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial 
fundoplication. PPI = Proton pump inhibitor.  
 
Tables 3.8 (rate data) and 3.9 (score data) report NMA results. Both showed similar overall 
findings and rankings across all time points, despite some variation in the treatment effect point 
estimates and confidence intervals. 
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Table 3.8 Network meta-analysis results – Dysphagia rate 
3-12 months 
 90o APF PPF Nissen Angelchik BM  IV Hill 
PPI 1.19 (0.39, 3.62) 2.13 (0.78, 5.86) 2.15 (0.82, 5.64) 5.51 (2.24, 13.55)* 18.94 (3.81, 94.06)* 0.57 (0.07, 4.27) 5.51 (0.56, 54.38) 
90o  1.79 (0.80, 4.00) 1.81 (0.86, 3.80) 4.63 (2.40, 8.93)* 15.93 (3.63, 69.96)* 0.48 (0.07, 3.27) 4.63 (0.51, 42.05) 
APF   1.01 (0.61, 1.66) 2.58 (1.63, 4.10)* 8.89 (2.18, 36.19)* 0.27 (0.04, 1.72) 2.58 (0.30, 22.31) 
PPF    2.56 (1.81, 3.62)* 8.80 (2.24, 34.66)* 0.26 (0.04, 1.66) 2.56 (0.30, 21.62) 
Nissen     3.44 (0.91, 12.95) 0.10 (0.02, 0.63)* 1.00 (0.12, 8.21) 
Angelchik      0.03 (0.00, 0.28)* 0.29 (0.02, 3.50) 
BM IV       9.75 (1.59, 59.69)* 
1-5 years 
 90o APF PPF Nissen Angelchik   
PPI 1.24 (0.26, 5.85) 1.03 (0.21, 5.16) 1.34 (0.32, 5.69) 3.29 (0.91, 11.81) 29.16 (2.96, 285.95)*   
90o  0.84 (0.22, 3.12) 1.09 (0.36, 3.27) 2.66 (1.10, 6.44)* 23.60 (2.91, 191.31)*   
APF   1.30 (0.40, 4.27) 3.19 (1.20, 8.48)* 28.26 (3.34, 238.92)*   
PPF    2.44 (1.25, 4.77)* 21.70 (2.91, 161.85)*   
Nissen     8.87 (1.33, 59.07)*   
5-10 years 
 Nissen Angelchik      
APF 2.10 (0.89, 4.95) 14.78 (1.35, 162.02)*      
Nissen  7.05 (0.75, 65.92)      
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Table 3.8 continued      
>10 years 
 PPF Nissen      
APF 0.87 (0.20, 3.71) 0.83 (0.25, 2.70)      
PPF  0.96 (0.41, 2.24)      
*P < 0.05. Values in parentheses are 95% confidence intervals. Unit is odds ratio. A value >1 indicates that patients who underwent the treatment in the 
corresponding cell in the top row had a higher dysphagia rate than patients who underwent the treatment in the corresponding cell in the left hand column, 
and a value <1 indicates the opposite. Missing treatments mean no data available at this follow-up time point. 
90o = 90 degree fundoplication. BM IV = Belsey Mark IV. APF = Anterior partial fundoplication. PPF = Posterior partial fundoplication. PPI = Proton 




Table 3.9 Network meta-analysis results – Dysphagia scores 
3-12 months  
 90o APF PPF Nissen Hill MHWC    
PPI 0.63 (-0.43, 1.70) 0.29 (-0.65, 1.23) 0.17 (-0.78, 1.13) -0.15 (-1.02, 0.72) 0.00 (-1.23, 1.23) -0.15 (-1.37, 1.08)    
90o  -0.34 (-1.06, 0.37) -0.46 (-1.19, 0.27) -0.78 (-1.40, -0.16)* -0.63 (-1.70, 0.43) -0.78 (-1.84, 0.28)    
APF   -0.12 (-0.49, 0.25) -0.44 (-0.80, -0.07)* -0.29 (-1.23, 0.65) -0.44 (-1.38, 0.50)    
PPF    -0.32 (-0.71, 0.07) -0.17 (-1.12, 0.78) -0.32 (-1.27, 0.63)    
Nissen     0.15 (-0.72, 1.01) 0.00 (-0.87, 0.87)    
Hill      -0.15 (-1.37, 1.08)    
1-5 years  
 APF PPF Nissen MHWC   
90o 0.09 (-0.32, 0.50) -0.03 (-0.64, 0.57) -0.38 (-0.72, -0.04)* -0.65 (-1.23, -0.07)*   
APF  -0.12 (-0.68, 0.43) -0.47 (-0.70, -0.23)* -0.74 (-1.27, -0.21)*   
PPF   -0.34 (-0.84, 0.16) -0.61 (-1.30, 0.07)   
Nissen    -0.27 (-0.75, 0.20)   
5-10 years  
 PPF Nissen       
APF 0.18 (-0.53, 0.89) -0.71 (-1.14, -0.28)*       
PPF  -0.89 (-1.72, -0.06)*       
*P < 0.05. Values in parentheses are 95% confidence intervals. Standardised mean difference, expressed as standard deviations. A positive value indicates 
that patients who underwent the treatment in the corresponding cell in the top row had a higher dysphagia assessment score (less dysphagia) than patients 
who underwent the treatment in the corresponding cell in the left hand column, and a negative value indicates the opposite. Missing treatments/time points 
mean no data available at this follow-up time point. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. MHWC = Mesh hiatoplasty with cardiophrenicopexy. PPF = Posterior partial 
fundoplication. PPI = Proton pump inhibitor. 
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At 3-12 month follow-up, NF patients had a significantly higher rate of dysphagia at 3-12 months 
than any other group apart from Angelchik and Hill repair. Sensitivity analysis reallocating 120o 
anterior partial fundoplications to 90o resulted in a statistically significant difference in dysphagia 
rates between PPF and 90o. NF also had significantly higher dysphagia scores compared to APF 
or 90o fundoplication. There were no significant differences between the partial fundoplications, 
or between any of them and PPI therapy. Sensitivity analysis by serial exclusion of individual PPF 
studies frequently resulted in the difference with Nissen at short-term follow-up to reach statistical 
significance. Fundoplication rankograms at short-term follow-up are shown in Figures 3.12 (rate 
data) and 3.13 (score data), with Nissen consistently ranking as the worst treatment, and PPF and 
APF ranking fairly similarly. 
 
At 1-5 years, those who underwent any partial fundoplication were still significantly less likely to 
suffer from dysphagia, and have lower dysphagia scores, compared to those who received an NF. 
This is reflected in the fundoplication rankograms (Figures 3.12 and 3.13), with Nissen again 
ranking as the worst treatment. 
 
At 5-10 year follow-up, NF still showed significantly higher dysphagia scores compared to APF 
or PPF. Rate data analysis showed similar point estimates, but with wider confidence intervals. 
One study reported >10 year score data for APF versus NF with no significant difference found. 
 
Predictive intervals for all comparisons in this outcome were narrow, and inconsistency factors for 





Figure 3.12 Rankogram of fundoplications according to dysphagia rate 
The probability of each included fundoplication ranking as the best, second best, third, fourth or 
worst treatment in the network is represented by the coloured bars, at each time point. Missing 
time points mean insufficient data available at that time point for ranking.  
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial 





Figure 3.13 Rankogram of fundoplications according to dysphagia scores 
The probability of each included fundoplication ranking as the best, second best, third, fourth or 
worst treatment in the network is represented by the coloured bars, at each time point. Missing 
time points/treatments mean insufficient data available at that time point for ranking.  
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial 




Comparison-adjusted funnel plots using reflux and dysphagia data for assessment of publication 
bias are shown in Figure 3.14. Study-specific effect sizes were evenly distributed around the 




Figure 3.14 Comparison-adjusted funnel plots for dysphagia and reflux 
3-12 month data. The zero line represents the null hypothesis that the study-specific effect sizes 
do not differ from the comparison-specific pooled estimates. Different coloured points on the plot 
represent the different comparisons, as in the key.  
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. BM IV = Belsey Mark IV. 
MHWC = Mesh hiatoplasty with cardiophrenicopexy. PPF = Posterior partial fundoplication. PPI 




3.4.5 Secondary outcomes 
Oesophageal acid exposure scores 
The direct evidence available for this outcome at 3-12 months is summarised in Figure 3.15. All 
studies reported DeMeester scores, except for one which reported a Minaire score (Segol et al., 
1989), which was subjected to sensitivity analysis by exclusion. 
 
 
Figure 3.15 Network map of direct evidence for oesophageal acid exposure scores 
3-12 month data. The size of each circle (node) is proportional to the number of patients who 
received the treatment. The width of the lines represents the number of RCTs that directly 
compared the connected pairs of treatments. The values in parentheses denote the number of RCTs 
that investigated the associated comparison, followed by the combined number of patients in those 
RCTs. 
APF = Anterior partial fundoplication. PPF = Posterior partial fundoplication. PPI = Proton pump 
inhibitor.  
 
Table 3.10 reports the NMA results. PPF and Nissen patients had significantly lower oesophageal 
acid scores than those on PPI therapy at 3-12 months. There were no significant differences 
otherwise between the treatments. Predictive intervals were of moderate width, suggesting some 
between-study heterogeneity, but sensitivity analysis results were similar to the main analysis. 
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Figure 3.16 shows the fundoplication rankogram at this time point, with PPF and Nissen ranking 
fairly equally, followed by APF and PPI. 
 
Table 3.10 Network meta-analysis results – Oesophageal acid exposure scores 
3-12 months† 
 APF PPF Nissen Hill  
PPI -7.57 (-17.62, 2.49) -8.79 (-16.64, -0.95)* -8.97 (-16.45, -1.49)* -4.67 (-14.72, 5.39)  
APF  -1.23 (-8.36, 5.90) -1.40 (-8.13, 5.32) 2.90 (-6.61, 12.41)  
PPF   -0.18 (-2.56, 2.20) 4.13 (-3.01, 11.26)  
Nissen    4.31 (-2.42, 11.03)  
1-5 years‡ 
 APF PPF Nissen   
90o -0.93 (-1.70, -0.17)* -0.63 (-1.32, 0.07) -1.12 (-1.81, -0.42)*   
APF  0.30 (-0.19, 0.80) -0.18 (-0.50, 0.14)   
PPF   -0.49 (-0.86, -0.11)*   
*P < 0.05. Values in parentheses are 95% confidence intervals. †Mean difference, unit is 
DeMeester score value. ‡ Standardised mean difference, expressed as standard deviations. A 
positive value indicates that patients who underwent the treatment in the corresponding cell in the 
top row had higher acid exposure scores (higher acid exposure) than patients who underwent the 
treatment in the corresponding cell in the left hand column, and a negative value indicates the 
opposite. Missing treatments/time points mean no data available at this follow-up time point. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPI = Proton pump 





Figure 3.16 Rankogram of fundoplications according to oesophageal acid exposure 
scores 
The probability of each included fundoplication ranking as the best, second best, third or worst 
treatment in the network is represented by the coloured bars. There were insufficient data for 
ranking at other time points, and no data for 90o fundoplication.  
APF = Anterior partial fundoplication. PPF = Posterior partial fundoplication. PPI = Proton pump 
inhibitor. 
 
At 1-5 year follow-up, APF and Nissen patients had significantly lower acid exposure scores than 
those who underwent a 90o fundoplication, and Nissen patients had significantly lower scores than 
PPF patients. However, these results were based on data from just four studies, and sensitivity 
analysis splitting the Nissen node showed different results (such as a significant decrease in acid 
exposure scores in PPF patients compared to APF patients and some Nissen groups). One study 
comparing APF with Nissen reported results at 5-10 years, and found no significant difference 





Total oesophageal acid exposure time 
Figure 3.17 summarises the direct evidence available at 3-12 months, and Table 3.11 reports the 
NMA results.  
 
 
Figure 3.17 Network map of direct evidence for total oesophageal acid exposure time 
3-12 month data. The size of each circle (node) is proportional to the number of patients who 
received the treatment. The width of the lines represents the number of RCTs that directly 
compared the connected pairs of treatments. The values in parentheses denote the number of RCTs 
that investigated the associated comparison, followed by the combined number of patients in those 
RCTs. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial 
fundoplication. PPI = Proton pump inhibitor.  
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Table 3.11 Network meta-analysis results – Total oesophageal acid exposure time 
3-12 months 
 90o APF PPF Nissen Angelchik Hill MHWC 
PPI -1.35 (-4.33, 1.63) -1.41 (-4.17, 1.35) -2.64 (-5.11, -0.18)* -2.25 (-4.27, -0.24)* 3.34 (0.36, 6.33) -1.15 (-4.85, 2.55) 14.25 (10.54, 17.95)* 
90o  -0.05 (-2.95, 2.84) -1.29 (-3.91, 1.33) -0.90 (-3.10, 1.30) 4.70 (1.58, 7.81)* 0.20 (-3.60, 4.01) 15.60 (11.79, 19.41)* 
APF   -1.24 (-2.83, 0.36) -0.85 (-2.73, 1.04) 4.75 (1.85, 7.66)* 0.26 (-3.38, 3.89) 15.66 (12.02, 19.29)* 
PPF    0.39 (-1.04, 1.82) 5.99 (3.36, 8.62)* 1.49 (-1.93, 4.91) 16.89 (13.47, 20.31)* 
Nissen     5.60 (3.39, 7.81)* 1.10 (-2.01, 4.21) 16.50 (13.39, 19.61)* 
Angelchik      -4.50 (-8.31, -0.69)* 10.90 (7.09, 14.72)* 
Hill       15.40 (11.00, 19.80)* 
1-5 years 
 PPF Nissen Hill     
PPI -1.70 (-3.86, 0.46) -2.18 (-4.34, -0.02)* -6.40 (-8.57, -4.22)*     
PPF  -0.48 (-0.57, -0.38)* -4.70 (-4.95, -4.44)*     
Nissen   -4.22 (-4.46, -3.98)*     
5-10 years 
 APF PPF Nissen Angelchik  
PPI -1.44 (-2.86, -0.02)* -12.78 (-14.30, -11.27)* -1.39 (-2.81, 0.03) -2.54 (-3.97, -1.10)*  
APF  -11.35 (-11.87, -10.82)* 0.05 (-0.01, 0.11) -1.10 (-1.32, -0.88)*  
PPF   11.40 (10.88, 11.92)* 10.25 (9.69, 10.81)*  
Nissen    -1.15 (-1.36, -0.94)*  
*P < 0.05. Values in parentheses are 95% confidence intervals. Mean difference, unit is percentage acid exposure time (pH<4). A positive 
value indicates that patients who underwent the treatment in the corresponding cell in the top row had a higher percentage exposure time 
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(longer duration of oesophageal acid exposure) than patients who underwent the treatment in the corresponding cell in the left hand column, 
and a negative value indicates the opposite. Missing treatments/time points mean no data available at this follow-up time point. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. MHWC = Mesh hiatoplasty with cardiophrenicopexy. PPF = Posterior 




At 3-12 month follow-up, PPF and Nissen patients had significantly shorter total acid exposure 
times than those on PPI therapy, and those who underwent an Angelchik procedure had 
significantly longer exposure times than those who underwent any fundoplication or a Hill repair. 
MHWC patients had much longer acid exposure times than all other patients, including those on 
PPI therapy. Sensitivity analysis excluding non-fundoplication procedures revealed a significant 
decrease in exposure time in patients who underwent a PPF compared to those who underwent an 
APF. There was no evidence of significant between-study heterogeneity or inconsistency. The 
fundoplication rankogram at this time point is shown in Figure 3.18. PPF ranks best, followed by 
Nissen, 90o and APF, then PPI therapy. 
 
 
Figure 3.18 Rankogram of fundoplications according to total oesophageal acid 
exposure time 
The probability of each included fundoplication ranking as the best, second best, third, fourth or 
worst treatment in the network is represented by the coloured bars. There were insufficient data 
for ranking at other time points.  
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial 
fundoplication. PPI = Proton pump inhibitor. 
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At 1-5 years, Hill repair patients had significantly shorter total exposure times than all others, 
though data were only available for three other treatments from four RCTs (each comparison with 
data from only one study). Nissen patients also had significantly shorter exposure times in 
comparison with PPF and PPI patients. Sensitivity analysis splitting the Nissen node according to 
bougie use and short gastric artery division/perseveration revealed a significant decrease in acid 
exposure time in patients who underwent a PPF in comparison with PPI, but results were otherwise 
similar. There were insufficient data at this time point to calculate rankings, predictive intervals or 
inconsistency factors. 
 
At 5-10 year follow-up, PPF patients had significantly shorter acid exposure times than all others. 
Those who underwent an Angelchik procedure had significantly shorter exposure times than all 
others except PPF patients. APF patients had significantly shorter times than those on PPI therapy. 
These results were however based on data from just four RCTs, and there were insufficient data 
available to statistically assess heterogeneity. 
 
Dilatation for dysphagia 
The direct evidence available at short-term follow-up is summarised in Figure 3.19, and NMA 
results are shown in Table 3.12.  
 
Apart from PPF patients being significantly less likely to undergo dilatation for dysphagia than 
those who underwent a Nissen or Hill procedure, there were no differences between the groups at 
both time points with available data (up to 5 years follow-up). However, data were extremely 
heterogeneous with very wide confidence and predictive intervals. There was no evidence of 
inconsistency between the direct and indirect evidence in this outcome’s networks. Figure 3.20 
summarises the fundoplication rankings, which show PPF being second only to PPI therapy, 
followed by Nissen and APF. 
 
One study comparing Nissen with Anglechik reported results at 5-10 years, with patients who 





Figure 3.19 Network map of direct evidence for dilatation for dysphagia rate 
3-12 month data. The size of each circle (node) is proportional to the number of patients who 
received the treatment. The width of the lines represents the number of RCTs that directly 
compared the connected pairs of treatments. The values in parentheses denote the number of RCTs 
that investigated the associated comparison, followed by the combined number of patients in those 
RCTs. 





Table 3.12 Network meta-analysis results – Dilatation for dysphagia rate 
3-12 months 
 APF PPF Nissen BM IV Hill  
PPI 28.52 (0.36, 2230.42) 3.42 (0.16, 73.87) 9.51 (0.50, 179.04) 11.30 (0.22, 568.51) 26.72 (0.91, 781.95)  
APF  0.12 (0.00, 3.41) 0.33 (0.01, 8.37) 0.40 (0.01, 24.83) 0.94 (0.02, 35.30)  
PPF   2.78 (1.12, 6.92)* 3.31 (0.21, 51.75) 7.82 (1.17, 52.32)*  
Nissen    1.19 (0.09, 15.92) 2.81 (0.53, 14.90)  
BM IV     2.36 (0.21, 26.81)  
1-5 years 
 PPF Nissen REY DD MHWC   
APF 2.73 (0.43, 17.37) 2.95 (0.69, 12.55) 0.36 (0.01, 10.44) 0.54 (0.02, 15.98)   
PPF  1.08 (0.34, 3.43) 0.13 (0.01, 3.41) 0.20 (0.01, 5.22)   
Nissen   0.12 (0.01, 2.55) 0.18 (0.01, 3.92)   
REY 
DD 
   1.48 (0.02, 109.46)   
*P < 0.05. Values in parentheses are 95% confidence intervals. Unit is odds ratio. A value >1 indicates that patients who underwent the 
treatment in the corresponding cell in the top row had a higher dilatation for dysphagia rate than patients who underwent the treatment in the 
corresponding cell in the left hand column, and a value <1 indicates the opposite. Missing treatments/time points mean no data available at 
this follow-up time point. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. BM IV = Belsey Mark IV. MHWC = Mesh hiatoplasty with 




Figure 3.20 Rankogram of fundoplications according to dilatation for dysphagia rate 
The probability of each included fundoplication ranking as the best, second best, third or worst 
treatment in the network is represented by the coloured bars. There were insufficient data for 
ranking at other time points, and no data for 90o fundoplication.  




Figure 3.21 summarises the direct evidence at 3-12 months for this outcome and Table 3.13 reports 
the NMA results. PPF patients were significantly less likely to require a reoperation by 5 years 
postoperatively compared to those who underwent a Nissen fundoplication. There was no evidence 
of significant between-study heterogeneity for this comparison. There were no significant 
differences otherwise between any of the groups at any time points. The fundoplication rankogram 








Figure 3.21 Network map of direct evidence for reoperation rate 
3-12 month data. The size of each circle (node) is proportional to the number of patients who 
received the treatment. The width of the lines represents the number of RCTs that directly 
compared the connected pairs of treatments. The values in parentheses denote the number of RCTs 
that investigated the associated comparison, followed by the combined number of patients in those 
RCTs. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial 




Table 3.13 Network meta-analysis results – Reoperation rate 
3-12 months 
 90o APF PPF Nissen Angelchik Hill  
PPI 1.00 (0.01, 114.98) 0.86 (0.01, 85.69) 0.34 (0.00, 30.09) 0.99 (0.01, 71.06) 3.67 (0.03, 461.71) 0.81 (0.01, 121.91) 
90o  0.87 (0.06, 13.10) 0.34 (0.03, 4.20) 1.00 (0.12, 7.98) 3.68 (0.17, 79.62) 0.81 (0.03, 23.23) 
APF   0.39 (0.09, 1.72) 1.15 (0.21, 6.35) 4.25 (0.25, 73.29) 0.94 (0.04, 21.57) 
PPF    2.94 (0.73, 11.76) 10.84 (0.76, 155.72) 2.39 (0.12, 46.79) 
Nissen     3.69 (0.38, 35.70) 0.81 (0.06, 11.30) 
Angelchik      0.22 (0.01, 7.12) 
1-5 years 
 APF PPF Nissen Angelchik REY DD Hill MHWC 
90o 1.14 (0.26, 4.98) 0.27 (0.08, 0.96)* 0.80 (0.25, 2.51) 1.52 (0.10, 23.22) 0.15 (0.01, 3.94) 0.69 (0.03, 14.01) 0.62 (0.10, 3.77) 
APF  0.23 (0.07, 0.79)* 0.70 (0.28, 1.75) 1.33 (0.10, 18.61) 0.13 (0.01, 3.21) 0.60 (0.03, 11.33) 0.54 (0.10, 2.88) 
PPF   2.97 (1.34, 6.56)* 5.67 (0.42, 76.01) 0.54 (0.02, 13.19) 2.56 (0.14, 46.45) 2.31 (0.46, 11.47) 
Nissen    1.91 (0.16, 22.63) 0.18 (0.01, 4.02) 0.86 (0.05, 14.02) 0.78 (0.19, 3.13) 
Angelchik     0.10 (0.00, 5.00) 0.45 (0.01, 18.70) 0.41 (0.02, 6.94) 
REY DD      4.73 (0.07, 304.95) 4.27 (0.14, 127.18) 
Hill       0.90 (0.04, 20.39) 
5-10 years 
 PPF Nissen    
APF 0.17 (0.02, 1.54) 0.72 (0.28, 1.84)    
PPF  4.17 (0.38, 45.18)    
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Table 3.13 continued   
>10 years 
 PPF Nissen    
APF 0.44 (0.02, 11.06) 0.44 (0.03, 6.04)    
PPF  1.00 (0.15, 6.62)    
*P < 0.05. Values in parentheses are 95% confidence intervals. Unit is odds ratio. A value >1 indicates that patients who underwent the 
treatment in the corresponding cell in the top row had a higher reoperation rate than patients who underwent the treatment in the corresponding 
cell in the left hand column, and a value <1 indicates the opposite. Missing treatments mean no data available at this follow-up time point. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. MHWC = Mesh hiatoplasty with cardiophrenicopexy. REY DD = 






Figure 3.22 Rankogram of fundoplications according to reoperation rate 
The probability of each included fundoplication ranking as the best, second best, third or worst 
treatment in the network is represented by the coloured bars. There were no significant differences 
between the treatments at all other time points, so rankograms were not calculated.  
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial 
fundoplication. PPI = Proton pump inhibitor. 
 
Postoperative complications 
Figure 3.23 summarises the direct evidence available for this outcome for both the main analysis, 
and the sensitivity analysis splitting the Nissen node according to bougie use and short gastric 
vessel division/preservation. None of the RCTs investigating PPI therapy reported complications 
in that group, so PPI was only included as a reference treatment to enable its use for indirect 
evidence. Allowing for this, there was no significant difference between any of the surgical 




Figure 3.23 Network map of direct evidence for postoperative complications 
A – main analysis, including all procedures with data for this outcome. B – sensitivity analysis (Nissen node split into four groups and non-
fundoplication procedures excluded). The size of each circle (node) is proportional to the number of patients who received the treatment. The 
width of the lines represents the number of RCTs that directly compared the connected pairs of treatments. The values in parentheses denote 
the number of RCTs that investigated the associated comparison, followed by the combined number of patients in those RCTs. 
90o = 90 degree fundoplication. APF = Anterior partial fundoplication. NSGVD = Nissen with short gastric vessel division. NSGVP = Nissen 





Table 3.14 Network meta-analysis results – Postoperative complications 
3-12 months 
 90o APF PPF Nissen Angelchik BM IV  
PPI 9.54 (1.00, 91.34) 31.60 (3.33, 300.02)* 22.37 (2.77, 180.78)* 15.02 (1.94, 116.09)* 19.52 (2.01, 189.80)* 13.08 (0.80, 214.55) 
90o  3.31 (0.87, 12.65) 2.35 (0.83, 6.66) 1.58 (0.60, 4.12) 2.05 (0.51, 8.17) 1.37 (0.16, 11.63)  
APF   0.71 (0.28, 1.77) 0.48 (0.19, 1.22) 0.62 (0.16, 2.43) 0.41 (0.05, 3.47)  
PPF    0.67 (0.44, 1.03) 0.87 (0.29, 2.58) 0.58 (0.08, 4.14)  
Nissen     1.30 (0.48, 3.52) 0.87 (0.13, 5.87)  
Angelchik      0.67 (0.08, 5.77)  
3-12 months (continued) 
 REY DD Hill MHWC     
PPI 15.02 (1.17, 193.40)* 19.24 (1.78, 207.56)* 9.33 (0.60, 146.02)     
90o 1.58 (0.26, 9.61) 2.02 (0.43, 9.50) 0.98 (0.12, 7.79)     
APF 0.48 (0.08, 2.87) 0.61 (0.13, 2.83) 0.30 (0.04, 2.33)     
PPF 0.67 (0.14, 3.30) 0.86 (0.24, 3.12) 0.42 (0.06, 2.76)     
Nissen 1.00 (0.22, 4.63) 1.28 (0.38, 4.31) 0.62 (0.10, 3.91)     
Angelchik 0.77 (0.12, 4.78) 0.99 (0.20, 4.74) 0.48 (0.06, 3.87)     
BM IV 1.15 (0.10, 13.27) 1.47 (0.23, 9.31) 0.71 (0.05, 10.10)     
REY DD  1.28 (0.18, 9.05) 0.62 (0.06, 6.80)     
Hill   0.48 (0.05, 4.39)     
*P < 0.05. Values in parentheses are 95% confidence intervals. Unit is odds ratio. A value >1 indicates that patients who underwent the 
treatment in the corresponding cell in the top row had a higher postoperative complication rate than patients who underwent the treatment in 
the corresponding cell in the left hand column, and a value <1 indicates the opposite. Missing treatments mean no postoperative complication 
rate data available. 
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90o = 90 degree fundoplication. APF = Anterior partial fundoplication. MHWC = Mesh hiatoplasty with cardiophrenicopexy. BM IV = Belsey 
Mark IV. MHWC = Mesh hiatoplasty with cardiophrenicopexy. REY DD = Roux-en-Y duodenal diversion. PPF = Posterior partial 





Gas bloat syndrome 
Figures 3.24 and 3.25 summarise the direct evidence available at 3-12 months, for rates and scores 
respectively. Most studies reported abdominal bloating or hyperflatulence only, and these data 
were not included. 
 
 
Figure 3.24 Network map of direct evidence for gas bloat rate 
3-12 month data. The size of each circle (node) is proportional to the number of patients who 
received the treatment. The width of the lines represents the number of RCTs that directly 
compared the connected pairs of treatments. The values in parentheses denote the number of RCTs 
that investigated the associated comparison, followed by the combined number of patients in those 
RCTs. 





Figure 3.25 Network map of direct evidence for gas bloat scores 
3-12 month data. The size of each circle (node) is proportional to the number of patients who 
received the treatment. The width of the lines represents the number of RCTs that directly 
compared the connected pairs of treatments. The values in parentheses denote the number of RCTs 
that investigated the associated comparison, followed by the combined number of patients in those 
RCTs. 
PPF = Posterior partial fundoplication.  
 
Tables 3.15 and 3.16 show the NMA results for rate and score data respectively. There were no 
significant differences between the groups at any of the time points, although there was a relative 
paucity of data for this outcome (Table 3.3). Predictive intervals were very wide, suggesting 
significant between-study heterogeneity. Pairwise meta-analysis and sensitivity analysis also 





Table 3.15 Network meta-analysis results – Gas bloat rate 
3-12 months 
 PPF Nissen Angelchik  
APF 1.36 (0.33, 5.66) 2.70 (0.50, 14.66) 0.34 (0.01, 12.76)  
PPF  1.98 (0.80, 4.94) 0.25 (0.01, 7.00)  
Nissen   0.13 (0.01, 3.11)  
1-5 years 
 Nissen Angelchik   
PPF 1.66 (0.69, 3.99) 1.52 (0.43, 5.40)   
Nissen  0.92 (0.28, 3.00)   
*P < 0.05. Values in parentheses are 95% confidence intervals. Unit is odds ratio. A value >1 
indicates that patients who underwent the treatment in the corresponding cell in the top row had a 
higher gas bloat rate than patients who underwent the treatment in the corresponding cell in the 
left hand column, and a value <1 indicates the opposite. Missing treatments/time points mean no 
data available. 
APF = Anterior partial fundoplication. PPF = Posterior partial fundoplication 
 
Table 3.16 Network meta-analysis results – Gas bloat scores 
3-12 months 
 Nissen MHWC   
PPF 1.95 (-1.79, 5.69) 1.90 (-5.55, 9.34)   
Nissen  -0.06 (-6.50, 6.38)   
1-5 years 
 Nissen MHWC   
PPF 0.09 (-0.38, 0.55) -0.23 (-0.87, 0.40)   
Nissen  -0.32 (-0.76, 0.12)   
*P < 0.05. Values in parentheses are 95% confidence intervals. Standardised mean difference, 
expressed as standard deviations. A positive value indicates that patients who underwent the 
treatment in the corresponding cell in the top row had higher scores (more gas bloat) than patients 
who underwent the treatment in the corresponding cell in the left hand column, and a negative 
value indicates the opposite. Missing treatments/time points mean no data available. 
MHWC = Mesh hiatoplasty with cardiophrenicopexy PPF = Posterior partial fundoplication.  
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3.4.6 Cluster plots of benefit and harm 
SUCRA clustered ranking plots are shown in Figure 3.26. Across all time points with sufficient 
data to enable this analysis, PPF was the only treatment which consistently ranked well in terms 




Figure 3.26 Clustered ranking plots of main treatments at different time points, according 











































Figure 3.26 Continued - Clustered ranking plots of main treatments at different time points, 











































Figure 3.26 Continued - Clustered ranking plots of main treatments at different time points, 
according to efficacy of reflux control and incidence of dysphagia  
Plots for dichotomous and continuous data analyses presented separately. The SUCRA value for 
each treatment is derived from the mean ranking in the network. A SUCRA value of 100 
corresponds to a 100% probability of that treatment ranking first for that outcome, and a value of 
0 corresponds to a 100% probability of that treatment ranking last. Treatments in the top right 
quadrant of the plot offer the best reflux control with the least dysphagia. Missing treatments 
indicate insufficient data to enable cluster analysis. There were insufficient continuous data 
beyond 5 years. Dichotomous data for the 5-10 year and 10+ year time points were combined to 
enable cluster analysis.  
90 deg = 90 degree fundoplication. APF = Anterior partial fundoplication. PPF = Posterior partial 





This NMA shows that a PPF strikes the best balance between reflux control and side effects 


















5+ year dichotomous data
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to medical therapy in terms of reflux control. These findings remain consistent through all follow-
up time points, and different outcome measures.  
 
Three previous pairwise MAs have compared PPF with NF alone (Broeders et al., 2010; Shan et 
al., 2010; Tan et al., 2011), concluding that PPF resulted in equivalent reflux control with less 
dysphagia, but these were not able to include other commonly performed procedures such as APF 
(Thompson and Watson, 2015). Other MAs have included PPF in a mixed “posterior” (Broeders 
et al., 2011; Memon et al., 2015) or “partial” (Ma et al., 2012; Varin et al., 2009) fundoplication 
group, and compared this to a second mixed group, with results that are difficult to interpret given 
the heterogeneous nature of the procedures within each group (Thompson and Watson, 2015). All 
of these prior MAs included a small number of RCTs (<12) as only direct comparisons could be 
used. Most only used the data reported at latest follow-up from each RCT, meaning that the 
analysis contained short and long term results from different patients. This introduces another 
source of heterogeneity as the prevalence of symptoms such as dysphagia changes considerably 
over time (Fuchs et al., 2014). 
 
The NMA methodology used in the present study has allowed much more RCT data to be included, 
with each procedure analysed simultaneously as a separate group in a manner that fully respects 
randomisation (Caldwell et al., 2005). The use of all available direct and indirect evidence 
substantially increased the precision of the effect estimates. Analysing data from different follow-
up time points separately also eliminated an important source of heterogeneity and allowed for the 
determination of outcome measures over time. These features substantially increase the external 
validity and clinical applicability of the results in comparison with previous reviews.  
 
Patient-reported symptoms and scores were used to assess all primary and several secondary 
outcomes in this review to enable a pragmatic evaluation of the procedures (Grant et al., 2013). 
More objective tools such as pH monitoring and endoscopy have traditionally been regarded as 
the best methods of assessing reflux control after surgery for GORD (Demeester et al., 1974), and 
manometry and mechanical studies have been used to assess side effects such as dysphagia (Booth 
et al., 2008). However there is evidence that the results of such investigations correlate poorly with 
clinical outcome following surgery (Anvari et al., 2011; Mathew et al., 1997; O'Boyle et al., 2002; 
Shaw et al., 2010; Walker et al., 1992). Furthermore, well patients with no substantial symptoms 
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are less likely to consent to further invasive tests postoperatively, which may bias the results (Cai 
et al., 2008).  
 
The best measure of surgical success is relief of symptoms without side effects as reported by the 
patient, particularly as the indication for anti-reflux surgery is usually patient preference and 
symptom severity (Shaw et al., 2010). Patient-reported symptom scores have been shown to 
correlate best with the actual outcome as perceived by the patient (Watson et al., 2012).  
 
This study has some potential limitations. The quality of included trials in any meta-analysis affect 
the validity of its results, and the risk of selection and performance bias in a proportion of included 
RCTs was assessed as unclear or high as blinding was not attempted or reported. Blinding was not 
possible in trials that compared surgical intervention with PPI therapy. Overall, trial quality did 
not considerably vary between comparisons and there was no evidence of systematic publication 
bias. 
 
The inclusion of non-fundoplication procedures, one of which is no longer performed because of 
safety concerns (Kmiot et al., 1991), may be questioned. However, this enabled the inclusion of 
indirect evidence from those RCTs, which increased the precision of the overall effect estimates. 
Furthermore, each of these older procedures were analysed as separate nodes in all analyses, and 
subjected to sensitivity analysis (by exclusion) to ensure that their inclusion did not influence the 
main findings. 
 
Endoscopic procedures for the treatment of GORD were not included in this review even though 
a number have been developed over the last decade as an alternative to surgery. Although initial 
reports showed some promise, subsequent sham-controlled studies have generally failed to 
demonstrate the efficacy of these techniques (Fry et al., 2007). The placebo response in some is 
up to 50% (Hogan, 2006) and several techniques were subsequently withdrawn from the market 
because of safety and durability concerns (Hogan, 2006). In view of this endoscopic anti-reflux 
procedures were not included in as specified a priori in the review protocol (Amer et al., 2014). 
 
Current US (Stefanidis et al., 2010) and European (Fuchs et al., 2014) guidelines suggest that the 
choice of anti-reflux procedure should be left to the individual surgeon according to their expertise 
117 
 
and regional practice as the conclusions of published trials and reviews have been mixed. This 
NMA, which incorporates the results of over 50 RCTs involving more than 5300 patients, 
challenges such guidelines by showing that a PPF provides the best balance of reflux control and 
dysphagia in comparison with all other anti-reflux procedures and medical therapy, and that this 
effect is durable. Future research should be directed at comparing novel procedures to PPF and 
improving the amount of long term follow-up data available for existing procedures, such as 




This review was able to incorporate the entirety of available RCT evidence on the surgical 
management of GORD, using NMA methodology. This has allowed for a simultaneous assessment 
and ranking of all the described interventions against clinically relevant measures of benefit and 
harm, which was not possible previously using standard MA methods. This methodology can be 
applied to other surgical research synthesis scenarios where multiple treatment options exist. 
 
The results of this review show that a PPF provides the best balance of long-term, durable reflux 
control with less dysphagia, compared to other treatments. While other procedures may be more 
suitable in carefully selected patients, PPF should be considered the standard intervention for the 



















Bias in surgical randomised trials: a meta-epidemiological study 
using laparoscopic versus open surgery as an example 
 
My contribution to this chapter 
This project was conceived by my supervisors (JLM, GPH and MDS) and myself. I drafted the 
project plan and revised it in conjunction with my supervisors. I designed the search strategy and 
performed all steps of the systematic search and review update process, and selected and extracted 
data from all identified eligible trials, with duplication by Samuel Grainger and Choo Khoo, two 
part-time research assistants employed for this project. Peter McCall assisted with data entry on a 
contract basis in preparation for analysis. I performed all of the analysis with expert advice from 
GPH. All drafts and the final text of this chapter were written by myself, with revisions in 
conjunction with my supervisors.  
 
 
4.1 Chapter summary 
Blinding, random sequence generation, and allocation concealment are established strategies to 
minimise bias in RCTs. Meta-epidemiological studies of drug trials have demonstrated 
exaggerated treatment effects in RCTs where such methods were not employed. As blinding is 
more difficult in surgical trials it is important to determine whether this applies to them. This study 
investigated whether lack of blinding, and other potential sources of bias in trial design, have a 
systematic effect on surgical RCT outcomes, using trials comparing laparoscopic and open surgery 
as an example. The Cochrane Database of Systematic Reviews was searched for systematic 
reviews of RCTs that compared laparoscopic and open abdominal surgical procedures. Each 
review was then scrutinised to determine whether at least one of the included trials was blinded. 
Eligible reviews were updated and individual RCTs retrieved. Extracted data included the primary 
outcomes of interest (length of stay and complications), secondary outcomes and a risk of bias 
assessment. A pairwise meta-analysis was performed for each procedure comparing laparoscopic 
and open surgery. Serial meta-regression was then used to determine how each bias-minimisation 
measure influences the size of the treatment effect within each procedure. The resulting 
coefficients were meta-analysed to obtain an overall difference between trials that employed bias-
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minimisation strategies, and those that did not. Five hundred and ninety six full-text articles were 
identified, and data from 316 RCTs were included, reporting on eight different procedures. Patient-
blinded RCTs reported a smaller difference in length of stay between laparoscopic and open groups 
(difference of standardised mean differences (DSMD) -0.36 (CI) -0.73, 0.00)), and complications 
(ratio of odds ratios (ROR) 0.76 (CI 0.61, 0.93)). Blinding of postoperative carers and outcome 
assessors had similar effects on reported outcomes. This study shows that lack of blinding 
significantly alters the treatment effect estimates of RCTs comparing laparoscopic and open 
surgery, and may lead to erroneous conclusions. Blinding should be implemented in procedural 




RCTs are well established as the ideal trial design for assessing the benefits and harms of 
healthcare interventions, as they can account for unmeasured confounders (Stirrat et al., 1992). 
This is important in the context of novel surgical techniques, which should undergo rigorous 
scientific validation prior to widespread uptake (Meakins, 2009; Potter et al., 2014; Russell, 1995). 
The objectiveness and validity of RCTs is critical as their results and the conclusions of subsequent 
meta-analyses substantially influence evidence-based clinical practice and health policy (Moher 
et al., 1998). 
 
One challenge for the validity of RCTs is the potential for outcome assessments of interventions 
to systematically deviate from the true effect size because of bias arising from preconceptions and 
predispositions such as optimism, the placebo effect and observer bias (Hrobjartsson et al., 2012; 
Schulz and Grimes, 2002). The different terms used to describe these biases, their sources and 
relevance to surgical RCTs in particular have been detailed in Chapter 1, as well as strategies to 
counter them such as blinding, random sequence generation and allocation concealment.  
 
There are several examples of novel procedural interventions where early non-blinded RCTs 
appeared to show superiority over established treatments, whereas subsequent appropriately 
blinded RCTs concluded that the novel procedure is no more effective than the established 
treatment or a sham procedure. Renal artery denervation for the treatment of hypertension (Shun-
Shin et al., 2014), endoscopic sphincterotomy for pain after cholecystectomy (Cotton et al., 2014), 
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embryonic dopamine neuron implantation for severe Parkinson’s (McRae et al., 2004) and 
arthroscopic partial meniscectomy for degenerative tears (Sihvonen et al., 2013) are all recent 
examples of this.  
 
Research methodology studies have shown that lack of blinding in RCTs results in an exaggeration 
of the treatment effect of interventions. In serial systematic reviews of RCTs with both blinded 
and non-blinded outcome assessors, Hrόbjartsson et al demonstrated an exaggerated treatment 
effect of between 27% and 68% with respect to binary (Hrobjartsson et al., 2012), continuous 
(Hrobjartsson et al., 2013) and time-to-event outcomes (Hrobjartsson et al., 2014). However, these 
systematic reviews included data from fewer than 25 RCTs each. Meta-epidemiological studies 
can incorporate a much greater number of studies and therefore much more data (Stirrat et al., 
1992). All such studies published to date have included trials investigating a wide range of 
treatments across a range of disciplines. The effect of blinding and other bias-minimisation 
measures specifically on RCTs of surgical procedures has not been examined. 
 
Laparoscopic surgery was first introduced into general surgical practice in the 1980s, having first 
been described by Georg Kelling in 1901 (Schollmeyer et al., 2007), and almost 30 years after its 
introduction to gynaecological practice (Cuschieri, 1989). It has been argued that no other 
development has had such a dramatic and pivotal impact on surgery worldwide (Neugebauer et 
al., 1995). Many general surgical procedures have subsequently transitioned from an open to a 
laparoscopic approach with the latter often becoming accepted as the ‘standard of care’ (Russell, 
1995) before definitive evidence from well-designed RCTs (Neugebauer et al., 1991). The added 
cost of laparoscopic surgery is widely considered to be offset by benefits such as shorter 
postoperative hospitalisation, quicker return to work, less postoperative pain and fewer 
postoperative complications (Cuschieri et al., 1990). This is in part based on MAs of RCTs, most 
of which were non-blinded (McCulloch et al., 2002). 
 
This chapter reports the results of a meta-epidemiological study using individual trial data to 
investigate whether lack of blinding and other potential sources of bias in surgical RCT design 
systematically affect subjective trial outcomes, using RCTs comparing laparoscopic and open 






A study protocol was prepared and agreed upon a priori. 
 
4.3.1 Search strategy and selection criteria 
Any abdominal surgical procedure which is performed both laparoscopically and open was 
included, where the two approaches have been compared in RCTs and where at least one of those 
trials was blinded. A blinded RCT was defined as a trial where the patients, healthcare staff, data 
collectors, outcome assessors, and/or data analysts were unaware of the patient’s assigned 
treatment (Fergusson et al., 2004; Haahr and Hrobjartsson, 2006; Montori et al., 2002) for at least 
the duration of the patient’s postoperative hospital stay. The definitions for these blinding 
categories were as follows: 
 
- Patients were defined as the individuals who were assigned to one of the approaches. 
- Healthcare staff were defined as the nurses, doctors and other personnel (apart from the operating 
surgeon) who cared for the patients during the study period. 
- Data collectors were defined as the individuals who collected data for the study outcomes (e.g. 
administered a questionnaire on postoperative pain). 
- Outcome assessors were defined as the individuals who decided if a participant had attained or 
suffered the outcome of interest (e.g. return of intestinal function or postoperative complications). 
- Data analysts were defined as the individuals who conducted the data analysis. 
 
All randomised and quasi-randomised trials were included. Quasi-randomisation was defined as 
the use of methods such as alternation, or assignment on the basis of date of birth, record number, 
day of admission or similar (Higgins and Green, 2011). No language, publication status or year of 
publication restrictions were applied. All citations were in English, as translated by the databases. 
Abstracts and full texts in French, German and Japanese were able to be translated by the data 
extractors. Studies in other languages were translated using Google translate (Jackson et al., 2019). 
Non-randomised trials and studies investigating single-incision laparoscopic or natural orifice 
endoscopic approaches were excluded. 
 
The systematic search for eligible trials was conducted in three stages. 
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Eligible procedure search 
Firstly, the Cochrane Library was searched from inception to March 2015 using a structured 
strategy (Appendix D1) to identify systematic reviews where a laparoscopic and open approach to 
an abdominal general surgical procedure was compared. The Cochrane Library search included 
the following resources: 
1. The Cochrane Database of Systematic Reviews.  
2. The Database of Abstracts of Reviews of Effects.  
3. The Cochrane Methodology Register. 
4. The Health Technology Assessment (HTA) Database. 
5. The NHS Economic Evaluation Database. 
 
The ‘related articles’ feature in PubMed and the reference lists of identified systematic reviews 
were also checked to identify further potentially relevant reviews. All potentially eligible 
systematic reviews were then scrutinised to determine whether at least one of the included RCTs 
were blinded. A list of eligible procedures was then drawn up.  
 
All RCTs included in the identified systematic reviews assessing each procedure were checked for 
eligibility for this study. Lists of studies excluded from those reviews were also checked where 
available to determine whether any were eligible for this study. This was pertinent in several 
instances where the published systematic review had excluded quasi-randomised trials. 
 
Review search update 
Secondly, for each eligible procedure, the published search strategy of the most recent review was 
used to update the systematic search for RCTs comparing a laparoscopic and open approach, by 
searching the same electronic databases as the original review, or the following at a minimum: the 
Cochrane Library, MEDLINE and EMBASE. 
 
If the most recent review had no available published search strategy, an alternative review for the 
same procedure with a published strategy was selected. The database search dates were customised 
to overlap with the most recent calendar year of the published reviews’ searches for that procedure 
(e.g. if the most recent published review’s search was to May 2010, the search start date was set 




The results of each search were combined in a spreadsheet and duplicate citation records were 
excluded. Multiple (non-duplicate) publications of the same trial were retained in case all data 
were not reported in both. Study protocols were also retained to aid in assessing study methodology 
(risk of bias assessment). Two reviewers independently screened all titles and abstracts for 
eligibility, then the full text of potentially eligible trials against the selection criteria. Systematic 
reviews identified in this update process were also retrieved, and the included and excluded studies 
lists checked for eligible RCTs. Disagreement was resolved by consensus and discussion with a 
third author when required. 
 
Retrieval of eligible trials 
Finally, procedure-specific lists of RCTs were drawn up, combining all eligible RCTs identified 
in either of the above two steps. These RCTs were individually retrieved and assessed for relevant 
outcomes before inclusion. 
 
4.3.2 Outcome measures 
Trials that reported any of the following outcomes for an eligible procedure were included. All 
outcomes and their definitions were agreed upon a priori. 
 
Primary outcomes 
1. Length of postoperative stay (in days). 
2. Postoperative complication rate (as defined by trial authors).  
 
Secondary outcomes 
1. Time to recovery (number of postoperative days to return to work or usual activity as defined 
by trial authors). 
2. Postoperative pain (measured by ordinal, visual analogue or composite scales). This outcome 
was divided into short-term (<4 weeks) and long-term pain (≥4 weeks) for all procedures.  
3. Return of intestinal function (number of postoperative days to first passage of flatus, and first 





4.3.3 Data extraction and quality assessment 
Two reviewers independently extracted and recorded data from each included RCT, including key 
patient and intervention characteristics and relevant outcome data, using a pre-piloted data 
extraction form (Appendix D2), based on the Cochrane Collaboration’s Data Collection Form 
Template (Cochrane, 2013). Discrepancies were resolved by discussion and arbitration by a third 
reviewer when required.  
 
Where studies reported both time to return to work and time to usual activity, the latter was 
preferentially extracted as return to employment is not universal and is influenced by the nature of 
each patient’s occupation. Postoperative pain data reported at multiple time points for different 
patient numbers within one of this study’s predefined time points (< and ≥ 4 weeks) were all 
extracted, and a ‘mini’ meta-analysis was performed using RevMan (Review Manager V5.3, The 
Nordic Cochrane Centre, Copenhagen) to obtain a summary statistic (MD) and measure of 
variance (standard error). These results were then entered as the data for postoperative pain (in the 
appropriate time subgroup) for that study. Different postoperative pain scales with an opposite 
direction of severity were inverted by subtracting the mean from the maximum possible value for 
the scale, to ensure all scales point in the same direction (Higgins and Green, 2011). Time to 
recovery and return of intestinal function data were converted from weeks and hours respectively 
into days when required to ensure data unit homogeneity.  
 
Missing statistics such as standard deviations were calculated from reported data where possible 
(Higgins and Green, 2011; Hozo et al., 2005). When standard deviations could not be calculated, 
these were imputed using the reported standard deviations from other trials for that outcome and 
procedure. 
 
Outcome data from RCTs reporting multiple laparoscopic or open arms (e.g. mini-incision and 
standard open, or gasless and standard laparoscopy) were combined where appropriate using the 
appropriate formulae (Higgins and Green, 2011). Ineligible treatment groups in multi-arm trials 
(such as robotic surgery) were excluded. 
 
The reviewers also independently conducted a detailed risk of bias assessment. This was based on 
the Cochrane Collaboration’s Risk of Bias tool (Higgins et al., 2011), with expansion of the 
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blinding domain into five separately assessed components to cover the blinding categories detailed 
earlier in Section 4.3.1. The following domains were also assessed: random sequence generation, 
allocation concealment, incomplete outcome data, selective outcome reporting, and other potential 
sources of bias (such as baseline imbalances or differential diagnostic activity). Each domain was 
assessed as low risk, high risk or unclear. Study protocols were used at this point where available, 
then excluded from subsequent steps. Disagreements were resolved by discussion or arbitration 
by a third reviewer where consensus could not be reached. 
4.3.4 Statistical analysis 
The extracted individual trial data were analysed using meta-epidemiological principles (Sterne et 
al., 2002) in three steps to determine the influence of each form of blinding, effective random 
sequence generation and allocation concealment on reported treatment effects, using the Stata 
(StataIC 13, StataCorp LP., College Station, Texas) statistical package and relevant commands. 
Firstly, a pairwise MA was performed for each procedure to determine the difference between a 
laparoscopic and open approach with regards each outcome of interest, using a random effects 
model and the metan command (Harris et al., 2008). The effect size for continuous data were 
summarised as an SMD (expressed as SD). Categorical data were summarised as odds ratios. 
Where reported data allowed for this, an intention-to-treat analysis was used. 
Secondly, binary codes were used for each study to separately denote whether each bias-
minimisation measure in question (such as blinding of patients) was used (0 = measure not used 
or unclear/high risk, 1 = measure used or low risk), as per the risk of bias assessment. Serial meta-
regression (sorted by procedure type) was then performed using the metareg command (Sharp, 
1998) to determine the difference in effect estimate between studies that used each measure and 
those that did not, for each outcome of interest using a random effects model (White, 2011). The 
results of this step were summarised as DSMDs for continuous data, and RORs for categorical 
data. 
Lastly, these meta-regression results were in turn meta-analysed using the metan command (Harris 
et al., 2008) across the procedures to obtain an overall difference in effect estimate between studies 
that used each bias-minimisation measure and those that did not, for each outcome of interest. 
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These results were summarised as DSMDs and RORs for continuous and categorical data 
respectively, and presented as forest plots with calculation of the I2 statistic to assess statistical 
heterogeneity between the procedures. A summative analysis comparing studies that used any 
form of blinding and those that did not was also performed for primary outcomes. 
 
Post hoc sensitivity analysis was performed where appropriate to determine the influence of the 
inclusion of procedures with fewer data. The results of these sensitivity analyses are reported 




4.4.1 Search results and study characteristics 
Eligible procedure search 
The results of the search for eligible procedures (first step of the systematic search) are summarised 
in Figure 4.1. Nine eligible procedures were identified through 50 systematic reviews of RCTs 
comparing a laparoscopic and open approach. An additional sixteen reviews were subsequently 
identified using Pubmed’s ‘related articles’ feature. The procedures and the number of potentially 
eligible RCTs identified at this stage of the search are listed in Table 4.1. 
 
 
Figure 4.1 Search for eligible procedures   
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Table 4.1 Selected Procedures 
Procedure Number of reviews* Number of articles† 
Appendicectomy 13 85 
Cholecystectomy 3 66 
Colonic resection 25 74 
Donor nephrectomy 4 20 
Fundoplicaton 2 22 
Gastric bypass 2 6 
Inguinal hernia 6 84 
Rectal resection 7 25 
Rectopexy 4 4 
Total 66 386 
*This includes systematic reviews identified using PubMed’s ‘related articles’ 
feature following the Cochrane Library’s database search. †The number of 
potentially eligible papers identified through the reviews’ included and 
excluded studies lists. These were later checked for duplicate publication and 
relevant outcomes (in step three) prior to inclusion. 
 
 
Review search update 
Table 4.2 lists the systematic reviews from which search strategies were used to update the search 
for each included procedure and the start date of each search. The study selection process following 
this is summarised in Figure 4.2 and detailed per procedure in Table 4.3. The potentially eligible 
RCTs identified at the conclusion of this step were then combined with those identified earlier 





Table 4.2 Review update strategies 
Procedure Review’s search strategy used Search start 
date* 
Appendicectomy (Sauerland et al., 2010) 2014 
Cholecystectomy (Keus et al., 2006) 2004 
Colonic resection (Sammour et al., 2011) 2012 
Donor nephrectomy (Wilson et al., 2011) 2013 
Fundoplicaton (Amer et al., 2014)† 2014 
Gastric bypass (Reoch et al., 2011)‡ 2010 
Inguinal hernia (McCormack et al., 2003) 2009 
Rectal resection (Vennix et al., 2014) 2013 
Rectopexy (Tou et al., 2008) 2010 
*Calendar year overlap with the latest published search for that procedure. 
Where the search strategy for the most recently published review was not 
available, another review’s strategy for that procedure was used instead. 
Therefore these dates do not necessarily correlate with the search dates of the 
systematic reviews from which the search strategy was used. †Study protocol 
with a published search strategy. ‡An initial search using this review’s 
strategy yielded over 10,000 citations, so after discussion with subject experts 





Figure 4.2 Review update search and study selection flowchart 





Table 4.3 Review update study selection process 
Procedure Database Citations* Abstracts† Full 
texts‡ 
Hand-search§ 
Appendicectomy Cochrane 84    
 MEDLINE 20    
 EMBASE 382    
 Total# 486 18 6 6 
      
Cholecystectomy Cochrane 1503    
 MEDLINE 2087    
 EMBASE 1260    
 Total# 4670 78 49 4 
      
Colonic resection Cochrane 122    
 MEDLINE 185    
 EMBASE 224    
 Total# 504 62 24 3 
      
Donor 
nephrectomy 
Cochrane 8    
MEDLINE 61    
 EMBASE 71    
 Total# 136 0 0 0 
      
Fundoplication Cochrane 29    
 MEDLINE 67    
 EMBASE 36    
 Total# 132 13 2 4 
      
Gastric bypass Cochrane 1642    
 MEDLINE 1144    
 EMBASE 2839    
 Total# 5426 22 3 0 
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Table 4.3 continued 
Procedure Database Citations* Abstracts† Full 
texts‡ 
Hand-search§ 
Inguinal hernia Cochrane 195    
 MEDLINE 742    
 EMBASE 1158    
 Total# 2034 79 59 22 
      
Rectal resection Cochrane 560    
 MEDLINE 110    
 EMBASE 1025    
 Total# 1666 47 23 4 
      
Rectopexy Cochrane 5    
 MEDLINE 520    
 EMBASE 1001    
 Total# 1467 2 1 0 
*Number of citation returns per database searched using the search strategy and search start date 
listed in Table 4.2. This includes duplicate citations. †Number of abstracts selected from the title 
search. ‡Number of full texts selected from abstract review. §Number of articles identified through 
a hand-search of additional systematic reviews identified through this review search update 
process. These were retrieved and subjected to full text review. #Total number of citation returns 
from all three databases for each procedure’s review search update. This total excludes duplicate 
citations from individual databases, so is usually a smaller number than the sum total of results 
from the databases. 
133 
 
Retrieval of eligible trials 
A combined total of 596 full text articles were assessed at this final stage of the search process for 
eligibility. Flowcharts summarising the exclusions and final number of included trials per 
procedure are presented in Figures 4.3 – 4.11. Three hundred and forty eight eligible papers were 
identified, reporting on a total of 318 RCTs (Appendix D3). RCTs comparing a laparoscopic and 
open approach for four procedures (appendicectomy, cholecystectomy, colonic resection and 
inguinal hernia) constituted over 85% of the included studies. There were only two eligible studies 
assessing rectal rectopexy, meaning that there were insufficient data to include this procedure in 
subsequent analysis.  
 
Table 4.4 lists the number of RCTs with each bias-minimisation measure included in every 
outcome analysis per procedure. Over 12% of the included studies were blinded according to the 
pre-specified definition in this study, with the proportion of blinded RCTs per procedure ranging 
from 6% to 50%. Most studies did not continue blinding beyond patient discharge. Only one study 
(Solomon et al., 2002) reported blinding of data analysts, but as there were insufficient other data 
for this procedure (rectal rectopexy) analysis of this bias-minimisation measure was not possible.  
 
 





Figure 4.4 Cholecystectomy eligible trial selection 
 
 








Figure 4.6 Donor nephrectomy eligible trial selection 
 
 





Figure 4.8 Gastric bypass eligible trial selection 
 
 







Figure 4.10 Rectal resection eligible trial selection 
 
 
Figure 4.11 Rectopexy eligible trial selection 
The eligible rectopexy RCTs could not be included in subsequent analyses as there were 
insufficient trials for meta-regression for this procedure.
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Table 4.4 Included trials with bias-minimisation measures  

























Length of stay Appendicectomy 7 7 6 4 35 7 
 Cholecystectomy 6 6 4 4 22 4 
 Colonic resection 7 6 8 3 29 15 
 Donor nephrectomy 1 1 - - 3 2 
 Fundoplication 2 2 2 1 4 2 
 Gastric bypass 2 2 - - - 1 
 Inguinal hernia 3 2 2 - 42 10 
 Rectal resection - - - - 10 7 
        
Complications Appendicectomy 6 6 5 3 36 7 
 Cholecystectomy 5 5 4 3 24 2 
 Colonic resection 7 6 8 3 29 16 
 Donor nephrectomy 1 1 - - 3 2 
 Fundoplication 2 2 2 1 3 2 
 Gastric bypass 2 2 - - - 1 
 Inguinal hernia 4 3 3 1 55 14 
 Rectal resection - - - 1 12 7 
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Table 4.4 continued 

























Time to recovery Appendicectomy 4 3 4 3 21 4 
 Cholecystectomy 4 4 3 2 12 3 
 Colonic resection 1 1 2 - - 1 
 Donor nephrectomy 1 1 - - 2 2 
 Fundoplication 1 1 1 1 2 1 
 Gastric bypass 2 2 - - 2 - 
 Inguinal hernia 4 3 2 1 45 11 
        
Short-term pain Appendicectomy 4 4 4 2 13 3 
 Cholecystectomy 3 3 1 1 11 1 
 Colonic resection 4 3 6 1 16 6 
 Donor nephrectomy 1 1 - - 3 2 
 Inguinal hernia 3 3 3 1 38 7 
 Rectal resection - - - - 3 3 
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Table 4.4 continued 

























Long-term pain Cholecystectomy 1 1 1 - - - 
 Colonic resection 1 1 1 1 5 3 
 Donor nephrectomy 1 1 - - 2 1 
 Inguinal hernia - - - - 11 5 
        
Time to flatus Cholecystectomy - - - - 2 1 
 Colonic resection 1 2 2 1 12 7 
 Rectal resection - - - 1 8 6 
        
Time to bowel 
motion 
Appendicectomy - - - - 1 - 
Cholecystectomy - - - - 1 - 
 Colonic resection 3 3 2 2 13 6 
 Rectal resection - - - 1 8 8 
*There were insufficient rectopexy trials to include this procedure in any analysis, so it is not listed here. Procedures with reported data for an outcome but where these 
were insufficient for inclusion in the relevant analysis are not listed under that outcome. †Only one trial (assessing rectopexy) reported blinding of data analysts (which 
could not be analysed due to insufficient data for that procedure), so assessment of this bias-minimisation measure was not possible. ‡A dash (-) indicates that there were 
insufficient data to include that procedure in the analysis for that bias-minimisation measure and outcome. For a procedure to be included at least one of the RCTs 
reporting that outcome had to report use of the bias-minimisation measure in question, with sufficient data available from other trials (which did not use that measure) 
assessing the same outcome for that procedure. §As non-randomised studies were not included, this domain assessed whether generation of the randomisation sequence 
was correctly performed according to the Cochrane Risk of Bias tool’s criteria, rather than the presence or absence of randomisation.
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4.4.2 Length of stay 
A total of 254 RCTs reported this outcome, of which two investigated rectopexy and were unable 
to be included in any of the analyses because of insufficient data. Length of stay meta-regression 
results are shown in Figures 4.12 – 4.18, with a summative analysis of any blinding in Figure 4.16.  
 
Studies that used a blinding measure reported a smaller difference in length of stay between the 
laparoscopic and open groups compared to those that did not use that blinding measure, and this 
difference was up to 0.5 SD. The point estimates in each analysis show that this was consistent 
across the majority of procedures, and the I2 statistic for most analyses was low, indicating low 
between-procedure heterogeneity. The summative analysis further demonstrates this with blinded 
trials reporting a smaller difference of 0.34 SD compared to non-blinded trials. 
 
RCTs judged to have generated an appropriate randomisation sequence also reported a smaller 
difference in length of stay between the laparoscopic and open groups. However, this difference 
was not statistically significant and the I2 statistic for this analysis showed evidence of significant 
between-procedure heterogeneity. This was largely driven by the result for donor nephrectomy 
trials, which were a relatively small number (seven). Sensitivity analysis excluding this procedure 
showed a much smaller I2 statistic, and a similar overall result. Allocation concealment did not 







Figure 4.12 Length of stay forest plot – meta-regression of patient blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.13 Length of stay forest plot – meta-regression of healthcare staff blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.14 Length of stay forest plot – meta-regression of data collector blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.15 Length of stay forest plot – meta-regression of outcome assessor blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 






Figure 4.16 Length of stay forest plot – meta-regression of any blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.17 Length of stay forest plot – meta-regression of random sequence generation 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 






Figure 4.18 Length of stay forest plot – meta-regression of allocation concealment 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





This was the most commonly reported outcome with data from 281 studies available for analysis, 
after exclusion of one study investigating rectopexy. Figures 4.19 – 4.25 summarise the meta-
regression results for this outcome, and the summary ‘any blinding’ analysis is shown in Figure 
4.23. 
 
Significantly smaller differences in the number of complications between the laparoscopic and 
open groups were reported by studies where patients and healthcare staff were blinded compared 
to those where those groups were not. The I2 statistic for both these analyses was zero, meaning 
no evidence of between-procedure heterogeneity. For most procedures, smaller differences were 
also reported by studies where data collectors and outcome assessors were blinded, though fewer 
data were available for these analyses and the confidence intervals included the null value (ROR 
= 1). The summative analysis (Figure 4.25) shows a similar result to the individual blinding 
analyses. 
 
Appropriate generation of a randomisation sequence was also associated with a smaller reported 
difference in the complication rate between the laparoscopic and open groups, though this was not 
statistically significant and point estimates for the procedures were variable. The reported 







Figure 4.19 Complications forest plot – meta-regression of patient blinding 
Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used this bias-minimisation measure 
reported a small difference compared to studies that did not. 





Figure 4.20 Complications forest plot – meta-regression of healthcare staff blinding 
Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used this bias-minimisation measure 
reported a small difference compared to studies that did not. 





Figure 4.21 Complications forest plot – meta-regression of data collector blinding 
Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used this bias-minimisation measure 
reported a small difference compared to studies that did not. 





Figure 4.22 Complications forest plot – meta-regression of outcome assessor blinding 
Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used this bias-minimisation measure 
reported a small difference compared to studies that did not. 






Figure 4.23 Complications forest plot – meta-regression of any blinding 
Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used this bias-minimisation measure 
reported a small difference compared to studies that did not. 





Figure 4.24 Complications forest plot – meta-regression of random sequence generation 
Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used this bias-minimisation measure 
reported a small difference compared to studies that did not. 





Figure 4.25 Complications forest plot – meta-regression of allocation concealment 
Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used this bias-minimisation measure 
reported a small difference compared to studies that did not. 




4.4.4 Secondary outcomes 
Time to recovery 
One hundred and forty one studies reported this outcome, with insufficient data available for rectal 
resection to enable inclusion in the analyses. Analysis results are summarised in Figures 4.26 – 
4.31. None of the blinding groups were still blinded at the time this outcome was attained by 
patients, so comparisons are between studies where blinding had occurred at the initial stages (e.g. 
before patient discharge) compared to others where no blinding was attempted during the trial. 
 
A smaller difference in time to recovery between laparoscopic and open groups was reported by 
studies where any of the blinding measures were undertaken compared to non-blinded RCTs, apart 
from data collectors. Although the 95% confidence intervals for these analyses included zero, this 
was partly influenced by the results for colonic resection RCTs, which were only four for this 
outcome with just one blinded study. Sensitivity analysis excluding this procedure resulted in 
narrower confidence intervals for the difference between blinded and non-blinded studies. 
 
Both correctly performed random sequence generation and allocation concealment also influenced 
the reported results of trials, with studies where those measures were used reporting a smaller 
difference in time to recovery across most procedures. Confidence intervals for both analyses 





Figure 4.26 Time to recovery forest plot – meta-regression of patient blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.27 Time to recovery forest plot – meta-regression of healthcare staff blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.28 Time to recovery forest plot – meta-regression of data collector blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 






Figure 4.29 Time to recovery forest plot – meta-regression of outcome assessor blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.30 Time to recovery forest plot – meta-regression of random sequence generation 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.31 Time to recovery forest plot – meta-regression of allocation concealment 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 




Short term pain 
Pain score data were reported by a total of 122 RCTs for six procedures, with insufficient data 
available to include fundoplication and gastric bypass trials. Figures 4.32 – 4.37 show the analysis 
results for each bias-minimisation measure. 
 
RCTs where outcome assessors were blinded reported a significantly smaller difference in short-
term pain between laparoscopic and open groups compared to studies where outcome assessors 
were not blinded (Figure 4.35). This effect was large (1.4 SD), and the I2 statistic for this analysis 
showed no evidence of between-study heterogeneity, as did the point estimates for the contributing 
procedures. Blinding of other groups also influenced the reported results of trials though this was 
not statistically significant, and with considerable heterogeneity between procedures. 
 
Studies judged to have generated an appropriate randomisation sequence reported a greater 
difference in short-term pain between laparoscopic and open groups compared to those that were 
not (Figure 4.36). This result was consistent across procedures, but not statistically significant. 
Analysis of the effect of allocation concealment showed a similar result though with significant 






Figure 4.32 Short-term pain forest plot – meta-regression of patient blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.33 Short-term pain forest plot – meta-regression of healthcare staff blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.34 Short-term pain forest plot – meta-regression of data collector blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 






Figure 4.35 Short-term pain forest plot – meta-regression of outcome assessor blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 






Figure 4.36 Short-term pain forest plot – meta-regression of random sequence generation 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.37 Short-term pain forest plot – meta-regression of allocation concealment 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Thirty-two trials comparing a laparoscopic and open approach to seven procedures reported this 
outcome, but a paucity of data meant that only up to three procedures (cholecystectomy, colonic 
resection and donor nephrectomy) were able to be included in each of the blinding analyses, with 
data from a total of just twelve trials. Data from RCTs investigating inguinal hernia were also 
included in the random sequence generation and allocation concealment analyses.  
 
The forest plot summarising the analysis for patient blinding is shown in Figure 4.38, and shows 
no significant influence on the reported difference in long-term pain. As mentioned earlier 
however, this should be interpreted with caution as the included data were from a very small 
number of studies, and there was evidence of substantial between-procedure heterogeneity with 
an I2 statistic of over 90%. Analysis results for healthcare staff and data collector blinding were 
similar (forest plots not shown). Only one procedure (colonic resection) reported sufficient data 
for outcome assessor blinding analysis with the result suggesting that studies with this form of 
blinding reported an increased difference in long-term pain (DSMD 1.00, 95% CI 0.57, 1.44). 
However, this was based on data from just five trials with only one blinded RCT, and between-
study heterogeneity was high (I2 = 100%). 
 
Data for the effect of appropriate random sequence generation and allocation concealment on 
reported long-term pain results were available from nineteen studies investigating three 
procedures. Analysis results (Figures 4.39 and 4.40) showed that use of either of these bias-
minimisation measures was associated with a greater reported difference in long-term pain 
between the laparoscopic and open groups. There was no statistical evidence of heterogeneity (I2 
= 0%), though the point estimates for each procedure varied in both analyses. These results were 





Figure 4.38 Long-term pain forest plot – meta-regression of patient blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 







Figure 4.39 Long-term pain forest plot – meta-regression of random sequence generation 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 







Figure 4.40 Long-term pain forest plot – meta-regression of allocation concealment 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 




Return of intestinal function 
This outcome was not commonly reported, with time to first passage of flatus reported by 32 RCTs 
investigating four procedures (appendicectomy, cholecystectomy, colonic resection and rectal 
resection), and time to first passage of bowel motion reported by 33 RCTs for five procedures (the 
same four procedures above with the addition of rectopexy). However, as few of these trials used 
bias-minimisation, the number of procedures included in each analysis for this outcome were much 
fewer. 
 
Data for only one to two procedures (colonic and rectal resection) were able to be included in the 
meta-regressions investigating the effect of each blinding measure on reported time to first passage 
of flatus and time to first bowel motion. All these analyses showed a smaller reported difference 
in time to return of intestinal function between studies that used each blinding measure and those 
that did not (Figure 4.41 shows one example), though confidence intervals were wide (all included 
zero), and some of the analyses showed evidence of significant heterogeneity.  
 
RCTs assessed as appropriately generating a randomisation sequence and concealing it effectively 
reported a smaller difference in time to return of intestinal function between laparoscopic and open 
groups compared to other studies (Figures 4.42 – 4.45), though this difference was often not 






Figure 4.41 Return of intestinal function (time to first passage of flatus) forest plot – meta-regression of outcome assessor 
blinding 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 






Figure 4.42 Return of intestinal function (time to first passage of flatus) forest plot – meta-regression of random sequence 
generation 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.43 Return of intestinal function (time to first passage of bowel motion) forest plot – meta-regression of random 
sequence generation 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.44 Return of intestinal function (time to first passage of flatus) forest plot – meta-regression of allocation 
concealment 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





Figure 4.45 Return of intestinal function (time to first passage of bowel motion) forest plot – meta-regression of allocation 
concealment 
Unit is standard deviations. Weights are based on random effects meta-analysis. Values to the left of midline indicate that studies that used 
this bias-minimisation measure reported a small difference compared to studies that did not. 





This study shows that trials comparing a laparoscopic and open approach to general surgical 
procedures reported significantly smaller differences in outcome measures between the 
intervention groups when patients, healthcare staff or outcome assessors were blinded, and when 
random sequence generation was performed correctly. This finding is consistent across procedures 
and multiple outcome measures, including outcomes where the endpoint is reached after un-
blinding such as time to recovery. Blinding of data collectors and concealment of the allocation 
sequence were also found to be influential but to a lesser extent, with no statistically significant 
differences in the reported results of RCTs that used either of those two measures compared to 
those that did not.  
 
Quantitative interpretation of the results using rules of thumb for SMDs (Higgins and Green, 2011) 
alone may suggest that the influence of lack of these bias-minimisation measures is small (SD < 
0.4). However, RCTs comparing a laparoscopic and open approach have commonly reported 
similar small differences between the intervention groups (McCulloch et al., 2002), but these have 
been interpreted as clinically important and have contributed to change in the accepted standard 
surgical practice (Russell, 1995). Systematic bias arising from failure to use bias-minimisation 
measures may have therefore contributed to a type I error in some of those trials. 
 
Several meta-epidemiology studies have concluded that RCTs where blinding is not performed 
report an exaggerated treatment effect (Savovic et al., 2012; Schulz et al., 1995; Wood et al., 2008). 
Similar results have been reported from studies investigating the influence of random sequence 
generation (Siersma et al., 2007). These studies have however been criticised for being too 
heterogeneous (Hrobjartsson et al., 2012) as they pooled meta-analyses from a wide range of 
disciplines reporting on a variety of different outcome measures, and some relied on a binary (yes 
or no) definition of blinding without differentiating between the various forms blinding can take 
(Devereaux et al., 2001). Furthermore, these studies relied on the risk of bias assessments of the 
included meta-analyses, which may have used different definitions or relied on ambiguous 
statements such as “this study was double-blinded” (Hill et al., 2002; Schulz and Grimes, 2002). 
The validity of these results, particularly in relation to procedural trials which were under-
represented in the data pool, is therefore questionable. Other studies have attempted to minimise 
heterogeneity by analysing data from studies that reported both blinded and un-blinded outcome 
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assessment thus ensuring that the same outcomes were being compared (Hrobjartsson et al., 2012, 
2013; Hrobjartsson et al., 2014). Only a small number of RCTs are designed in this manner 
however, so such studies have included very limited data. Additionally, these studies could only 
assess the influence of one form of blinding. 
 
The present study incorporated design elements from both types of studies including individual 
trial data, a standardised comprehensive risk of bias assessment across all included studies, a 
defined set of relevant outcome measures and meta-epidemiological analysis, as well as other 
elements such as an assessment of individual forms of blinding and standardisation of the 
intervention comparison (laparoscopic versus open). The outcome measures used in this study are 
more likely to be influenced by systematic bias arising from trial design and are patient-relevant 
endpoints commonly reported in studies comparing surgical techniques. All of these features 
allowed for a novel, systematic and pragmatic assessment of the influence of each of several bias-
minimisation strategies on the reported results of surgical RCTs in a manner that substantially 
minimises heterogeneity and ensures external validity. 
 
There are some potential limitations to this study. The proportion of blinded studies was relatively 
small for some procedures, which may affect power, and there were insufficient data to allow for 
an assessment of the influence of data analyst blinding. Although this may be due to incomplete 
reporting of methods leading to a high proportion of unclear risk of bias assessments, the procedure 
and trial selection process was systematic and sensitive, so this is more likely reflective of the 
relative paucity of blinded trials in the surgical trial literature (Karanicolas et al., 2008), which 
highlights the need for the present study.  
 
The statistical analysis was performed as a univariate meta-regression model, meaning that the 
result for each bias-minimisation measure did not independently take into account the presence or 
absence of other measures. This means that confounding may be contributing to some of the 
findings. Multivariate meta-regression was not possible due to the low proportion and number of 
blinded trials for each procedure, and combining trials across procedures to facilitate this would 
have introduced significant heterogeneity and decreased the validity of the findings. The 
consistency of the findings across outcomes and procedures for specific bias-minimisation 




Only one risk of bias assessment was completed for each included study, instead of a breakdown 
by outcome, which may affect the validity of the results with regards to end-points that are reached 
well beyond discharge from hospital (and un-blinding) such as time to recovery. However, the 
main purpose of this study was to pragmatically assess the influence of blinding per se within an 
RCT’s design on outcomes which are commonly reported in surgical RCTs, and it is 
acknowledged that it is difficult to maintain blinding in surgical trials beyond discharge, 
particularly of patients and healthcare staff. It is also pertinent to note that even such long-term 
outcomes were significantly affected by the presence or lack of the studied measures, suggesting 
that their bias-minimising effect extends well beyond their period of implementation in a study. 
 
The Consolidated Standards of Reporting Trials (CONSORT) statement (Schulz et al., 2010), a 
comprehensive set of guidelines on the reporting of randomised trials produced by an international 
expert group, specifies measures such as blinding and random sequence generation as features of 
robust RCT design. Some authors have argued that blinding is too difficult or unrealistic in surgical 
RCTs, and that non-blinding may not materially alter results (Patel et al., 2013; Pham et al., 2009; 
Vinuela et al., 2012). This systematic meta-epidemiological study, which included trial data from 
over 300 individual surgical RCTs, shows that lack of patient, healthcare staff and outcome 
assessor blinding, and lack of adequate random sequence generation, systematically alter the 
results of trials comparing different surgical approaches, which may lead to erroneous results and 
conclusions. These findings need to be taken into account when interpreting the results of 
published studies, and should be used to guide the design of future surgical trials. Further efforts 





The present study used meta-epidemiological methods at an individual trial level to 
comprehensively assess the effect of bias-minimisation measures including blinding on the 
reported outcomes of surgical RCTs comparing a laparoscopic and open approach to common 
abdominal surgical procedures. Although several previous studies have investigated the influence 
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of such measures on RCT results in general, none had specifically examined this effect on 
procedural trials where additional challenges to effective blinding exist. 
 
The results of this study show that RCTs that did not use blinding or adequate random sequence 
generation reported a significantly greater difference between treatment groups compared to trials 
where these bias-minimisation measures were used. This may lead to exaggerated differences in 
outcome measures in individual trials, and could also influence the results of subsequent meta-








The continuous development and refinement of techniques and treatments has long been a key 
attribute of the discipline of surgery (Brennan, 2008), in a quest to offer patients optimal care 
(Potter et al., 2014). Robust evidence derived from RCTs and subsequent MAs is therefore an 
indispensable tool in modern surgical practice. There are several challenges however to the 
development of this evidence. This thesis has addressed two of these challenges, namely the 
statistical synthesis of RCT data where multiple treatment comparisons exist, and the influence of 
non-blinding and other potential sources of bias on the results of surgical RCTs. 
 
The application of NMA methodology to surgical research synthesis to enable inclusive analysis 
of all available data and succinct conclusions was demonstrated in this thesis, using two examples. 
Both were conducted in accordance with the Cochrane Collaboration’s recommended 
methodology (Higgins and Green, 2011) and PRISMA guidelines (Hutton et al., 2015; Moher et 
al., 2009; Shamseer et al., 2015) to ensure rigor and validity.  
 
International guidelines groups have regarded preoperative carbohydrate loading as an integral 
part of enhanced recovery protocols and advocated for its routine use for all elective surgery 
(Cerantola et al., 2013; Gustafsson et al., 2013; Lassen et al., 2012; Mortensen et al., 2014; Nygren 
et al., 2013), even though individual RCTs had shown quite variable results. The NMA detailed in 
Chapter Two is the first study to include all data from all trials, regardless of the control treatment 
used in contributing RCTs. It showed conclusively that there was no additional benefit gained 
from CHO loading compared to water across all the clinically relevant outcomes assessed. This 
finding has already led to a change in the guidelines of two major international surgical societies 
(The American Society of Colon and Rectum Surgeons and the Society of American 
Gastrointestinal and Endoscopic Surgeons) (Carmichael et al., 2017), and reflects an evidence-
based change in practice. The paper reporting this NMA has been cited more than 25 times since 




Chapter Three of this thesis describes an NMA of surgical treatments for GORD, a very common 
condition for which multiple different surgical procedures exist. International surgical society 
recommendations were that the choice of procedure should be left to the individual surgeon due 
to conflicting data (Stefanidis et al., 2010), despite more than 50 RCTs involving thousands of 
patients published over more than four decades. The NMA detailed in Chapter Three included all 
published trials, analysed all of the available data and produced an objective ranking of the 
different procedures according to clinically important outcomes of benefit and harm. It showed 
that the best balance of risk and benefit for patients undergoing surgical treatment of GORD is 
obtained with posterior partial fundoplication. This NMA represents the first comprehensive 
synthesis of all the available RCT data and provides a definite answer to a clinical question that 
had been the subject of debate among surgeons for years (Amer et al., 2018). 
 
It has been known for some time that failure to implement bias-minimisation measures in clinical 
trials systematically alters the results and may lead to incorrect conclusions (Savovic et al., 2012; 
Schulz et al., 1995; Wood et al., 2008). Before now this issue had not been examined specifically 
in procedural trials despite the fact that procedures have a greater placebo effect than other forms 
of treatment (Kaptchuk et al., 2000; McRae et al., 2004) and may therefore be more prone to 
systematic bias. In addition, some of the standard bias-minimisation measures such as blinding are 
more difficult to implement in surgical trials. Chapter Four reports on a comprehensive meta-
epidemiological study using trial data from 316 individual RCTs to explore this question in detail, 
using the practical example of trials that compared laparoscopic versus open access for common 
abdominal surgical procedures. The results showed that trials where blinding or adequate random 
sequence generation were not performed reported a greater difference between the laparoscopic 
and open groups for endpoints such as length of stay and postoperative complication rates, 
compared to RCTs that used those bias-minimisation measures. These findings help to better 
inform the interpretation of already published trials, and guide the design of future surgical trials 
to ensure their objectiveness and validity.  
 
5.2 Future directions 
NMA methodology can be used to answer many more surgical research questions. During the 
course of this PhD, the author has been involved in three other collaborations using NMA 
methodology to assess the treatment options for early hepatocellular carcinoma (Swan et al., 
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2017), the surgical management of obesity (Grainger et al., 2018) and bowel preparation prior to 
colorectal surgery (Woodfield et al., 2017). Many more clinically relevant questions can be 
answered using NMA methodology where sufficient data exist to enable this. This potential has 
been a recurring theme in discussions following presentation of components of this thesis at 
national and international surgical meetings (List of Awards, Grants and Presentations). 
 
While it is important to produce trial reviews that can inform evidence-based recommendations, it 
is equally important that there is timely uptake of this information into clinical practice. Although 
many surgeons were among the early pioneers of RCTs, some recent qualitative studies have raised 
concerns regarding surgeons’ attitudes and uptake of RCT and systematic review findings (Lassen 
et al., 2005; Melis et al., 2010; Potter et al., 2014; Slim et al., 2004). This is in contrast to other 
surveys that concluded that modern surgical practice is evidence-based (Howes et al., 1997; Kenny 
et al., 1997; Kingston et al., 2001). All of these studies were conducted in Europe and North 
America, and there is little information about attitudes among the surgical community in 
Australasia. Michael Solomon and colleagues (Gattellari et al., 2001) conducted an Australasian 
survey and found mixed results: while most respondents were positive towards RCTs, they were 
sceptical regarding the applicability of the results to their everyday practice. However, this study 
was restricted to colorectal surgeons and is more than 15 years old. More information on current 
attitudes towards evidence-based practice is required through a large representative survey of 
Australasian surgeons across a range of surgical disciplines. This will help determine whether 
additional interventions and programmes are required to ensure recognition and timely uptake of 
high quality evidence. 
 
Finally, the importance of considering blinding and other bias-minimisation measures in 
evaluating current evidence and future surgical RCT design needs to be prioritised. Initiatives such 
as the Balliol Colloquia a decade ago may go some way in achieving this by bringing together 
experts and facilitating discussion, consensus and recommendations (Lancet, 2009; McCulloch et 
al., 2009). The inclusion of material on bias and trial design in courses for trainees and surgeons, 
such as the CLEAR (Critical Literature Evaluation and Research) course run by the Royal 
Australasian College of Surgeons (RACS, 2019) and similar courses in other jurisdictions (Potter 
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A1 Network meta-analysis of the effect of preoperative carbohydrate 





































































































A2 Registered review protocol – Surgical management of gastro-
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Preoperative carbohydrate loading systematic review and NMA – 
additional material 
 
B1 Search strategies  
CENTRAL search 
#1 MeSH descriptor Carbohydrates explode all trees 
#2 ((carbohydrat* or CHO) near (oral or load* or treatment or drink* or fluid* or administrat* or 
rich)) 
#3 (oral fluid* or CHO or fasting):ti,ab 
#4 nutricia* or maltodextrin 
#5 (#1 OR #2 OR #3 OR #4) 
#6 MeSH descriptor Postoperative Care, this term only 
#7 MeSH descriptor Postoperative Period, this term only 
#8 MeSH descriptor Insulin Resistance, this term only 
#9 MeSH descriptor Surgical Procedures, Elective, this term only 
#10 MeSH descriptor Postoperative Complications, this term only 
#11 MeSH descriptor Cholecystectomy, Laparoscopic, this term only 
#12 MeSH descriptor Pain, Postoperative, this term only 
#13 pre?op*:ti,ab 
#14 (postoperative near (recovery or pain or nausea or vomiting or fatigue)):ti,ab 
#15 (insulin near resistance):ti,ab 
#16 (surgery near (elective or abdominal)):ti,ab 
#17 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16) 
#18 (#5 AND #17) 
 
Medline search 
1. ((carbohydrat* or CHO) adj3 (oral or load* or treatment or drink* or fluid* or administrat* or 





2. Postoperative Care/ or Postoperative Period/ or Insulin Resistance/ or Surgical Procedures, 
Elective/ or Postoperative Complications/ or Cholecystectomy, Laparoscopic/ or Pain, 
Postoperative/ or pre?op*.ti,ab. or (post?operative adj3 (recovery or pain or nausea or vomiting or 
fatigue)).ti,ab. or (insulin adj3 resistance).ti,ab. or (surgery adj3 (elective or abdominal)).ti,ab. 
3. 1 and 2 
4. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or 
clinical trials as topic.sh. or randomly.ab. or trial.ti.) not (animals not (humans and animals)).sh. 
5. 3 and 4 
 
EMBASE search 
1. ((carbohydrat* or CHO) adj3 (oral or load* or treatment or drink* or fluid* or administrat* or 
rich)).mp. or (oral fluid* or CHO or fasting).ti,ab. or (nutricia* or maltodextrin).mp. or 
carbohydrate/ 
2. pre?op*.ti,ab. or (post?operative adj3 (recovery or pain or nausea or vomiting or fatigue)).ti,ab. 
or (insulin adj3 resistance).ti,ab. or (surgery adj3 (elective or abdominal)).ti,ab. or postoperative 
care/ or postoperative period/ or postoperative pain/ or insulin resistance/ or elective surgery/ or 
postoperative complication/ or cholecystectomy/ 
3. (placebo.sh. or controlled study.ab. or random*.ti,ab. or trial*.ti,ab.) not (animals.sh not 
(humans.sh and animals.sh)) 
4. 3 and 2 and 1 
 
CINAHL search 
S1 TX ( carbohydrat* or CHO ) and AB ( oral or load* or treatment or drink* or fluid* or 
administrat* or rich ) 
S2 AB oral fluid* or CHO or fasting 
S3 TX nutricia* or maltodextrin 
S4 (MM “Carbohydrates”) 
S5 S1 or S2 or S3 or S4 
S6 (MH “Postoperative Pain”) OR (MH “Postoperative Period”) OR (MH “Postoperative Care”) 
OR (MH “Postoperative Complications”) OR (MH “Insulin Resistance”) OR (MH “Surgery, 




S7 TI pre?op* or AB pre?op* 
S8 AB postoperative and AB ( recovery or pain or nausea or vomiting or fatigue ) 
S9 AB insulin and AB resistance 
S10 AB surgery and AB ( elective or abdominal ) 
S11 S6 or S7 or S8 or S9 or S10 
S12 S5 and S11 
S13 ( random* or placebo or trial* ) or ( ((single or double or triple or treble) and (mask* or 
blind*)) ) or ( multicenter* or prospective ) 
S14 (MH “Random Assignment”) OR (MH “Clinical Trials”) OR (MH “Placebos”) OR (MH 
“Double-Blind Studies”) OR (MH “Single-Blind Studies”) OR (MH “Triple-Blind Studies”) OR 
(MH “Prospective Studies”) OR (MH “Multicenter Studies”) 
S15 S13 or S14 
S16 S12 and S15 
 
Web of Science search 
1. TS=(pre$op*) or TS=((cholecystectomy or surgery or surgical) same (elective or abdominal or 
laparoscopic)) 
2. TS=((carbohydrat* or CHO) same (oral or load or treatment or drink* or fluid* or administrat* 
or rich)) or TS=(nutricia* or maltodextrin) 
3. TS=(post$op* same (care or period or complications or pain or recovery or nausea or vomiting 
or fatigue)) or TS=(insulin same resistance) 













































































Anti-reflux surgery systematic review and NMA – additional material 
 
C1 Search strategies  
CENTRAL search 
1. (MeSH descriptor gastroesophageal reflux, explode all trees) or (MeSH descriptor bile reflux, 
explode all trees) or (MeSH descriptor heartburn, explode all trees) or (MeSH descriptor 
esophagitis, explode all trees) or (MeSH descriptor gastritis, explode all trees) or (MeSH descriptor 
gastroparesis, explode all trees) or (MeSH descriptor gastric emptying, explode all trees) or (MeSH 
descriptor esophageal motility disorders, explode all trees) or (MeSH descriptor dyspepsia, 
explode all trees) or (MeSH descriptor eructation, explode all trees) or (MeSH descriptor hernia, 
hiatal, explode all trees) or (esophag* or oesophag*) or (acid regurgitation) or (gastric acid) or 
(gastr* near reflux):ti,ab or (gord or gerd):ti,ab or (duodenogastric reflux) or (acid near reflux) or 
(gastr* acid secret*) or (stomach acid secret*) or (gastr* near erosion) or (gastr* near ulcer) or 
(stomach erosion) or (stomach near ulcer) or (peptic near ulcer) or (heartburn or indigestion) or 
(esophagitis or oesophagitis) or (les):ti,ab or (low* sphinct* pressure) or (gastr* empt* disorder) 
or (stomach empt* disorder) or (dyspep*) or (eructat*) or (regurg*) 
2. (MeSH descriptor fundoplication, explode all trees) or (fundoplic*):ti,ab or (nissen or rossetti 
or toupet or lind or watson or belsey or dor or hill procedure):ti,ab or (part* near fundoplication) 
or (antireflux surg*):ti,ab or (antireflux interven*):ti,ab or (laparosc* near fundoplication) or (open 
near fundoplication) 
3. (#1 and #2)  
 
Medline search 
1. (randomized controlled trial or randomised controlled trial or controlled clinical trial).pt or 
randomized.ti,ab or randomised.ti,ab or placebo.ti,ab or drug therapy.sh or randomly.ti,ab or 
trial.ti,ab or groups.ti,ab 
2. animals.sh NOT humans.sh 




4. esophagus/ or gastroesophageal reflux/ or exp laryngopharyngeal reflux/ or duodenogastric 
reflux/ or bile reflux/ or heartburn/ or esophagitis/ or esophagitis, peptic/ or gastritis/ or exp peptic 
ulcer/ or gastroparesis/ or gastric emptying/ or dyspepsia/ or eructation/ or exp hernia, 
diaphragmatic/ or $esophag*.mp or acid regurgitation.mp or (gastr* adj3 reflux).tw or gord.tw or 
gerd.tw or (acid adj3 reflux).tw or (gastr* adj3 acid adj3 secret*).tw or (stomach adj3 acid adj3 
secret*).tw or (gastr* adj3 erosion).tw or (gastr* adj3 ulcer).tw or (stomach adj3 erosion).tw or 
(stomach adj3 ulcer).tw or (peptic adj3 ulcer).tw or (heartburn or indigestion).tw or 
$esophagitis.tw or (peptic adj3 $esophagitis).tw or les.tw or (low* adj3 sphincter adj3 pressure).tw 
or ($esophag* adj3 motil* adj3 disorder).tw or (gastr* adj3 empt* adj3 disorder).tw or (stomach 
adj3 empt* adj3 disorder).tw or dyspep*.tw or eructat*.tw or regurg*.tw 
5. fundoplication/ or gastric fundus/ or fundoplic*.tw or (nissen or rossetti or toupet or lind or 
watson or belsey or dor or hill procedure).tw or (part* adj3 fundoplication).tw or (antireflux adj3 
surg*).tw or (antireflux adj3 interven*).tw or (laparosc* adj3 fundoplication).tw or (open adj3 
fundoplication).tw or (minim* adj3 fundoplication).tw 
6. 3 and 4 and 5 
 
EMBASE search 
1. (random$ or factorial$ or crossover$ or cross-over$ or cross over$ or placebo$ or singl$ adj 
blind$ or doubl$ adj blind$ or triple blind$ or assign$ or allocate$ or volunteer$).ti,ab or crossover 
procedure/ or double-blind procedure/ or randomized controlled trial/ or single-blind procedure/ 
2. (animal$ not human$).sh,hw  
3. (book or conference paper or editorial or letter or review).pt not exp randomized controlled trial/  
4. (random sampl$ or random digit$ or random effect$ or random survey or random 
regression).ti,ab not exp randomized controlled trial/ 
5. 1 not (2 or 3 or 4) 
6. esophagus/ or gastroesophageal reflux/ or exp laryngopharyngeal reflux/ or duodenogastric 
reflux/ or bile reflux/ or heartburn/ or esophagitis/ or esophagitis, peptic/ or gastritis/ or exp peptic 
ulcer/ or gastroparesis/ or gastric emptying/ or dyspepsia/ or eructation/ or exp hernia, 
diaphragmatic/ or $esophag*.mp or acid regurgitation.mp or (gastr* adj3 reflux).tw or gord.tw or 
gerd.tw or (acid adj3 reflux).tw or (gastr* adj3 acid adj3 secret*).tw or (stomach adj3 acid adj3 




(stomach adj3 ulcer).tw or (peptic adj3 ulcer).tw or (heartburn or indigestion).tw or 
$esophagitis.tw or (peptic adj3 $esophagitis).tw or les.tw or (low* adj3 sphincter adj3 pressure).tw 
or ($esophag* adj3 motil* adj3 disorder).tw or (gastr* adj3 empt* adj3 disorder).tw or (stomach 
adj3 empt* adj3 disorder).tw or dyspep*.tw or eructat*.tw or regurg*.tw 
7. fundoplication/ or gastric fundus/ or fundoplic*.tw or (nissen or rossetti or toupet or lind or 
watson or belsey or dor or hill procedure).tw or (part* adj3 fundoplication).tw or (antireflux adj3 
surg*).tw or (antireflux adj3 interven*).tw or (laparosc* adj3 fundoplication).tw or (open adj3 
fundoplication).tw or (minim* adj3 fundoplication).tw 
8. 5 and 6 and 7 
 
Web of Science search 
1. TS=(($esophag* or gastr* or duod*) same (reflux or regurg* or acid or erosion or ulcer)) or 
TS=(GORD or GERD or heartburn or indigestion or dyspepsia) or TS=($esophagitis or gastritis 
or gastr* empty* or stomach empty*) or TS=(lower esophag* sphincter or $esophageal motility) 
or TS=(eructat*) or TS=(hiat* near/3 hernia) 
2. TS=(fundoplic* or Nissen or Rossetti or toupet or Watson or belsey or dor or hill procedure) or 
TS=((antireflux or acid near/3 suppr*) SAME (surg* or laparosc* or open)) 





























































































Bias in surgical trials – additional material 
 
D1 Cochrane Library search 
1. (MeSH descriptor general surgery, explode all trees) OR (MeSH descriptor gynecology, explode 
all trees) OR (MeSH descriptor elective surgical procedures, explode all trees) OR (Mesh 
descriptor digestive system surgical procedures, explode all trees) OR (MeSH descriptor surgical 
procedures, operative, explode all trees) OR (MeSH descriptor laparotomy, explode all trees) OR 
(MeSH descriptor obstetric surgical procedures, explode all trees) OR (open near surgery):ti,ab 
OR (standard near surgery):ti,ab OR (general surgery) OR (gynecology) OR (operative surgery) 
 
2. (MeSH descriptor minimally invasive surgical procedures, explode all trees) OR (MeSH 
descriptor ambulatory surgical procedures, explode all trees) OR (MeSH descriptor surgery, 
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